PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20565459-6	2010	CONCLUSION: These results suggest that a possible inhibition of biliary excretion of MPA metabolites by CsA and a decreased intestinal production of these metabolites in UGT1A8 2 carriers may be protective factors against MMF-induced diarrhoea.	Mycophenolic Acid	222-225	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	170-176
20431509-3	2010	Other potential candidates are CYP3A5 and sirolimus and UGT1A9 for mycophenolate.	Mycophenolic Acid	67-80	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	56-62
20431509-4	2010	There are also genetic predictors of pharmacodynamics, including IMPDH1 for mycophenolate and ABCB1 for cyclosporine that may identify individuals at particular risk of efficacy failure or toxicity with a given drug.	Mycophenolic Acid	76-89	inosine monophosphate dehydrogenase 1	Homo sapiens	65-71
20302854-0	2010	Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells.	Mycophenolic Acid	0-17	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
20302854-5	2010	Pre-incubation of the cells with mycophenolic acid (MPA) resulted in reduced phosphorylation of both JNKs and NF-kappaB, and reduced IL-8 release in H(2)O(2)-stimulated HK-2 cells.	Mycophenolic Acid	33-50	C-X-C motif chemokine ligand 8	Homo sapiens	133-137
20334925-0	2010	Mycophenolic acid differentially affects dendritic cell maturation induced by tumor necrosis factor-alpha and lipopolysaccharide through a different modulation of MAPK signaling.	Mycophenolic Acid	0-17	tumor necrosis factor	Homo sapiens	78-105
20334925-0	2010	Mycophenolic acid differentially affects dendritic cell maturation induced by tumor necrosis factor-alpha and lipopolysaccharide through a different modulation of MAPK signaling.	Mycophenolic Acid	0-17	mitogen-activated protein kinase 3	Homo sapiens	163-167
20412855-0	2010	Mycophenolate mofetil modifies kidney tubular injury and Foxp3+ regulatory T cell trafficking during recovery from experimental ischemia-reperfusion.	Mycophenolic Acid	0-21	forkhead box P3	Mus musculus	57-62
20305583-7	2010	CONCLUSION: These results demonstrate that inhibition of CD40-CD40L interaction or treatment with rapamycin could be successfully combined with in vitro-expanded Treg cell therapy, but the concomitant use of mycophenolate mofetil or cyclosporine A in this type of Treg cell therapy should be carefully considered.	Mycophenolic Acid	208-229	CD40 antigen	Mus musculus	57-61
20305583-7	2010	CONCLUSION: These results demonstrate that inhibition of CD40-CD40L interaction or treatment with rapamycin could be successfully combined with in vitro-expanded Treg cell therapy, but the concomitant use of mycophenolate mofetil or cyclosporine A in this type of Treg cell therapy should be carefully considered.	Mycophenolic Acid	208-229	CD40 ligand	Mus musculus	62-67
20067954-1	2010	OBJECTIVE: This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing beta-cells in subjects with new-onset type 1 diabetes.	Mycophenolic Acid	60-63	insulin	Homo sapiens	121-128
20207170-0	2010	Lung transplantation under a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen results in low titers of HLA and MICA IgG antibodies which are not related to development of BOS.	Mycophenolic Acid	40-61	MHC class I polypeptide-related sequence A	Homo sapiens	127-131
19578979-0	2010	Mycophenolic acid inhibits albumin-induced MCP-1 expression in renal tubular epithelial cells through the p38 MAPK pathway.	Mycophenolic Acid	0-17	mitogen-activated protein kinase 14	Homo sapiens	106-109
19578979-0	2010	Mycophenolic acid inhibits albumin-induced MCP-1 expression in renal tubular epithelial cells through the p38 MAPK pathway.	Mycophenolic Acid	0-17	C-C motif chemokine ligand 2	Homo sapiens	43-48
20573295-9	2010	Among the observed immunosuppressive agents, corticosteroids, prednisolone, 6alpha-methylprednisolone, dexamethasone, and beclomethasone inhibited PS-PLA(1) expression with half-maximal inhibitory concentrations less than 3.0 nM, while methotrexate, cyclosporine A, tacrolimus, 6-mercaptopurine, and mycophenoic acid showed either a weak or moderate inhibition.	Mycophenolic Acid	300-316	phospholipase A1 member A	Homo sapiens	147-156
20155737-7	2010	They developed a base and final model with a genotype covariate for CL/F in patients receiving calcineurin inhibitor (CNI)-free therapy with SRL, mycophenolate mofetil and corticosteroids.	Mycophenolic Acid	146-167	calcineurin binding protein 1	Homo sapiens	95-116
20032964-0	2010	Long-term study of mycophenolate mofetil treatment in IgA nephropathy.	Mycophenolic Acid	19-40	CD79a molecule	Homo sapiens	54-57
20032964-1	2010	Since the efficacy of mycophenolate mofetil (MMF) to treat immunoglobulin A (IgA) nephropathy is controversial, we extended our original study by following 40 Chinese patients with established IgA nephropathy for 6 years.	Mycophenolic Acid	45-48	CD79a molecule	Homo sapiens	59-75
20032964-1	2010	Since the efficacy of mycophenolate mofetil (MMF) to treat immunoglobulin A (IgA) nephropathy is controversial, we extended our original study by following 40 Chinese patients with established IgA nephropathy for 6 years.	Mycophenolic Acid	45-48	CD79a molecule	Homo sapiens	77-80
19923226-4	2010	Disruption of Lge1 abolished ubiquitylation of histone H2B on lysine 123 and H3 methylation on lysines 4 and 79 and resulted in significant sensitivity to 6-azauracil and mycophenolic acid.	Mycophenolic Acid	171-188	LARGE xylosyl- and glucuronyltransferase 1	Homo sapiens	14-18
19923226-4	2010	Disruption of Lge1 abolished ubiquitylation of histone H2B on lysine 123 and H3 methylation on lysines 4 and 79 and resulted in significant sensitivity to 6-azauracil and mycophenolic acid.	Mycophenolic Acid	171-188	H2B clustered histone 21	Homo sapiens	55-58
20139394-0	2010	Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.	Mycophenolic Acid	15-36	erythropoietin	Homo sapiens	147-161
20042922-1	2010	Within the scope of this study, the potential antifibrotic effect of mycophenolate mofetil (MMF) on COL4A3-deficient mice as an animal model for progressive renal fibrosis was investigated regarding kidney function and survival.	Mycophenolic Acid	69-90	collagen, type IV, alpha 3	Mus musculus	100-106
20042922-1	2010	Within the scope of this study, the potential antifibrotic effect of mycophenolate mofetil (MMF) on COL4A3-deficient mice as an animal model for progressive renal fibrosis was investigated regarding kidney function and survival.	Mycophenolic Acid	92-95	collagen, type IV, alpha 3	Mus musculus	100-106
19890249-1	2010	The goal of this study was to determine the roles of the organic anion-transporting polypeptides (OATPs) OATP1A2, OATP1B1, and OATP1B3 and their genetic variants in the pharmacokinetics of the immunosuppressive drug mycophenolate mofetil (MMF).	Mycophenolic Acid	216-237	solute carrier organic anion transporter family member 1A2	Homo sapiens	105-112
19890249-1	2010	The goal of this study was to determine the roles of the organic anion-transporting polypeptides (OATPs) OATP1A2, OATP1B1, and OATP1B3 and their genetic variants in the pharmacokinetics of the immunosuppressive drug mycophenolate mofetil (MMF).	Mycophenolic Acid	216-237	solute carrier organic anion transporter family member 1B3	Homo sapiens	127-134
19890249-1	2010	The goal of this study was to determine the roles of the organic anion-transporting polypeptides (OATPs) OATP1A2, OATP1B1, and OATP1B3 and their genetic variants in the pharmacokinetics of the immunosuppressive drug mycophenolate mofetil (MMF).	Mycophenolic Acid	239-242	solute carrier organic anion transporter family member 1A2	Homo sapiens	105-112
19890249-1	2010	The goal of this study was to determine the roles of the organic anion-transporting polypeptides (OATPs) OATP1A2, OATP1B1, and OATP1B3 and their genetic variants in the pharmacokinetics of the immunosuppressive drug mycophenolate mofetil (MMF).	Mycophenolic Acid	239-242	solute carrier organic anion transporter family member 1B3	Homo sapiens	127-134
19890249-2	2010	Using OATP-transfected human embryonic kidney (HEK) cells, we measured the uptake of mycophenolic acid (MPA) and its glucuronide (MPAG).	Mycophenolic Acid	85-102	solute carrier organic anion transporter family member 1A2	Homo sapiens	6-10
19890249-4	2010	The pharmacokinetics of both MPA and MPAG were significantly influenced by the OATP1B3 polymorphism 334T>G/699G>A in 70 renal transplant patients receiving combination treatment of MMF with either tacrolimus or sirolimus, but not in 115 patients receiving MMF and cyclosporine.	Mycophenolic Acid	187-190	solute carrier organic anion transporter family member 1B3	Homo sapiens	79-86
19890249-4	2010	The pharmacokinetics of both MPA and MPAG were significantly influenced by the OATP1B3 polymorphism 334T>G/699G>A in 70 renal transplant patients receiving combination treatment of MMF with either tacrolimus or sirolimus, but not in 115 patients receiving MMF and cyclosporine.	Mycophenolic Acid	262-265	solute carrier organic anion transporter family member 1B3	Homo sapiens	79-86
19542890-4	2009	Use of mycophenolate is superior when compared with azathioprine to allow for CNI reduction.	Mycophenolic Acid	7-20	calcineurin binding protein 1	Homo sapiens	78-81
21117362-3	2010	MATERIAL AND METHODS: In all experiments we used mycophenolic acid (MPC), which is the biologically active form of MME Its activity was assessed on the cultures of immortalized non-transformed cells line from a human donor (ARPE19).	Mycophenolic Acid	49-66	membrane metalloendopeptidase	Homo sapiens	115-118
21117362-3	2010	MATERIAL AND METHODS: In all experiments we used mycophenolic acid (MPC), which is the biologically active form of MME Its activity was assessed on the cultures of immortalized non-transformed cells line from a human donor (ARPE19).	Mycophenolic Acid	68-71	membrane metalloendopeptidase	Homo sapiens	115-118
19820002-1	2010	ABO-incompatible kidney transplantation is possible after pre-treatment with rituximab, intravenous immunoglobulin and basiliximab combined with tacrolimus, mycophenolate mofetil and prednisolone.	Mycophenolic Acid	157-178	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	0-3
20175802-1	2009	OBJECTIVE: The aim of this study was to elucidate the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activating angiotensin receptor blocker (ARB) telmisartan and the non-PPAR-gamma activating ARB valsartan and candesartan on mycophenolic acid (MPA) pharmacokinetics in renal transplant recipients.	Mycophenolic Acid	255-272	peroxisome proliferator activated receptor gamma	Homo sapiens	68-116
20175802-1	2009	OBJECTIVE: The aim of this study was to elucidate the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activating angiotensin receptor blocker (ARB) telmisartan and the non-PPAR-gamma activating ARB valsartan and candesartan on mycophenolic acid (MPA) pharmacokinetics in renal transplant recipients.	Mycophenolic Acid	255-272	peroxisome proliferator activated receptor gamma	Homo sapiens	118-128
20175802-1	2009	OBJECTIVE: The aim of this study was to elucidate the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activating angiotensin receptor blocker (ARB) telmisartan and the non-PPAR-gamma activating ARB valsartan and candesartan on mycophenolic acid (MPA) pharmacokinetics in renal transplant recipients.	Mycophenolic Acid	274-277	peroxisome proliferator activated receptor gamma	Homo sapiens	68-116
20175802-1	2009	OBJECTIVE: The aim of this study was to elucidate the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activating angiotensin receptor blocker (ARB) telmisartan and the non-PPAR-gamma activating ARB valsartan and candesartan on mycophenolic acid (MPA) pharmacokinetics in renal transplant recipients.	Mycophenolic Acid	274-277	peroxisome proliferator activated receptor gamma	Homo sapiens	118-128
20039429-6	2010	Levels of complement C3, C4, and CH50 and titers of anti-double-stranded DNA antibodies were normalized after treatment with either mycophenolate mofetil or intravenous cyclophosphamide.	Mycophenolic Acid	132-153	complement C3	Homo sapiens	10-23
19730281-0	2009	Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.	Mycophenolic Acid	109-126	ATP binding cassette subfamily C member 2	Homo sapiens	25-29
19730281-0	2009	Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.	Mycophenolic Acid	109-126	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	34-40
19730281-1	2009	The aim of this study was to determine the relationship between single nucleotide polymorphisms in multidrug resistance protein 2 (MRP2) and uridine diphosphate glucuronosyltransferase (UGT) 2B7 and the severity of gastrointestinal (GI) symptoms in patients receiving mycophenolic acid (MPA).	Mycophenolic Acid	268-285	ATP binding cassette subfamily C member 2	Homo sapiens	99-129
19730281-1	2009	The aim of this study was to determine the relationship between single nucleotide polymorphisms in multidrug resistance protein 2 (MRP2) and uridine diphosphate glucuronosyltransferase (UGT) 2B7 and the severity of gastrointestinal (GI) symptoms in patients receiving mycophenolic acid (MPA).	Mycophenolic Acid	268-285	ATP binding cassette subfamily C member 2	Homo sapiens	131-135
19730281-1	2009	The aim of this study was to determine the relationship between single nucleotide polymorphisms in multidrug resistance protein 2 (MRP2) and uridine diphosphate glucuronosyltransferase (UGT) 2B7 and the severity of gastrointestinal (GI) symptoms in patients receiving mycophenolic acid (MPA).	Mycophenolic Acid	268-285	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	141-194
19494809-9	2009	UGT1A9 -275T>A and/or -2152C>T genotyping may identify patients at risk of MPA underexposure and acute rejection when receiving treatment with MMF and tacrolimus.	Mycophenolic Acid	149-152	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	0-6
19715905-0	2009	The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients.	Mycophenolic Acid	168-185	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	18-65
19458944-4	2009	RESULTS: There was a highly significant correlation between blood CsA C2 levels and blood CsA AUC(0-12) in groups of patients treated with MMF or everolimus (R(2) 0.93 and 0.96, respectively; P < 0.001 for both).	Mycophenolic Acid	139-142	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	66-69
19458944-4	2009	RESULTS: There was a highly significant correlation between blood CsA C2 levels and blood CsA AUC(0-12) in groups of patients treated with MMF or everolimus (R(2) 0.93 and 0.96, respectively; P < 0.001 for both).	Mycophenolic Acid	139-142	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	90-93
19398001-1	2009	We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation.	Mycophenolic Acid	114-135	CD4 molecule	Homo sapiens	48-51
19398001-1	2009	We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation.	Mycophenolic Acid	114-135	interleukin 2 receptor subunit alpha	Homo sapiens	54-58
19398001-1	2009	We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation.	Mycophenolic Acid	114-135	forkhead box P3	Homo sapiens	65-70
19398001-1	2009	We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation.	Mycophenolic Acid	137-140	CD4 molecule	Homo sapiens	48-51
19398001-1	2009	We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation.	Mycophenolic Acid	137-140	interleukin 2 receptor subunit alpha	Homo sapiens	54-58
19398001-1	2009	We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation.	Mycophenolic Acid	137-140	forkhead box P3	Homo sapiens	65-70
19715905-1	2009	UNLABELLED: The aim of this study was to evaluate the distribution of UGT1A9 promoter region T-275A and C-2152T single nucleotide polymorphisms (SNPs) in stable transplant patients and to investigate the impact of these SNPs on mycophenolic acid (MPA) pharmacokinetics.	Mycophenolic Acid	228-245	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	70-76
19715905-0	2009	The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients.	Mycophenolic Acid	168-185	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	67-73
19953878-0	2009	[Mycophenolate mofetil-based calcineurin inhibitor reduced immunosuppressive protocol for the improvement of renal dysfunction after liver transplantation].	Mycophenolic Acid	1-22	calcineurin binding protein 1	Homo sapiens	29-50
19680830-10	2009	Reduction of immunosuppression and switch to mTOR inhibitors and potentially, mycophenolate, may reduce the incidence of further SCC.	Mycophenolic Acid	78-91	serpin family B member 3	Homo sapiens	129-132
19274604-0	2009	Influence of carboxylesterase 2 genetic polymorphisms  on mycophenolic acid pharmacokinetics in Japanese  renal transplant recipients.	Mycophenolic Acid	58-75	carboxylesterase 2	Homo sapiens	13-31
19515133-3	2009	Newer therapies, including mycophenolate mofetil, leflunomide and rituximab, are providing a real opportunity for improved outcomes of AAV in the future.	Mycophenolic Acid	27-48	adeno-associated virus integration site 1	Homo sapiens	135-138
18992054-0	2009	Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection.	Mycophenolic Acid	50-71	calcineurin binding protein 1	Homo sapiens	0-21
19377794-1	2009	Experimental data and few clinical non-randomized studies have shown that inhibition of the renin-angiotensin system by angiotensin-converting enzyme (ACE) associated or not with the use of mycophenolate mofetil (MMF) could delay or even halt the progression of chronic allograft nephropathy (CAN).	Mycophenolic Acid	213-216	angiotensin I converting enzyme	Homo sapiens	120-149
19481022-0	2009	Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.	Mycophenolic Acid	44-57	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
19225446-0	2009	UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.	Mycophenolic Acid	72-93	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	0-3
19379692-4	2009	Cells lacking the Set1-Set3 complex pathway are sensitive to mycophenolic acid and have reduced polymerase levels at a Set3 target gene, suggesting a positive role in transcription.	Mycophenolic Acid	61-78	SET domain containing 1A, histone lysine methyltransferase	Homo sapiens	18-22
19352129-0	2009	Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells.	Mycophenolic Acid	41-62	CD4 molecule	Homo sapiens	126-129
19352129-0	2009	Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells.	Mycophenolic Acid	41-62	forkhead box P3	Homo sapiens	130-135
19093139-0	2009	Mycophenolic acid inhibits oleic acid-induced mesangial cell activation through both cellular reactive oxygen species and inosine monophosphate dehydrogenase 2 pathways.	Mycophenolic Acid	0-17	inosine monophosphate dehydrogenase 2	Mus musculus	122-159
19093139-2	2009	Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase 2 (IMPDH2), suppresses MC proliferation and ECM synthesis.	Mycophenolic Acid	0-17	inosine monophosphate dehydrogenase 2	Mus musculus	41-78
19093139-2	2009	Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase 2 (IMPDH2), suppresses MC proliferation and ECM synthesis.	Mycophenolic Acid	0-17	inosine monophosphate dehydrogenase 2	Mus musculus	80-86
19093139-2	2009	Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase 2 (IMPDH2), suppresses MC proliferation and ECM synthesis.	Mycophenolic Acid	19-22	inosine monophosphate dehydrogenase 2	Mus musculus	41-78
19093139-2	2009	Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase 2 (IMPDH2), suppresses MC proliferation and ECM synthesis.	Mycophenolic Acid	19-22	inosine monophosphate dehydrogenase 2	Mus musculus	80-86
19214148-0	2009	Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase 3-induced cleavage of rho GDP dissociation inhibitor 2.	Mycophenolic Acid	60-77	caspase 3	Homo sapiens	86-95
19214148-0	2009	Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase 3-induced cleavage of rho GDP dissociation inhibitor 2.	Mycophenolic Acid	60-77	Rho GDP dissociation inhibitor beta	Homo sapiens	116-148
19300195-8	2009	Discontinuation of AZA or MMF resulted in significant increased numbers of third-party (P=0.003) and tetanus toxoid-reactive (P=0.008) IL-10 producing cells, and a trend in higher numbers of donor-reactive IL-10 producing cells (P=0.06).	Mycophenolic Acid	26-29	interleukin 10	Homo sapiens	135-140
19299544-1	2009	BACKGROUND: The immunosuppressive effect of mycophenolic acid (MPA) is essentially attributed to IMPDH II inhibition, which leads to a reduction of lymphocyte proliferation.	Mycophenolic Acid	44-61	inosine monophosphate dehydrogenase 2	Homo sapiens	97-105
19299544-1	2009	BACKGROUND: The immunosuppressive effect of mycophenolic acid (MPA) is essentially attributed to IMPDH II inhibition, which leads to a reduction of lymphocyte proliferation.	Mycophenolic Acid	63-66	inosine monophosphate dehydrogenase 2	Homo sapiens	97-105
19300195-8	2009	Discontinuation of AZA or MMF resulted in significant increased numbers of third-party (P=0.003) and tetanus toxoid-reactive (P=0.008) IL-10 producing cells, and a trend in higher numbers of donor-reactive IL-10 producing cells (P=0.06).	Mycophenolic Acid	26-29	interleukin 10	Homo sapiens	206-211
19300195-10	2009	CONCLUSIONS: In HLA-identical LR renal transplant recipients, therapy with AZA and MMF suppress the IL-10 production and the maturation of DC.	Mycophenolic Acid	83-86	interleukin 10	Homo sapiens	100-105
19041939-0	2009	The RhoGDI-alpha/JNK signaling pathway plays a significant role in mycophenolic acid-induced apoptosis in an insulin-secreting cell line.	Mycophenolic Acid	67-84	Rho GDP dissociation inhibitor alpha	Homo sapiens	4-10
19328959-0	2009	Mycophenolic Acid Inhibits p38 Mitogen-Activated Protein Kinase in Human Monocyte-Derived Dendritic Cells Stimulated by Lipopolysaccharide.	Mycophenolic Acid	0-17	mitogen-activated protein kinase 14	Homo sapiens	27-63
19041939-0	2009	The RhoGDI-alpha/JNK signaling pathway plays a significant role in mycophenolic acid-induced apoptosis in an insulin-secreting cell line.	Mycophenolic Acid	67-84	mitogen-activated protein kinase 8	Homo sapiens	17-20
19010451-0	2009	Expression of IMPDH1 is regulated in response to mycophenolate concentration.	Mycophenolic Acid	49-62	inosine monophosphate dehydrogenase 1	Homo sapiens	14-20
19374250-9	2009	In contrast to cyclosporine and tacrolimus, the immunosuppressant mycophenolate inhibits the Rac 1 subunit thus inhibiting NADPH oxidase in the vasculature.	Mycophenolic Acid	66-79	Rac family small GTPase 1	Homo sapiens	93-98
18727660-2	2009	Mycophenolate mofetil and CSA (MMF-CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source.	Mycophenolic Acid	0-21	colony stimulating factor 3	Homo sapiens	189-194
19065122-0	2009	Regulation of IL2 and NUCB1 in mononuclear cells treated with acyl glucuronide of mycophenolic acid reveals effects independent of inosine monophosphate dehydrogenase inhibition.	Mycophenolic Acid	82-99	interleukin 2	Homo sapiens	14-17
19065122-0	2009	Regulation of IL2 and NUCB1 in mononuclear cells treated with acyl glucuronide of mycophenolic acid reveals effects independent of inosine monophosphate dehydrogenase inhibition.	Mycophenolic Acid	82-99	nucleobindin 1	Homo sapiens	22-27
19169900-0	2009	Mycophenolate mofetil for the treatment of autoimmune diseases: hype or hope?	Mycophenolic Acid	0-21	FIC domain protein adenylyltransferase	Homo sapiens	64-68
19187647-1	2009	BACKGROUND: It was reported that combination of mycophenolate mofetil (MMF) and enalapril could reduce proteinuria, improve renal function, and down-regulate diabetes-induced macrophage recruitment and expression of monocyte chemotactic protein 1 (MCP-1) and transforming growth factor beta (TGF-beta) in diabetic renal tissue.	Mycophenolic Acid	48-69	C-C motif chemokine ligand 2	Rattus norvegicus	216-246
19187647-1	2009	BACKGROUND: It was reported that combination of mycophenolate mofetil (MMF) and enalapril could reduce proteinuria, improve renal function, and down-regulate diabetes-induced macrophage recruitment and expression of monocyte chemotactic protein 1 (MCP-1) and transforming growth factor beta (TGF-beta) in diabetic renal tissue.	Mycophenolic Acid	48-69	C-C motif chemokine ligand 2	Rattus norvegicus	248-253
19187647-1	2009	BACKGROUND: It was reported that combination of mycophenolate mofetil (MMF) and enalapril could reduce proteinuria, improve renal function, and down-regulate diabetes-induced macrophage recruitment and expression of monocyte chemotactic protein 1 (MCP-1) and transforming growth factor beta (TGF-beta) in diabetic renal tissue.	Mycophenolic Acid	71-74	C-C motif chemokine ligand 2	Rattus norvegicus	216-246
19187647-1	2009	BACKGROUND: It was reported that combination of mycophenolate mofetil (MMF) and enalapril could reduce proteinuria, improve renal function, and down-regulate diabetes-induced macrophage recruitment and expression of monocyte chemotactic protein 1 (MCP-1) and transforming growth factor beta (TGF-beta) in diabetic renal tissue.	Mycophenolic Acid	71-74	C-C motif chemokine ligand 2	Rattus norvegicus	248-253
19500470-0	2009	Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets.	Mycophenolic Acid	43-64	insulin	Homo sapiens	87-94
18723570-0	2009	Mycophenolic acid inhibits the autocrine PDGF-B synthesis and PDGF-BB-induced mRNA expression of Egr-1 in rat mesangial cells.	Mycophenolic Acid	0-17	platelet derived growth factor subunit B	Rattus norvegicus	41-47
19125765-3	2009	She was found to have circulating polyclonal anti-insulin antibodies of the IgG subtype and responded clinically to a course of plasma exchange and immunosuppression with mycophenolate mofetil and, subsequently, intravenous immunoglobulin.	Mycophenolic Acid	171-192	insulin	Homo sapiens	50-57
18723570-0	2009	Mycophenolic acid inhibits the autocrine PDGF-B synthesis and PDGF-BB-induced mRNA expression of Egr-1 in rat mesangial cells.	Mycophenolic Acid	0-17	early growth response 1	Rattus norvegicus	97-102
18976158-1	2008	Inosine monophosphate dehydrogenase type II (IMPDH2) is the target for immunosuppression by mycophenolic acid and has been linked to resistance of tumor cells to chemotherapy.	Mycophenolic Acid	92-109	inosine monophosphate dehydrogenase 2	Homo sapiens	0-43
18976158-1	2008	Inosine monophosphate dehydrogenase type II (IMPDH2) is the target for immunosuppression by mycophenolic acid and has been linked to resistance of tumor cells to chemotherapy.	Mycophenolic Acid	92-109	inosine monophosphate dehydrogenase 2	Homo sapiens	45-51
18568343-0	2008	Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.	Mycophenolic Acid	51-64	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	30-33
18622022-1	2008	BACKGROUND: Late introduction of mycophenolate mofetil (MMF) is used in renal transplant patients to allow calcineurin inhibitor (CNI) withdrawal.	Mycophenolic Acid	33-54	calcineurin binding protein 1	Homo sapiens	107-128
18622022-1	2008	BACKGROUND: Late introduction of mycophenolate mofetil (MMF) is used in renal transplant patients to allow calcineurin inhibitor (CNI) withdrawal.	Mycophenolic Acid	56-59	calcineurin binding protein 1	Homo sapiens	107-128
19100409-1	2008	We have designed a protocol for ABO-incompatible kidney transplantations based on preoperative plasmapheresis with a tacrolimus/mycophenolate mofetil/methylprednisolone/basiliximab protocol using low-dose rituximab (200 mg/body) instead of splenectomy to prevent antibody-mediated acute rejection.	Mycophenolic Acid	128-149	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	32-35
19100455-8	2008	All 3 recipients were given FK506 (tacrolimus) regularly combined with periodic mycophenolate mofetil.	Mycophenolic Acid	80-101	paired box 5	Homo sapiens	0-5
18568343-1	2008	BACKGROUND: Mycophenolic acid (MPA) is glucuronidated primarily by uridine diphosphate glucuronosyltransferase enzymes (UGT) 1A9 and 1A8.	Mycophenolic Acid	12-29	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	67-136
18568343-1	2008	BACKGROUND: Mycophenolic acid (MPA) is glucuronidated primarily by uridine diphosphate glucuronosyltransferase enzymes (UGT) 1A9 and 1A8.	Mycophenolic Acid	31-34	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	67-136
18568343-8	2008	RESULTS: Mycophenolic acid dose-corrected trough concentrations were 60% higher in subjects heterozygous or homozygous for UGT1A8*2 than in those with the wild type (p = 0.02); however, this effect was dependent on concomitant calcineurin inhibitor.	Mycophenolic Acid	9-26	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	123-129
18568343-10	2008	Mycophenolic acid dose-corrected trough concentrations were 70% lower in carriers of the UGT1A9 -275T>A/-2152 C>T polymorphism who received cyclosporine (p < 0.01).	Mycophenolic Acid	0-17	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	89-95
18930138-8	2008	Minimization of calcineurin inhibitor exposure may be achieved with concurrent use of the more potent anti-proliferative agents mycophenolate mofetil and sirolimus.	Mycophenolic Acid	128-149	calcineurin binding protein 1	Homo sapiens	16-37
18823333-5	2008	Disruption of the SUB1 gene partially suppressed sensitivity to the transcription elongation inhibitor mycophenolate (MPA) in a dst1 gene deletion mutant.	Mycophenolic Acid	103-116	chromatin-binding transcription coactivator SUB1	Saccharomyces cerevisiae S288C	18-22
18823333-5	2008	Disruption of the SUB1 gene partially suppressed sensitivity to the transcription elongation inhibitor mycophenolate (MPA) in a dst1 gene deletion mutant.	Mycophenolic Acid	103-116	transcription elongation factor DST1	Saccharomyces cerevisiae S288C	128-132
18823333-5	2008	Disruption of the SUB1 gene partially suppressed sensitivity to the transcription elongation inhibitor mycophenolate (MPA) in a dst1 gene deletion mutant.	Mycophenolic Acid	118-121	chromatin-binding transcription coactivator SUB1	Saccharomyces cerevisiae S288C	18-22
18823333-5	2008	Disruption of the SUB1 gene partially suppressed sensitivity to the transcription elongation inhibitor mycophenolate (MPA) in a dst1 gene deletion mutant.	Mycophenolic Acid	118-121	transcription elongation factor DST1	Saccharomyces cerevisiae S288C	128-132
18946804-0	2008	Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.	Mycophenolic Acid	123-140	ATP binding cassette subfamily C member 2	Homo sapiens	68-73
18946804-1	2008	The aim was to investigate the effect of UGT1A9, UGT1A8, UGT2B7 and ABCC2 polymorphism on the pharmacokinetics of mycophenolic acid (MPA) and its metabolites phenolic glucuronide (MPAG) and acyl glucuronide (AcMPAG) in Chinese renal transplant recipients.	Mycophenolic Acid	114-131	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	41-47
19080229-1	2008	OBJECTIVE: The aim of this study is to examine the effect of mycophenolate mofetil (MMF) on epithelial-myofibroblast translation (EMT) in adenine-induced chronic renal failure (CRF) rat model and the role of vascular endothelial growth factor(VEGF) and inhibitor of differentiation (Id2 and Id3) in EMT in the rat kidney.	Mycophenolic Acid	84-87	vascular endothelial growth factor A	Rattus norvegicus	243-247
18946804-1	2008	The aim was to investigate the effect of UGT1A9, UGT1A8, UGT2B7 and ABCC2 polymorphism on the pharmacokinetics of mycophenolic acid (MPA) and its metabolites phenolic glucuronide (MPAG) and acyl glucuronide (AcMPAG) in Chinese renal transplant recipients.	Mycophenolic Acid	114-131	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	49-55
18946804-1	2008	The aim was to investigate the effect of UGT1A9, UGT1A8, UGT2B7 and ABCC2 polymorphism on the pharmacokinetics of mycophenolic acid (MPA) and its metabolites phenolic glucuronide (MPAG) and acyl glucuronide (AcMPAG) in Chinese renal transplant recipients.	Mycophenolic Acid	114-131	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	57-63
18946804-1	2008	The aim was to investigate the effect of UGT1A9, UGT1A8, UGT2B7 and ABCC2 polymorphism on the pharmacokinetics of mycophenolic acid (MPA) and its metabolites phenolic glucuronide (MPAG) and acyl glucuronide (AcMPAG) in Chinese renal transplant recipients.	Mycophenolic Acid	114-131	ATP binding cassette subfamily C member 2	Homo sapiens	68-73
18946804-1	2008	The aim was to investigate the effect of UGT1A9, UGT1A8, UGT2B7 and ABCC2 polymorphism on the pharmacokinetics of mycophenolic acid (MPA) and its metabolites phenolic glucuronide (MPAG) and acyl glucuronide (AcMPAG) in Chinese renal transplant recipients.	Mycophenolic Acid	133-136	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	57-63
19080229-1	2008	OBJECTIVE: The aim of this study is to examine the effect of mycophenolate mofetil (MMF) on epithelial-myofibroblast translation (EMT) in adenine-induced chronic renal failure (CRF) rat model and the role of vascular endothelial growth factor(VEGF) and inhibitor of differentiation (Id2 and Id3) in EMT in the rat kidney.	Mycophenolic Acid	84-87	inhibitor of DNA binding 2	Rattus norvegicus	283-286
19080229-1	2008	OBJECTIVE: The aim of this study is to examine the effect of mycophenolate mofetil (MMF) on epithelial-myofibroblast translation (EMT) in adenine-induced chronic renal failure (CRF) rat model and the role of vascular endothelial growth factor(VEGF) and inhibitor of differentiation (Id2 and Id3) in EMT in the rat kidney.	Mycophenolic Acid	84-87	inhibitor of DNA binding 3, HLH protein	Rattus norvegicus	291-294
18667332-0	2008	Mycophenolate mofetil promotes down-regulation of expanded B cells and production of TNF-alpha in an experimental murine model of colitis.	Mycophenolic Acid	0-21	tumor necrosis factor	Mus musculus	85-94
18838793-0	2008	Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level.	Mycophenolic Acid	31-48	histone deacetylase 9	Homo sapiens	57-76
18838793-1	2008	Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARgamma agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients.	Mycophenolic Acid	0-17	peroxisome proliferator activated receptor gamma	Homo sapiens	83-92
18926413-1	2008	BACKGROUND: The purpose of this study was to determine the utility of post-transplant serum soluble CD30 levels as a biomarker for the development of the bronchiolitis obliterans syndrome (BOS) after lung transplantation during a tacrolimus/mycophenolate mofetil-based regimen.	Mycophenolic Acid	241-262	TNF receptor superfamily member 8	Homo sapiens	100-104
18667332-7	2008	Furthermore, mycophenolic acid (MPA) reduced TNF-alpha-stimulated NF-kappaB activation in HT-29 colon epithelial cells.	Mycophenolic Acid	13-30	tumor necrosis factor	Homo sapiens	45-54
18667332-7	2008	Furthermore, mycophenolic acid (MPA) reduced TNF-alpha-stimulated NF-kappaB activation in HT-29 colon epithelial cells.	Mycophenolic Acid	32-35	tumor necrosis factor	Homo sapiens	45-54
18937726-0	2008	A case report of plasma exchange, steroids, mycophenolate mofetil and cyclophosphamide in acquired factor VIII inhibitors.	Mycophenolic Acid	44-65	coagulation factor VIII	Homo sapiens	99-110
18611986-0	2008	Induction of human CD4+ regulatory T cells by mycophenolic acid-treated dendritic cells.	Mycophenolic Acid	46-63	CD4 molecule	Homo sapiens	19-22
18937726-12	2008	Hence, we present a case of severe idiopathic FVIII inhibitor-positive hemophilia successfully treated with the combination of plasma exchange, corticosteroids, cyclophosphamide and MMF.	Mycophenolic Acid	182-185	coagulation factor VIII	Homo sapiens	46-51
18929863-0	2008	Effects of mycophenolate mofetil on chronic allograft nephropathy by affecting RHO/ROCK signal pathways.	Mycophenolic Acid	11-32	Rho-associated coiled-coil containing protein kinase 1	Rattus norvegicus	83-87
18929863-1	2008	AIM: We sought to investigate the effects of mycophenolate mofetil (MMF) on chronic allograft nephropathy (CAN) by affecting Rho and ROCK signal pathways.	Mycophenolic Acid	45-66	Rho-associated coiled-coil containing protein kinase 1	Rattus norvegicus	133-137
18929863-1	2008	AIM: We sought to investigate the effects of mycophenolate mofetil (MMF) on chronic allograft nephropathy (CAN) by affecting Rho and ROCK signal pathways.	Mycophenolic Acid	68-71	Rho-associated coiled-coil containing protein kinase 1	Rattus norvegicus	133-137
18651539-4	2008	This review focuses on the polymorphism of genes that encode enzymes of the uridino-glucuronosyltransferase (UGT) family, responsible for the bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF), used as an immunosuppressant in solid organ transplantation.	Mycophenolic Acid	161-178	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	76-107
18946610-1	2008	INTRODUCTION: The aim of this study was to determine the effectiveness of mycophenolate mofetil (MMF) in IgA nephropathy (IgAN).	Mycophenolic Acid	74-95	IGAN1	Homo sapiens	105-120
18946610-1	2008	INTRODUCTION: The aim of this study was to determine the effectiveness of mycophenolate mofetil (MMF) in IgA nephropathy (IgAN).	Mycophenolic Acid	74-95	IGAN1	Homo sapiens	122-126
18946610-1	2008	INTRODUCTION: The aim of this study was to determine the effectiveness of mycophenolate mofetil (MMF) in IgA nephropathy (IgAN).	Mycophenolic Acid	97-100	IGAN1	Homo sapiens	105-120
18946610-1	2008	INTRODUCTION: The aim of this study was to determine the effectiveness of mycophenolate mofetil (MMF) in IgA nephropathy (IgAN).	Mycophenolic Acid	97-100	IGAN1	Homo sapiens	122-126
18515331-4	2008	Glucuronidation activity for mycophenolic acid, a substrate for rat UGT1A1, 1A6, and 1A7, was significantly elevated approximately 2-fold in renal microsomes from testosterone propionate-treated animals.	Mycophenolic Acid	29-46	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	68-74
18628958-7	2008	In this regard, we used a specific IMPDH inhibitor mycophenolic acid (MPA) and found that MPA dramatically inhibits c-Myc-induced P493-6 cell proliferation through S-phase arrest and apoptosis.	Mycophenolic Acid	51-68	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	116-121
18622297-2	2008	We describe a case of a 47-year-old African American man with end-stage renal disease secondary to HIV-induced nephropathy who underwent a live unrelated (spouse) donor ABO blood group incompatible transplant using an intravenous immunoglobulin/plasmapheresis preconditioning regimen with interleukin-2 receptor antagonist induction along with tacrolimus and mycophenolate mofetil maintenance.	Mycophenolic Acid	359-380	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	169-172
18725182-0	2008	Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy.	Mycophenolic Acid	41-62	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	0-7
18725182-0	2008	Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy.	Mycophenolic Acid	41-62	NPHS2 stomatin family member, podocin	Rattus norvegicus	12-19
18463325-14	2008	Absolute lymphocyte counts decreased significantly in patients with eGFR < 60 ml/min/1.73 m(2) after 3 months of MMF treatment compared to the counts before MMF was initiated (1.71 +/- 0.23 versus 2.43 +/- 0.17 x 10(9)/l, P = 0.04).	Mycophenolic Acid	116-119	epidermal growth factor receptor	Homo sapiens	68-72
18463325-14	2008	Absolute lymphocyte counts decreased significantly in patients with eGFR < 60 ml/min/1.73 m(2) after 3 months of MMF treatment compared to the counts before MMF was initiated (1.71 +/- 0.23 versus 2.43 +/- 0.17 x 10(9)/l, P = 0.04).	Mycophenolic Acid	160-163	epidermal growth factor receptor	Homo sapiens	68-72
18724224-0	2008	Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium.	Mycophenolic Acid	89-109	erythropoietin	Homo sapiens	13-27
18724224-11	2008	DISCUSSION: Conversion from SRL to enteric coated mycophenolate sodium led to an increase in Hb and a decrease in erythropoietin resistance in stable kidney transplant recipients.	Mycophenolic Acid	50-70	erythropoietin	Homo sapiens	114-128
18641546-3	2008	This conversion of MPA to AcylMPAG is catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7).	Mycophenolic Acid	19-22	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	51-82
18641546-3	2008	This conversion of MPA to AcylMPAG is catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7).	Mycophenolic Acid	19-22	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	84-90
18651539-4	2008	This review focuses on the polymorphism of genes that encode enzymes of the uridino-glucuronosyltransferase (UGT) family, responsible for the bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF), used as an immunosuppressant in solid organ transplantation.	Mycophenolic Acid	228-231	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	76-107
18651539-4	2008	This review focuses on the polymorphism of genes that encode enzymes of the uridino-glucuronosyltransferase (UGT) family, responsible for the bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF), used as an immunosuppressant in solid organ transplantation.	Mycophenolic Acid	228-231	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	109-112
18651539-4	2008	This review focuses on the polymorphism of genes that encode enzymes of the uridino-glucuronosyltransferase (UGT) family, responsible for the bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF), used as an immunosuppressant in solid organ transplantation.	Mycophenolic Acid	161-178	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	109-112
18651539-4	2008	This review focuses on the polymorphism of genes that encode enzymes of the uridino-glucuronosyltransferase (UGT) family, responsible for the bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF), used as an immunosuppressant in solid organ transplantation.	Mycophenolic Acid	205-226	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	76-107
18651539-4	2008	This review focuses on the polymorphism of genes that encode enzymes of the uridino-glucuronosyltransferase (UGT) family, responsible for the bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF), used as an immunosuppressant in solid organ transplantation.	Mycophenolic Acid	205-226	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	109-112
18709005-0	2008	Clinical importance of insulin resistance after renal transplantation in patients on triple immunosuppressive therapy with cyclosporine, corticosteroids and mycophenolate mofetil.	Mycophenolic Acid	157-178	insulin	Homo sapiens	23-30
18586494-0	2008	The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice.	Mycophenolic Acid	41-58	prolactin family 2, subfamily c, member 3	Mus musculus	33-37
18597651-1	2008	UNLABELLED: We previously reported that polymorphisms in the UGT2B7 and UGT1A9 genes are associated with significant alteration in the disposition of mycophenolic acid (MPA) in healthy volunteers.	Mycophenolic Acid	169-172	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	72-78
18282242-0	2008	Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.	Mycophenolic Acid	110-131	calcineurin binding protein 1	Homo sapiens	0-21
18597651-1	2008	UNLABELLED: We previously reported that polymorphisms in the UGT2B7 and UGT1A9 genes are associated with significant alteration in the disposition of mycophenolic acid (MPA) in healthy volunteers.	Mycophenolic Acid	150-167	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	61-67
18597651-1	2008	UNLABELLED: We previously reported that polymorphisms in the UGT2B7 and UGT1A9 genes are associated with significant alteration in the disposition of mycophenolic acid (MPA) in healthy volunteers.	Mycophenolic Acid	150-167	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	72-78
18597651-1	2008	UNLABELLED: We previously reported that polymorphisms in the UGT2B7 and UGT1A9 genes are associated with significant alteration in the disposition of mycophenolic acid (MPA) in healthy volunteers.	Mycophenolic Acid	169-172	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	61-67
18418858-0	2008	Insulin-like growth factor I improves aspects of mycophenolate mofetil-impaired anastomotic healing in an experimental model.	Mycophenolic Acid	49-70	insulin-like growth factor 1	Rattus norvegicus	0-28
18547238-1	2008	We have evaluated the use of the immunosuppressant mycophenolate mofetil (MMF) in the treatment of severe insulin resistance caused by neutralising anti-insulin antibodies in type 1 diabetes mellitus (T1DM).	Mycophenolic Acid	51-72	insulin	Homo sapiens	106-113
18538114-0	2008	Mycophenolate mofetil in anti-MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity.	Mycophenolic Acid	0-21	myeloperoxidase	Homo sapiens	30-33
18408053-6	2008	Disruption of RTR1 resulted in mycophenolic acid sensitivity and synthetic genetic interactions with a number of genes involved in multiple phases of transcription.	Mycophenolic Acid	31-48	RNA polymerase II subunit B1 CTD phosphatase RTR1	Saccharomyces cerevisiae S288C	14-18
18547238-1	2008	We have evaluated the use of the immunosuppressant mycophenolate mofetil (MMF) in the treatment of severe insulin resistance caused by neutralising anti-insulin antibodies in type 1 diabetes mellitus (T1DM).	Mycophenolic Acid	51-72	insulin	Homo sapiens	153-160
18547238-1	2008	We have evaluated the use of the immunosuppressant mycophenolate mofetil (MMF) in the treatment of severe insulin resistance caused by neutralising anti-insulin antibodies in type 1 diabetes mellitus (T1DM).	Mycophenolic Acid	74-77	insulin	Homo sapiens	106-113
18547238-1	2008	We have evaluated the use of the immunosuppressant mycophenolate mofetil (MMF) in the treatment of severe insulin resistance caused by neutralising anti-insulin antibodies in type 1 diabetes mellitus (T1DM).	Mycophenolic Acid	74-77	insulin	Homo sapiens	153-160
18305114-0	2008	Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11.	Mycophenolic Acid	0-17	tumor protein p53	Homo sapiens	32-35
18448283-9	2008	LPL activity in post-heparin normal human plasma was suppressed following the co-incubation with CsA, RAPA, FK-506 or MMF whereas HL activity remained unaffected.	Mycophenolic Acid	118-121	lipoprotein lipase	Homo sapiens	0-3
17851563-1	2008	Inosine 5"-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA).	Mycophenolic Acid	179-196	inosine monophosphate dehydrogenase 1	Homo sapiens	0-40
17851563-1	2008	Inosine 5"-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA).	Mycophenolic Acid	179-196	inosine monophosphate dehydrogenase 1	Homo sapiens	42-48
17851563-1	2008	Inosine 5"-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA).	Mycophenolic Acid	198-201	inosine monophosphate dehydrogenase 1	Homo sapiens	0-40
17851563-1	2008	Inosine 5"-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA).	Mycophenolic Acid	198-201	inosine monophosphate dehydrogenase 1	Homo sapiens	42-48
18305114-0	2008	Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11.	Mycophenolic Acid	0-17	ribosomal protein L11	Homo sapiens	45-74
18315786-1	2008	OBJECTIVE: The aim of this study was to investigate drug interactions between mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF) and tacrolimus, as well as the impact of CYP3A5 and UGT2B7 genetic polymorphisms on these drug interactions in 71 Japanese renal transplant recipients.	Mycophenolic Acid	97-100	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	197-203
18315786-1	2008	OBJECTIVE: The aim of this study was to investigate drug interactions between mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF) and tacrolimus, as well as the impact of CYP3A5 and UGT2B7 genetic polymorphisms on these drug interactions in 71 Japanese renal transplant recipients.	Mycophenolic Acid	97-100	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	208-214
18374103-2	2008	Although inosine monophosphate dehydrogenase 2 (IMPDH2), as a target of mycophenolic acid (MPA), is important for de novo guanosine synthesis in lymphocytes, mesenchymal cells are not wholly dependent on it.	Mycophenolic Acid	72-89	inosine monophosphate dehydrogenase 2	Mus musculus	9-46
18454990-4	2008	Maintenance immunosuppression consisted in the use of a calcineurin inhibitor in association with mycophenolic acid.	Mycophenolic Acid	98-115	calcineurin binding protein 1	Homo sapiens	56-77
18454993-0	2008	Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients.	Mycophenolic Acid	58-79	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	13-40
18454993-2	2008	Its active metabolite, mycophenolic acid, is mainly metabolized by UDP-glucuronosyltransferase (UGT) enzymes.	Mycophenolic Acid	23-40	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	67-94
18454993-2	2008	Its active metabolite, mycophenolic acid, is mainly metabolized by UDP-glucuronosyltransferase (UGT) enzymes.	Mycophenolic Acid	23-40	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	96-99
18374103-2	2008	Although inosine monophosphate dehydrogenase 2 (IMPDH2), as a target of mycophenolic acid (MPA), is important for de novo guanosine synthesis in lymphocytes, mesenchymal cells are not wholly dependent on it.	Mycophenolic Acid	72-89	inosine monophosphate dehydrogenase 2	Mus musculus	48-54
18374103-2	2008	Although inosine monophosphate dehydrogenase 2 (IMPDH2), as a target of mycophenolic acid (MPA), is important for de novo guanosine synthesis in lymphocytes, mesenchymal cells are not wholly dependent on it.	Mycophenolic Acid	91-94	inosine monophosphate dehydrogenase 2	Mus musculus	9-46
18374103-2	2008	Although inosine monophosphate dehydrogenase 2 (IMPDH2), as a target of mycophenolic acid (MPA), is important for de novo guanosine synthesis in lymphocytes, mesenchymal cells are not wholly dependent on it.	Mycophenolic Acid	91-94	inosine monophosphate dehydrogenase 2	Mus musculus	48-54
18374104-0	2008	Effects of mycophenolic Acid on high glucose-induced fibronectin secretion and cellular reactive oxygen species in rat vascular smooth muscle cells.	Mycophenolic Acid	11-28	fibronectin 1	Rattus norvegicus	53-64
17908922-0	2008	Glucuronidation of mycophenolic acid by Wistar and Mrp2-deficient TR- rat liver microsomes.	Mycophenolic Acid	19-36	ATP binding cassette subfamily C member 2	Rattus norvegicus	51-55
18751501-1	2008	A sensitive and selective high-performance liquid chromatographic-ultraviolet (HPLC-UV) method for the determination of mycophenolic acid (MPA, CAS 24280-93-1) in human plasma has been developed.	Mycophenolic Acid	120-137	BCAR1 scaffold protein, Cas family member	Homo sapiens	144-147
18431231-2	2008	The aim of this study was to assess the incidence of PTA 1 year after transplantation in patients treated with calcineurin inhibitors and mycophenolate mofetil, and to determine the impact of 1-year PTA upon long-term patient and graft survival.	Mycophenolic Acid	138-159	CD226 molecule	Homo sapiens	53-58
17713475-1	2008	The objective of the study was to evaluate the effect of mycophenolate mofetil (MMF) on the regulation of inosine monophosphate dehydrogenase (IMPDH) during the first 2 years after renal transplantation.	Mycophenolic Acid	57-78	inosine monophosphate dehydrogenase 1	Homo sapiens	143-148
17713475-1	2008	The objective of the study was to evaluate the effect of mycophenolate mofetil (MMF) on the regulation of inosine monophosphate dehydrogenase (IMPDH) during the first 2 years after renal transplantation.	Mycophenolic Acid	80-83	inosine monophosphate dehydrogenase 1	Homo sapiens	143-148
18192912-10	2008	Two weeks posttransplant, MPA-treated patients displayed elevated IMPDH 1 and 2 in reticulocytes, suggesting enzyme induction in these cells during prolonged MPA therapy.	Mycophenolic Acid	26-29	inosine monophosphate dehydrogenase 1	Homo sapiens	66-79
18578558-6	2008	Because de novo immunosuppression uses CNI in more than 93% of patients, reduction of CNI-related adverse effects has focused on CNI sparing or withdrawal.A recurring theme where sirolimus and mycophenolate mofetil have been used for this purpose is the importance of their early introduction to limit CNI damage and provide long-term benefit: for example, long-term renal function critically reflects that at 1 year post-transplant.	Mycophenolic Acid	193-214	5'-nucleotidase, cytosolic IA	Homo sapiens	39-42
18578558-6	2008	Because de novo immunosuppression uses CNI in more than 93% of patients, reduction of CNI-related adverse effects has focused on CNI sparing or withdrawal.A recurring theme where sirolimus and mycophenolate mofetil have been used for this purpose is the importance of their early introduction to limit CNI damage and provide long-term benefit: for example, long-term renal function critically reflects that at 1 year post-transplant.	Mycophenolic Acid	193-214	5'-nucleotidase, cytosolic IA	Homo sapiens	86-89
18578558-6	2008	Because de novo immunosuppression uses CNI in more than 93% of patients, reduction of CNI-related adverse effects has focused on CNI sparing or withdrawal.A recurring theme where sirolimus and mycophenolate mofetil have been used for this purpose is the importance of their early introduction to limit CNI damage and provide long-term benefit: for example, long-term renal function critically reflects that at 1 year post-transplant.	Mycophenolic Acid	193-214	5'-nucleotidase, cytosolic IA	Homo sapiens	86-89
17906856-1	2007	OBJECTIVE: We investigated the association between mycophenolic acid (MPA) pharmacokinetics and organic anion-transporting polypeptide (OATP/SLCO)1B1, 1B3, 2B1 and multidrug resistance-association protein 2 (MRP2/ABCC2) genetic polymorphisms and diarrhea.	Mycophenolic Acid	51-68	solute carrier organic anion transporter family member 1A2	Homo sapiens	136-140
17662475-5	2007	The replicon cells were subjected to treatment with several antiviral compounds and inhibition of the replicon was observed in treatment with known nucleoside analog inhibitors of NS5 such as 2"-C-methyladenosine (EC(50)=2.42 +/- 0.59 microM), or ribavirin (EC(50)=6.77 +/- 1.33 microM), mycophenolic acid (EC(50)=1.31 +/- 0.27 microM) and siRNA against NS3.	Mycophenolic Acid	288-305	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	180-183
17906856-1	2007	OBJECTIVE: We investigated the association between mycophenolic acid (MPA) pharmacokinetics and organic anion-transporting polypeptide (OATP/SLCO)1B1, 1B3, 2B1 and multidrug resistance-association protein 2 (MRP2/ABCC2) genetic polymorphisms and diarrhea.	Mycophenolic Acid	70-73	solute carrier organic anion transporter family member 1A2	Homo sapiens	136-140
17910648-13	2007	Similarly, SBP and DBP trended higher and CHOL was significantly higher in patients receiving SRL vs. mycophenolate mofetil.	Mycophenolic Acid	102-123	selenium binding protein 1	Homo sapiens	11-14
17805303-4	2007	One gene is a variant of the inosine monophosphate dehydrogenase 2, inosine monophosphate dehydrogenase (IMPDH(IY)), conferring resistance to the immunosuppressive drug mycophenolate mofetil (MMF).	Mycophenolic Acid	169-190	inosine monophosphate dehydrogenase 2	Homo sapiens	29-66
17805303-4	2007	One gene is a variant of the inosine monophosphate dehydrogenase 2, inosine monophosphate dehydrogenase (IMPDH(IY)), conferring resistance to the immunosuppressive drug mycophenolate mofetil (MMF).	Mycophenolic Acid	192-195	inosine monophosphate dehydrogenase 2	Homo sapiens	29-66
18217899-7	2008	RESULTS: Calcineurin inhibitor minimization using mycophenolate mofetil or sirolimus may be associated with a modest increase in creatinine clearance (CrCl) and a decrease in serum creatinine (SCr) in the short term.	Mycophenolic Acid	50-71	calcineurin binding protein 1	Homo sapiens	9-30
17609423-4	2007	Administration of a 3-drug regimen consisting of mycophenolate mofetil (MMF), sirolimus, and the anti-IL-2 receptor antibody daclizumab consistently resulted in formation of inhibitory antibodies to human F.IX following hepatic artery administration of an AAV-hF.IX vector, whereas a 2-drug regimen consisting only of MMF and sirolimus did not.	Mycophenolic Acid	318-321	interleukin 2 receptor subunit beta	Homo sapiens	102-115
17618115-0	2007	Mycophenolic acid as a latent agonist of PPARgamma.	Mycophenolic Acid	0-17	peroxisome proliferator activated receptor gamma	Homo sapiens	41-50
17526543-11	2007	Human OAT3, but not hOAT1, was additionally inhibited by both glucuronide metabolites of MPA in a concentration-dependent manner (IC50 15.2 microM for MPAG and 2.88 microM for AcMPAG), consistent with a preference of hOAT3 for more bulky substrates compared with hOAT1.	Mycophenolic Acid	89-92	solute carrier family 22 member 8	Homo sapiens	6-10
17526543-11	2007	Human OAT3, but not hOAT1, was additionally inhibited by both glucuronide metabolites of MPA in a concentration-dependent manner (IC50 15.2 microM for MPAG and 2.88 microM for AcMPAG), consistent with a preference of hOAT3 for more bulky substrates compared with hOAT1.	Mycophenolic Acid	89-92	solute carrier family 22 member 8	Homo sapiens	217-222
17526543-11	2007	Human OAT3, but not hOAT1, was additionally inhibited by both glucuronide metabolites of MPA in a concentration-dependent manner (IC50 15.2 microM for MPAG and 2.88 microM for AcMPAG), consistent with a preference of hOAT3 for more bulky substrates compared with hOAT1.	Mycophenolic Acid	89-92	solute carrier family 22 member 6	Homo sapiens	263-268
17924828-0	2007	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.	Mycophenolic Acid	78-95	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	35-41
17924828-1	2007	INTRODUCTION: The immunosuppressive agent mycophenolic acid (MPA) is metabolized by uridine diphosphate glucuronosyltransferase 1A9 (UGT1A9) to 7-O-glucuronide (MPAG) and excreted by multidrug resistance-associated protein 2 in the bile.	Mycophenolic Acid	42-59	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	133-139
17924828-1	2007	INTRODUCTION: The immunosuppressive agent mycophenolic acid (MPA) is metabolized by uridine diphosphate glucuronosyltransferase 1A9 (UGT1A9) to 7-O-glucuronide (MPAG) and excreted by multidrug resistance-associated protein 2 in the bile.	Mycophenolic Acid	61-64	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	133-139
17532750-1	2007	The aim of this study was to determine whether plasma concentrations of the acyl (AcMPAG) and phenolic (MPAG) glucuronide metabolites of mycophenolic acid (MPA) were related to diarrhoea in renal transplant patients on mycophenolate mofetil (MMF) with cyclosporine (CsA) or tacrolimus (TCL).	Mycophenolic Acid	137-154	ras homolog family member J	Homo sapiens	286-289
17462604-0	2007	Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3.	Mycophenolic Acid	45-62	solute carrier family 22 member 6	Homo sapiens	120-125
17462604-0	2007	Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3.	Mycophenolic Acid	45-62	solute carrier family 22 member 8	Homo sapiens	130-135
17463174-10	2007	Changes in IMPDH1 and 2 expression were observed in patient samples after initiation of an immunosuppressive regimen that included calcineurin inhibitors, mycophenolate mofetil, and steroids.	Mycophenolic Acid	155-176	inosine monophosphate dehydrogenase 1	Homo sapiens	11-23
17429314-1	2007	INTRODUCTION: The polymorphic enzyme UGT2B7 metabolizes mycophenolic acid into acyl-mycophenolic acid-glucuronide (AcMPAG), a presumably toxic metabolite.	Mycophenolic Acid	56-73	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	37-43
17529886-1	2007	UGT1A7 and UGT1A9 are uridine diphosphate-glucuronosyltransferase isoforms involved in the glucuronidation of mycophenolic acid (MPA).	Mycophenolic Acid	110-127	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	0-6
17529886-1	2007	UGT1A7 and UGT1A9 are uridine diphosphate-glucuronosyltransferase isoforms involved in the glucuronidation of mycophenolic acid (MPA).	Mycophenolic Acid	110-127	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	11-17
17529886-1	2007	UGT1A7 and UGT1A9 are uridine diphosphate-glucuronosyltransferase isoforms involved in the glucuronidation of mycophenolic acid (MPA).	Mycophenolic Acid	129-132	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	0-6
17529886-1	2007	UGT1A7 and UGT1A9 are uridine diphosphate-glucuronosyltransferase isoforms involved in the glucuronidation of mycophenolic acid (MPA).	Mycophenolic Acid	129-132	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	11-17
17429314-2	2007	This study aimed at investigating in vitro and in vivo the impact on AcMPAG production of: (i) the UGT2B7 gene G-842A single nucleotide polymorphism, in complete linkage disequilibrium with most other known single nucleotide polymorphisms in the promoter region of this gene and with the C802T single nucleotide polymorphism in exon 2 (UGT2B*2); and (ii) of the other immunosuppressants given to renal transplant patients in association with mycophenolate mofetil.	Mycophenolic Acid	442-463	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	99-105
17598423-5	2007	We start from the assumption that the concomitant use of cyclosporin with mycophenolate mofetil and lamivudine, despite normal concentrations of cyclosporin, might cause the accumulation of toxic metabolites and lead to neurotoxicity that mimics PML in a chronic viral environment.	Mycophenolic Acid	74-95	PML nuclear body scaffold	Homo sapiens	246-249
17235550-8	2007	At the age of 14 years, mycophenolate mofetil (MMF) was added to the maintenance therapy and the CSA dosage was reduced.	Mycophenolic Acid	24-45	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	97-100
17496727-2	2007	Variants in the IMPDH2 gene may account for the large inter-individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving mycophenolic acid.	Mycophenolic Acid	191-208	inosine monophosphate dehydrogenase 2	Homo sapiens	16-22
17284993-4	2007	Novel immunosuppressive regimens including mycophenolate mofetil and/or rapamycin that lack nephrotoxicity promise new therapeutic strategies with the efficacy of calcineurin inhibitor-based combinations.	Mycophenolic Acid	43-64	calcineurin binding protein 1	Homo sapiens	163-184
17211619-0	2007	Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.	Mycophenolic Acid	56-73	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	24-30
17339869-0	2007	The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.	Mycophenolic Acid	97-114	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	14-20
17339869-0	2007	The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.	Mycophenolic Acid	97-114	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	34-40
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	150-167	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	40-46
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	150-167	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	48-54
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	150-167	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	60-66
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	110-113	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	40-46
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	110-113	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	48-54
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	110-113	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	60-66
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	237-258	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	40-46
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	237-258	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	60-66
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	260-263	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	40-46
17339869-1	2007	We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs).	Mycophenolic Acid	260-263	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	60-66
17211619-1	2007	OBJECTIVE: UGT1A8 and UGT2B7 are important uridine diphosphate-glucuronosyltransferase isoforms for the glucuronidation of mycophenolic acid (MPA).	Mycophenolic Acid	123-140	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	11-17
17211619-1	2007	OBJECTIVE: UGT1A8 and UGT2B7 are important uridine diphosphate-glucuronosyltransferase isoforms for the glucuronidation of mycophenolic acid (MPA).	Mycophenolic Acid	123-140	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	22-28
17211619-1	2007	OBJECTIVE: UGT1A8 and UGT2B7 are important uridine diphosphate-glucuronosyltransferase isoforms for the glucuronidation of mycophenolic acid (MPA).	Mycophenolic Acid	142-145	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	11-17
17211619-1	2007	OBJECTIVE: UGT1A8 and UGT2B7 are important uridine diphosphate-glucuronosyltransferase isoforms for the glucuronidation of mycophenolic acid (MPA).	Mycophenolic Acid	142-145	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	22-28
17220790-9	2007	Mean CRP level was 5.18+/-5.7 mg/L in patients not taking MMF compared with 3.13+/-3.5 mg/L in those on 2000 mg per day (P=0.002).	Mycophenolic Acid	58-61	C-reactive protein	Homo sapiens	5-8
17258688-0	2007	Alterations in cytoskeletal protein expression by mycophenolic acid in human mesangial cells requires Rac inactivation.	Mycophenolic Acid	50-67	AKT serine/threonine kinase 1	Homo sapiens	102-105
17133564-1	2006	UNLABELLED: The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk.	Mycophenolic Acid	54-75	calcineurin binding protein 1	Homo sapiens	148-169
17060520-6	2007	Mycophenolic acid (MPA), an inhibitor of IMP dehydrogenase, also resulted in a decrease in vRNA levels; however, treatment with MPA resulted in a much greater decrease in GTP levels than that seen with RBV.	Mycophenolic Acid	0-17	vault RNA 1-1	Homo sapiens	91-95
17060520-6	2007	Mycophenolic acid (MPA), an inhibitor of IMP dehydrogenase, also resulted in a decrease in vRNA levels; however, treatment with MPA resulted in a much greater decrease in GTP levels than that seen with RBV.	Mycophenolic Acid	19-22	vault RNA 1-1	Homo sapiens	91-95
17302598-0	2007	Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.	Mycophenolic Acid	94-102	calcineurin binding protein 1	Homo sapiens	109-130
17302598-16	2007	CONCLUSION: Early steroid-withdrawal in renal transplant recipients with a sirolimus and CellCept-based calcineurin inhibitor-minimimization protocol can effectively reduce many of the steroid-related side effects, decrease risk factors for cardiovascular disease, and is associated with improved recipient survival without compromising graft function.	Mycophenolic Acid	89-97	calcineurin binding protein 1	Homo sapiens	104-125
17101843-0	2007	Mycophenolic acid is a new Nox2 inhibitor.	Mycophenolic Acid	0-17	cytochrome b-245 beta chain	Homo sapiens	27-31
17498396-0	2007	Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form.	Mycophenolic Acid	39-56	ATP binding cassette subfamily C member 2	Homo sapiens	127-131
17498396-0	2007	Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form.	Mycophenolic Acid	58-61	ATP binding cassette subfamily C member 2	Homo sapiens	127-131
16868307-1	2006	Transient administration of ANG II causes persistent salt-sensitive hypertension associated with arteriolopathy, interstitial inflammation, and cortical vasoconstriction; blocking the vascular and inflammatory changes with mycophenolate mofetil (MMF) prevents vasoconstriction.	Mycophenolic Acid	223-244	angiotensinogen	Rattus norvegicus	28-34
16868307-1	2006	Transient administration of ANG II causes persistent salt-sensitive hypertension associated with arteriolopathy, interstitial inflammation, and cortical vasoconstriction; blocking the vascular and inflammatory changes with mycophenolate mofetil (MMF) prevents vasoconstriction.	Mycophenolic Acid	246-249	angiotensinogen	Rattus norvegicus	28-34
17133564-1	2006	UNLABELLED: The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk.	Mycophenolic Acid	54-75	calcineurin binding protein 1	Homo sapiens	171-174
17133564-1	2006	UNLABELLED: The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk.	Mycophenolic Acid	77-80	calcineurin binding protein 1	Homo sapiens	148-169
17133564-1	2006	UNLABELLED: The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk.	Mycophenolic Acid	77-80	calcineurin binding protein 1	Homo sapiens	171-174
17097956-7	2006	The target range levels between 5 and 10 ng/mL seemed to be sufficient for complete CNI elimination, especially in patients also receiving antiproliferative drugs (such as mycophenolate mofetil or azathioprine) in whom levels near the lower end of the range might be adequate.	Mycophenolic Acid	172-193	calcineurin binding protein 1	Homo sapiens	84-87
16790554-0	2006	Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid.	Mycophenolic Acid	137-154	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	44-50
16790554-0	2006	Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid.	Mycophenolic Acid	137-154	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	55-61
16790558-10	2006	Studies are ongoing to investigate the relationship between intestinal UGT1A enzymes and susceptibility to MMF-induced gastrointestinal toxicity.	Mycophenolic Acid	107-110	Ugt1a@	Rattus norvegicus	71-76
17495435-13	2007	The role of mycophenolate mofetil (MMF) in IgAN has been examined in four major trials.	Mycophenolic Acid	35-38	IGAN1	Homo sapiens	43-47
17112807-1	2006	BACKGROUND: Exposure to mycophenolic acid (MPA) and its main metabolites (MPA 7-O-glucuronide [MPAG] and MPA acyl-glucuronide [AcMPAG]) is characterized by a large interindividual and intraindividual variability, resulting in part from variability in glucuronidation (via uridine diphosphate-glucuronosyltransferase isoforms) and excretion via multidrug resistance-associated protein 2 (MRP2).	Mycophenolic Acid	24-41	ATP binding cassette subfamily C member 2	Homo sapiens	344-385
17112807-1	2006	BACKGROUND: Exposure to mycophenolic acid (MPA) and its main metabolites (MPA 7-O-glucuronide [MPAG] and MPA acyl-glucuronide [AcMPAG]) is characterized by a large interindividual and intraindividual variability, resulting in part from variability in glucuronidation (via uridine diphosphate-glucuronosyltransferase isoforms) and excretion via multidrug resistance-associated protein 2 (MRP2).	Mycophenolic Acid	24-41	ATP binding cassette subfamily C member 2	Homo sapiens	387-391
17112807-12	2006	CONCLUSION: This study demonstrates an interaction between mycophenolate mofetil and rifampin, which is a result of induction of MPA glucuronidation and possibly also rifampin-associated alterations in MRP2-mediated transport of MPAG and AcMPAG.	Mycophenolic Acid	59-80	ATP binding cassette subfamily C member 2	Homo sapiens	202-206
17038874-0	2006	Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.	Mycophenolic Acid	115-132	CD4 molecule	Homo sapiens	71-74
16740277-0	2006	Mycophenolic acid inhibits mesangial cell activation through p38 MAPK inhibition.	Mycophenolic Acid	0-17	mitogen activated protein kinase 14	Rattus norvegicus	61-64
16740277-0	2006	Mycophenolic acid inhibits mesangial cell activation through p38 MAPK inhibition.	Mycophenolic Acid	0-17	mitogen activated protein kinase 3	Rattus norvegicus	65-69
16763095-4	2006	Mycophenolic acid, the active metabolite of the anti-transplant rejection drug mycophenolate mofetil and suspected gastrointestinal toxicant, was used as a model UGT1A-dependent substrate.	Mycophenolic Acid	0-17	Ugt1a@	Rattus norvegicus	162-167
16763095-5	2006	Treatment with UGT1A adenoviruses normalized the plasma mycophenolic acid and 7-O-mycophenolate glucuronide (MPAG) (concentration-time curves after mycophenolic acid administration (80 mg/kg intraperitoneally).	Mycophenolic Acid	56-73	Ugt1a@	Rattus norvegicus	15-20
16763095-5	2006	Treatment with UGT1A adenoviruses normalized the plasma mycophenolic acid and 7-O-mycophenolate glucuronide (MPAG) (concentration-time curves after mycophenolic acid administration (80 mg/kg intraperitoneally).	Mycophenolic Acid	148-165	Ugt1a@	Rattus norvegicus	15-20
16763095-11	2006	The ability to selectively manipulate multiple hepatic UGT1A enzymes in Gunn rats should provide a novel way to assess the importance of intestinal or other extrahepatic UGT1A enzymes in toxicities induced by mycophenolic acid and other cytotoxic drugs and dietary agents.	Mycophenolic Acid	209-226	Ugt1a@	Rattus norvegicus	55-60
16980051-0	2006	Comparison of cyclosporine versus mycophenolate mofetil on expression of Fractalkine and CX3CR1 in chronic allograft nephropathy.	Mycophenolic Acid	34-55	C-X3-C motif chemokine ligand 1	Rattus norvegicus	73-84
16980051-0	2006	Comparison of cyclosporine versus mycophenolate mofetil on expression of Fractalkine and CX3CR1 in chronic allograft nephropathy.	Mycophenolic Acid	34-55	C-X3-C motif chemokine receptor 1	Rattus norvegicus	89-95
16980051-1	2006	INTRODUCTION: We sought to investigate whether there was a difference between cyclosporine (CsA) and mycophenolate mofetil (MMF) to affect the expression of Fractalkine/CX3CR1 in chronic allograft nephropathy (CAN).	Mycophenolic Acid	101-122	C-X3-C motif chemokine ligand 1	Rattus norvegicus	157-168
16980051-1	2006	INTRODUCTION: We sought to investigate whether there was a difference between cyclosporine (CsA) and mycophenolate mofetil (MMF) to affect the expression of Fractalkine/CX3CR1 in chronic allograft nephropathy (CAN).	Mycophenolic Acid	101-122	C-X3-C motif chemokine receptor 1	Rattus norvegicus	169-175
16980051-1	2006	INTRODUCTION: We sought to investigate whether there was a difference between cyclosporine (CsA) and mycophenolate mofetil (MMF) to affect the expression of Fractalkine/CX3CR1 in chronic allograft nephropathy (CAN).	Mycophenolic Acid	124-127	C-X3-C motif chemokine ligand 1	Rattus norvegicus	157-168
16980051-1	2006	INTRODUCTION: We sought to investigate whether there was a difference between cyclosporine (CsA) and mycophenolate mofetil (MMF) to affect the expression of Fractalkine/CX3CR1 in chronic allograft nephropathy (CAN).	Mycophenolic Acid	124-127	C-X3-C motif chemokine receptor 1	Rattus norvegicus	169-175
16830106-10	2006	Renal overexpression of ICAM-1 was not retarded by enalapril and attenuated by MMF or combined enalapril with MMF.	Mycophenolic Acid	79-82	intercellular adhesion molecule 1	Rattus norvegicus	24-30
17048204-0	2006	Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy.	Mycophenolic Acid	0-17	IGAN1	Homo sapiens	71-86
16704434-3	2006	We introduced a third immunosuppressive agent to standard h-ATG/CsA, mycophenolate mofetil (MMF), in an attempt to improve the response rate and survival, and to decrease the relapse rate and clonal evolution to myelodysplasia.	Mycophenolic Acid	69-90	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	64-67
16797370-0	2006	Mycophenolic acid upregulates B7-DC expression on dendritic cells, which is associated with impaired allostimulatory capacity of dendritic cells.	Mycophenolic Acid	0-17	programmed cell death 1 ligand 2	Mus musculus	30-35
16830106-12	2006	CONCLUSION: The combination of enalapril and MMF confers superiority over monotherapy in renoprotection, a mechanism which may be at least partly correlated with synergistic suppression of increased macrophage recruitment and overexpression of MCP-1 and TGF-beta1 in renal tissue in diabetic rats.	Mycophenolic Acid	45-48	C-C motif chemokine ligand 2	Rattus norvegicus	244-249
16830106-12	2006	CONCLUSION: The combination of enalapril and MMF confers superiority over monotherapy in renoprotection, a mechanism which may be at least partly correlated with synergistic suppression of increased macrophage recruitment and overexpression of MCP-1 and TGF-beta1 in renal tissue in diabetic rats.	Mycophenolic Acid	45-48	transforming growth factor, beta 1	Rattus norvegicus	254-263
16303017-0	2005	Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.	Mycophenolic Acid	41-62	5'-nucleotidase, cytosolic IA	Homo sapiens	79-82
16545729-1	2006	We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m(2), 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally.	Mycophenolic Acid	290-311	colony stimulating factor 3	Homo sapiens	113-150
16545729-1	2006	We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m(2), 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally.	Mycophenolic Acid	313-316	colony stimulating factor 3	Homo sapiens	113-150
17048977-12	2006	CONCLUSION: This study presents an accurate population pharmacokinetic model showing the significant influence of the CYP3A5*1/*3 polymorphism on sirolimus apparent oral clearance, and a Bayesian estimator accurately predicting sirolimus pharmacokinetics in patients co-administered mycophenolate mofetil, but no calcineurin inhibitor.	Mycophenolic Acid	283-304	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	118-124
16263818-15	2006	Surprisingly, all APECED-related symptoms including candidiasis and autoantibody levels decreased, presumably due to the reinforced immunosuppression (tacrolimus, mycophenolate mofetil, prednisone).	Mycophenolic Acid	163-184	autoimmune regulator	Homo sapiens	18-24
17065099-1	2006	The efficiency of Mycophenolate mofetil (MMF) and Azathioprine (AZA) as immunosuppressive agents depends on the activity of 2 enzymes, inosine monophosphate dehydrogenase (IMPDH) and thiopurine methyltransferase (TPMT) respectively.	Mycophenolic Acid	18-39	thiopurine S-methyltransferase	Homo sapiens	183-211
17065099-1	2006	The efficiency of Mycophenolate mofetil (MMF) and Azathioprine (AZA) as immunosuppressive agents depends on the activity of 2 enzymes, inosine monophosphate dehydrogenase (IMPDH) and thiopurine methyltransferase (TPMT) respectively.	Mycophenolic Acid	18-39	thiopurine S-methyltransferase	Homo sapiens	213-217
17065099-1	2006	The efficiency of Mycophenolate mofetil (MMF) and Azathioprine (AZA) as immunosuppressive agents depends on the activity of 2 enzymes, inosine monophosphate dehydrogenase (IMPDH) and thiopurine methyltransferase (TPMT) respectively.	Mycophenolic Acid	41-44	thiopurine S-methyltransferase	Homo sapiens	183-211
17065099-1	2006	The efficiency of Mycophenolate mofetil (MMF) and Azathioprine (AZA) as immunosuppressive agents depends on the activity of 2 enzymes, inosine monophosphate dehydrogenase (IMPDH) and thiopurine methyltransferase (TPMT) respectively.	Mycophenolic Acid	41-44	thiopurine S-methyltransferase	Homo sapiens	213-217
16272406-0	2006	Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine.	Mycophenolic Acid	43-60	ATP binding cassette subfamily C member 2	Rattus norvegicus	8-12
16961272-0	2006	Effects of mycophenolic acid on high glucose-induced expression of TGF-beta and CTGF in mesangial cells.	Mycophenolic Acid	11-28	transforming growth factor, beta 1	Rattus norvegicus	67-75
16961272-0	2006	Effects of mycophenolic acid on high glucose-induced expression of TGF-beta and CTGF in mesangial cells.	Mycophenolic Acid	11-28	cellular communication network factor 2	Rattus norvegicus	80-84
16417450-3	2005	Here, we report a patient with fulminant hepatic failure who received an ABO-incompatible liver transplantation who was treated with pre- and posttransplantation double-volume total plasma exchange, splenectomy, and triple immunosuppression (tacrolimus, mycophenolate mofetil, and prednisone) in July 2003.	Mycophenolic Acid	254-275	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	73-76
16313313-5	2005	In this setting, use of an IL-2R antagonist with mycophenolate mofetil and steroids with delayed cyclosporine appears to be associated with a low incidence of biopsy-proven rejection and comparable renal function to patients with immediate function.	Mycophenolic Acid	49-70	interleukin 2 receptor subunit alpha	Homo sapiens	27-32
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P < 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Mycophenolic Acid	147-150	caspase 3	Rattus norvegicus	10-19
16242456-12	2005	The salutary effect of mycophenolate mofetil may be related to its ability to decrease interferon-gamma expression in the myocardium and prevent the generation of alloantibodies.	Mycophenolic Acid	23-44	interferon gamma	Sus scrofa	87-103
16237714-8	2005	The use of calcineurin inhibitor (CNI)-based immunosuppression is an important factor in the development of chronic kidney disease, and the use of mycophenolic acid- or sirolimus-based immunosuppression with reduced-dose CNI may be of benefit.	Mycophenolic Acid	147-164	calcineurin binding protein 1	Homo sapiens	221-224
16278936-3	2005	Although Imd2 is 92% identical to Imd3, it is the only S. cerevisiae IMPDH that is resistant to mycophenolic acid in vitro and is the only one of the four that supports drug-resistant growth.	Mycophenolic Acid	96-113	IMP dehydrogenase IMD2	Saccharomyces cerevisiae S288C	9-13
16230499-6	2005	Finally, a case-control study showed that reduction of cardiac allograft rejection by mycophenolic acid was accompanied by reduced CD40 ligand serum levels and the prevention of IgM-to-IgG anti-HLA class II antibody switching.	Mycophenolic Acid	86-103	CD40 molecule	Homo sapiens	131-135
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P < 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Mycophenolic Acid	147-150	caspase 3	Rattus norvegicus	50-59
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P < 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Mycophenolic Acid	147-150	caspase 3	Rattus norvegicus	50-59
16030050-0	2005	Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.	Mycophenolic Acid	0-21	IGAN1	Homo sapiens	76-91
16198654-0	2005	The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.	Mycophenolic Acid	152-169	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	63-69
16198654-7	2005	CONCLUSION: The T-275A and C-2152T SNPs of the UGT1A9 gene promoter are associated with significantly lower MPA exposure in renal recipients treated with 2 g mycophenolate mofetil daily, and part of this effect is caused by interruption of enterohepatic recirculation of MPA.	Mycophenolic Acid	158-179	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	47-53
16030050-0	2005	Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.	Mycophenolic Acid	23-26	IGAN1	Homo sapiens	76-91
16030050-4	2005	We studied the use of mycophenolate mofetil (MMF) vs placebo in a group of North American IgAN patients at high risk for progressive disease.	Mycophenolic Acid	22-43	IGAN1	Homo sapiens	90-94
16030050-4	2005	We studied the use of mycophenolate mofetil (MMF) vs placebo in a group of North American IgAN patients at high risk for progressive disease.	Mycophenolic Acid	45-48	IGAN1	Homo sapiens	90-94
15769934-0	2005	Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.	Mycophenolic Acid	0-21	Thy-1 cell surface antigen	Rattus norvegicus	48-52
16120063-1	2005	BACKGROUND: Controversy remains about the interaction between mycophenolate mofetil (MMF) and the calcineurin inhibitors cyclosporin (CsA) and tacrolimus (TACR).	Mycophenolic Acid	62-83	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
16120063-2	2005	The need to double the dose of MMF in case of CsA co-administration to achieve the same mycophenolic acid (MPA) levels as in TACR co-administration, has been attributed to either inhibition by CsA of the enterohepatic cycle, or an inhibition of glucuronidation to mycophenolate glucuronide (MPAG) by TACR.	Mycophenolic Acid	88-105	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	46-49
16120063-2	2005	The need to double the dose of MMF in case of CsA co-administration to achieve the same mycophenolic acid (MPA) levels as in TACR co-administration, has been attributed to either inhibition by CsA of the enterohepatic cycle, or an inhibition of glucuronidation to mycophenolate glucuronide (MPAG) by TACR.	Mycophenolic Acid	107-110	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	46-49
15978615-9	2005	Mycophenolic acid (MPA) did inhibit agonist-induced OPN expression in cultured cardiomyocytes.	Mycophenolic Acid	0-17	secreted phosphoprotein 1	Rattus norvegicus	52-55
15978615-9	2005	Mycophenolic acid (MPA) did inhibit agonist-induced OPN expression in cultured cardiomyocytes.	Mycophenolic Acid	19-22	secreted phosphoprotein 1	Rattus norvegicus	52-55
16014059-0	2005	Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy.	Mycophenolic Acid	0-21	immunoglobulin heavy variable 4-38-2-like	Homo sapiens	59-62
15942045-16	2005	Nephrin loss is an indication of proteinuria in NS and the antiproteinuric effects of ACE inhibitors, vasopeptidase inhibitors, and mycophenolate mofetil attenuate this reduction.	Mycophenolic Acid	132-153	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	0-7
15998421-0	2005	Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.	Mycophenolic Acid	155-176	neural precursor cell expressed, developmentally down-regulated 9	Homo sapiens	133-137
15998670-9	2005	Treatment of Fgl-2-/- xenografts with mycophenolate mofetil and tacrolimus, a clinically relevant immune suppression protocol, led to long-term graft acceptance.	Mycophenolic Acid	38-59	fibrinogen like 2	Homo sapiens	13-18
16267794-6	2005	Current therapy tends to reduce steroid treatment doses and, optimizing induction therapy with IL-2R inhibitors, using tacrolimus or mycophenolate or sirolimus.	Mycophenolic Acid	133-146	interleukin 2 receptor subunit alpha	Homo sapiens	95-100
16245248-1	2005	We report our experience in using mycophenolate mofetil (MMF) for the treatment of steroid-resistant focal segmental glomerulosclerosis (FSGS) in two patients.	Mycophenolic Acid	34-55	actinin alpha 4	Homo sapiens	137-141
16002550-0	2005	Short-term treatment with mycophenolic acid and tacrolimus is tolerogenic for INS-1 cell clone transplantation and the deleterious effects of the drugs are limited: in vivo and in vitro studies.	Mycophenolic Acid	26-43	insulin 1	Rattus norvegicus	78-83
16245248-1	2005	We report our experience in using mycophenolate mofetil (MMF) for the treatment of steroid-resistant focal segmental glomerulosclerosis (FSGS) in two patients.	Mycophenolic Acid	57-60	actinin alpha 4	Homo sapiens	137-141
15973181-0	2005	Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil.	Mycophenolic Acid	109-130	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	24-27
15797890-3	2005	We examined the impact of mycophenolate mofetil immunosuppression on recurrence of IgAN.	Mycophenolic Acid	26-47	IGAN1	Homo sapiens	83-87
15880067-9	2005	CONCLUSIONS: The combination of alemtuzumab and mycophenolate mofetil was associated with an acceptable rejection rate, a good safety profile, and good (graft and native) kidney function; it eliminated undesired calcineurin inhibitor- and steroid-related side effects.	Mycophenolic Acid	48-69	calcineurin binding protein 1	Homo sapiens	212-233
15604220-0	2005	Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.	Mycophenolic Acid	29-46	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	94-101
15990643-0	2005	Mycophenolate mofetil in the management of alloimmune hemolytic anemia in ABO-compatible but non-identical pediatric liver transplantation.	Mycophenolic Acid	0-21	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	74-77
15816878-0	2005	Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.	Mycophenolic Acid	28-45	ATP binding cassette subfamily C member 2	Rattus norvegicus	64-105
15816878-8	2005	This finding suggests that CsA-mediated inhibition of the biliary excretion of MPAG by the Mrp2 transporter is the mechanism responsible for the interaction between CsA and MMF.	Mycophenolic Acid	173-176	ATP binding cassette subfamily C member 2	Rattus norvegicus	91-95
15919453-1	2005	In a single-center prospective randomized controlled study, the impact of calcineurin inhibitor (CNI) reduction or withdrawal on the pharmacokinetics of mycophenolic acid (MPA) was studied in a group of renal transplant recipients with impaired renal function.	Mycophenolic Acid	153-170	calcineurin binding protein 1	Homo sapiens	74-95
15919453-1	2005	In a single-center prospective randomized controlled study, the impact of calcineurin inhibitor (CNI) reduction or withdrawal on the pharmacokinetics of mycophenolic acid (MPA) was studied in a group of renal transplant recipients with impaired renal function.	Mycophenolic Acid	172-175	calcineurin binding protein 1	Homo sapiens	74-95
15604220-4	2005	We have demonstrated that mycophenolic acid (MPA), a specific inosine monophosphate dehydrogenase (IMPDH) inhibitor that results in depletion of intracellular guanine nucleotides, is synergistic with imatinib in inducing apoptosis in Bcr-Abl-expressing cell lines.	Mycophenolic Acid	26-43	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	234-241
15604220-4	2005	We have demonstrated that mycophenolic acid (MPA), a specific inosine monophosphate dehydrogenase (IMPDH) inhibitor that results in depletion of intracellular guanine nucleotides, is synergistic with imatinib in inducing apoptosis in Bcr-Abl-expressing cell lines.	Mycophenolic Acid	45-48	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	234-241
15677500-3	2005	In this study, we report that tacrolimus, sirolimus, and mycophenolic acid, when added to cultures of freshly isolated human islets, induce a downregulation of the synthesis and secretion of insulin.	Mycophenolic Acid	57-74	insulin	Homo sapiens	191-198
15760408-8	2005	Complete abandonment of calcineurin inhibitor therapy by de novo use of the combination sirolimus/mycophenolate mofetil resulted in low rejection rate and avoidance of renal impairment, but should not be used without further evaluation of potential complications in a lager setting.	Mycophenolic Acid	98-119	calcineurin binding protein 1	Homo sapiens	24-45
15785384-0	2005	Mycophenolate mofetil is compatible with CD28/CD154 costimulatory blockade in preventing transplant rejection.	Mycophenolic Acid	0-21	CD28 molecule	Homo sapiens	41-45
15780939-4	2005	The drugs 6-azauracil and mycophenolic acid reduce both the elongation rate and processivity, and this processivity defect is aggravated by mutations in Spt4, TFIIS, and CTDK-1.	Mycophenolic Acid	26-43	SPT4 homolog, DSIF elongation factor subunit	Homo sapiens	153-157
15780939-4	2005	The drugs 6-azauracil and mycophenolic acid reduce both the elongation rate and processivity, and this processivity defect is aggravated by mutations in Spt4, TFIIS, and CTDK-1.	Mycophenolic Acid	26-43	transcription elongation factor A2	Homo sapiens	159-164
15944996-0	2005	One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study.	Mycophenolic Acid	55-76	IGAN1	Homo sapiens	118-133
15848526-5	2005	The tubular expression of mRNA for IL-6 and TGF-beta1 was significantly lower in biopsies with AR (n = 34) obtained from patients treated with MMF (n = 12) than in biopsies obtained from patients treated with azathioprine (n = 22) (P < .02).	Mycophenolic Acid	143-146	interleukin 6	Homo sapiens	35-39
15848526-5	2005	The tubular expression of mRNA for IL-6 and TGF-beta1 was significantly lower in biopsies with AR (n = 34) obtained from patients treated with MMF (n = 12) than in biopsies obtained from patients treated with azathioprine (n = 22) (P < .02).	Mycophenolic Acid	143-146	transforming growth factor beta 1	Homo sapiens	44-53
15848720-11	2005	CONCLUSION: For the first time, the immunosuppressive effects of the combination CsA plus MMF were quantified in whole blood of human HTx at different time points.	Mycophenolic Acid	90-93	Zic family member 3	Homo sapiens	134-137
15470161-11	2005	In conclusion, UGT 1A9 and 2B7 were clearly identified as the main UGT isoforms involved in mycophenolic acid glucuronidation, presumably due to their high hepatic and renal expression.	Mycophenolic Acid	92-109	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	15-22
15470161-11	2005	In conclusion, UGT 1A9 and 2B7 were clearly identified as the main UGT isoforms involved in mycophenolic acid glucuronidation, presumably due to their high hepatic and renal expression.	Mycophenolic Acid	92-109	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	15-18
15614187-10	2005	Changes in IMPDH2 mRNA levels were confirmed and functional analyses were performed by inhibiting IMPDH with either benzamide riboside, mycophenolic acid, or tiazofurin.	Mycophenolic Acid	136-153	inosine monophosphate dehydrogenase 2	Homo sapiens	11-17
15654821-0	2005	Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis.	Mycophenolic Acid	0-21	proliferating cell nuclear antigen	Rattus norvegicus	47-53
15654821-0	2005	Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis.	Mycophenolic Acid	0-21	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	78-81
15654821-0	2005	Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis.	Mycophenolic Acid	0-21	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	82-86
15654821-0	2005	Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis.	Mycophenolic Acid	0-21	Thy-1 cell surface antigen	Rattus norvegicus	107-111
15607671-0	2004	Reduction of ICAM-1 and LFA-1-positive leukocytes in the perivascular space of arteries under mycophenolate mofetil therapy reduces rat heart transplant vasculopathy.	Mycophenolic Acid	94-107	intercellular adhesion molecule 1	Rattus norvegicus	13-19
15598270-4	2005	METHODS: Life-supporting hDAF-transgenic kidney transplantation was performed in cynomolgus monkeys, using cyclophosphamide induction, and maintenance immunosuppression with cyclosporin A, mycophenolate sodium, and tapering steroids.	Mycophenolic Acid	189-209	CD55 molecule (Cromer blood group)	Homo sapiens	25-29
15575910-4	2004	CsA+Rapa was associated with significantly lower graft survival (74.6% vs. 79.3% at 4 years, p = 0.002) and death-censored graft survival (83.7% vs. 87.2%, p = 0.003) compared to CsA+MMF.	Mycophenolic Acid	183-186	transcriptional regulating factor 1	Homo sapiens	4-8
15570183-0	2004	Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5.	Mycophenolic Acid	44-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
15621150-2	2004	It inhibits the inducible isoform of the enzyme inosine-monophosphate dehydrogenase (IMPDH II) via its active metabolite mycophenolic acid (MPA).	Mycophenolic Acid	121-138	inosine monophosphate dehydrogenase 2	Homo sapiens	85-93
15621150-2	2004	It inhibits the inducible isoform of the enzyme inosine-monophosphate dehydrogenase (IMPDH II) via its active metabolite mycophenolic acid (MPA).	Mycophenolic Acid	140-143	inosine monophosphate dehydrogenase 2	Homo sapiens	85-93
15470036-6	2004	Surprisingly, in the presence of mycophenolate mofetil, activated F5 cells are still able to produce granzyme B and to kill target cells but to a lesser extent compared with control.	Mycophenolic Acid	33-54	granzyme B	Mus musculus	101-111
15365603-0	2004	Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction.	Mycophenolic Acid	33-54	calcineurin binding protein 1	Homo sapiens	91-112
15365603-2	2004	Several studies have shown the efficacy of mycophenolate mofetil (MMF) in improving calcineurin inhibitor (CI)-induced nephrotoxicity with concomitant reduction or withdrawal of CI.	Mycophenolic Acid	43-64	calcineurin binding protein 1	Homo sapiens	84-105
15365603-2	2004	Several studies have shown the efficacy of mycophenolate mofetil (MMF) in improving calcineurin inhibitor (CI)-induced nephrotoxicity with concomitant reduction or withdrawal of CI.	Mycophenolic Acid	66-69	calcineurin binding protein 1	Homo sapiens	84-105
15644133-0	2005	Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy.	Mycophenolic Acid	0-21	integrin subunit beta 1	Homo sapiens	58-72
15518791-0	2004	Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid.	Mycophenolic Acid	128-149	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	21-24
15607671-0	2004	Reduction of ICAM-1 and LFA-1-positive leukocytes in the perivascular space of arteries under mycophenolate mofetil therapy reduces rat heart transplant vasculopathy.	Mycophenolic Acid	94-107	integrin subunit alpha L	Rattus norvegicus	24-29
15366440-0	2004	Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure.	Mycophenolic Acid	14-35	calcineurin binding protein 1	Homo sapiens	39-60
15258099-0	2004	The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants.	Mycophenolic Acid	53-70	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	17-23
15284532-8	2004	Compared to wild-type individuals, there were statistically significant higher glucuronidating activities in livers with the -275 and -2152 using mycophenolic acid and propofol as UGT1A9 substrates, indicating an extensive glucuronidator phenotype associated with these variants.	Mycophenolic Acid	146-163	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	180-186
15213268-5	2004	In addition, the effects of enalapril, losartan, and mycophenolate mofetil (MMF) on AngII expression in animals with chronic renal disease was also analyzed.	Mycophenolic Acid	53-74	angiotensinogen	Rattus norvegicus	84-89
15213268-5	2004	In addition, the effects of enalapril, losartan, and mycophenolate mofetil (MMF) on AngII expression in animals with chronic renal disease was also analyzed.	Mycophenolic Acid	76-79	angiotensinogen	Rattus norvegicus	84-89
15213268-11	2004	Moreover, mycophenolate mofetil lowered interstitial AngII expression, suggesting that inflammatory signaling may be involved in interstitial AngII generation.	Mycophenolic Acid	10-31	angiotensinogen	Rattus norvegicus	53-58
15213268-11	2004	Moreover, mycophenolate mofetil lowered interstitial AngII expression, suggesting that inflammatory signaling may be involved in interstitial AngII generation.	Mycophenolic Acid	10-31	angiotensinogen	Rattus norvegicus	142-147
15201664-10	2004	Using cultured rat vascular smooth muscle cells (VSMC), effects of mycophenolic acid (MPA) on ET-1-induced proliferation and ERK1/2 activation were also examined in vitro.	Mycophenolic Acid	67-84	endothelin 1	Rattus norvegicus	94-98
15201664-10	2004	Using cultured rat vascular smooth muscle cells (VSMC), effects of mycophenolic acid (MPA) on ET-1-induced proliferation and ERK1/2 activation were also examined in vitro.	Mycophenolic Acid	86-89	endothelin 1	Rattus norvegicus	94-98
15103747-0	2004	Effects of mycophenolic acid (MPA) treatment on expression of Fc receptor (FcRn) and polymeric immunoglobulin receptor (pIgR) mRNA in adult sheep tissues.	Mycophenolic Acid	11-28	IgG receptor FcRn large subunit p51	Ovis aries	75-79
15103747-0	2004	Effects of mycophenolic acid (MPA) treatment on expression of Fc receptor (FcRn) and polymeric immunoglobulin receptor (pIgR) mRNA in adult sheep tissues.	Mycophenolic Acid	30-33	IgG receptor FcRn large subunit p51	Ovis aries	75-79
15103747-1	2004	AIM: To quantify the expression of Fc receptor (FcRn) and polymeric immunoglobulin receptor (pIgR) mRNA under a long-term influence of mycotoxin mycophenolic acid (MPA), which is used in human transplantation medicine due to its immunosuppressive properties and is a common contaminant in silage.	Mycophenolic Acid	145-162	Fc gamma receptor and transporter	Homo sapiens	48-52
15103747-1	2004	AIM: To quantify the expression of Fc receptor (FcRn) and polymeric immunoglobulin receptor (pIgR) mRNA under a long-term influence of mycotoxin mycophenolic acid (MPA), which is used in human transplantation medicine due to its immunosuppressive properties and is a common contaminant in silage.	Mycophenolic Acid	145-162	polymeric immunoglobulin receptor	Homo sapiens	93-97
15103747-1	2004	AIM: To quantify the expression of Fc receptor (FcRn) and polymeric immunoglobulin receptor (pIgR) mRNA under a long-term influence of mycotoxin mycophenolic acid (MPA), which is used in human transplantation medicine due to its immunosuppressive properties and is a common contaminant in silage.	Mycophenolic Acid	164-167	Fc gamma receptor and transporter	Homo sapiens	48-52
15103747-1	2004	AIM: To quantify the expression of Fc receptor (FcRn) and polymeric immunoglobulin receptor (pIgR) mRNA under a long-term influence of mycotoxin mycophenolic acid (MPA), which is used in human transplantation medicine due to its immunosuppressive properties and is a common contaminant in silage.	Mycophenolic Acid	164-167	polymeric immunoglobulin receptor	Homo sapiens	93-97
15039300-7	2004	Mutant UGT1A10 (I211T(*)) also lost all detectable activity toward mycophenolic acid.	Mycophenolic Acid	67-84	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	7-14
15021829-0	2004	Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.	Mycophenolic Acid	39-60	transforming growth factor, beta 1	Rattus norvegicus	91-123
15019644-5	2004	MMF 5 mg/kg BID produced greater (p < 0.001) suppression of lymphocyte proliferation (area under the PD effect-time curve, AUE = 2,010% inhibition.	Mycophenolic Acid	0-3	BH3 interacting domain death agonist	Rattus norvegicus	12-15
14712481-6	2004	These results suggest that in neuroblastoma cell lines clinically attainable concentrations of mycophenolic acid deplete guanine nucleotide pools triggering G(1) arrest and apoptosis through p53-mediated pathways, indicating a potential role of its morpholinoethyl ester pro-drug in the management of patients with neuroectodermal tumors.	Mycophenolic Acid	95-112	tumor protein p53	Homo sapiens	191-194
15019644-10	2004	MMF 5 mg/kg BID produced more sustained suppression of both PD and rejection than MMF 10 mg/kg QD.	Mycophenolic Acid	0-3	BH3 interacting domain death agonist	Rattus norvegicus	12-15
15041382-7	2004	In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).	Mycophenolic Acid	63-66	interleukin 2	Homo sapiens	23-27
15086925-0	2004	Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.	Mycophenolic Acid	0-21	IGAN1	Homo sapiens	25-40
15086925-1	2004	BACKGROUND: Because humoral immunity is believed to play a pivotal role in the pathogenesis of IgA nephropathy (IgAN), a prospective placebo-controlled randomized study was started in patients with IgAN using mycophenolate mofetil (MMF).	Mycophenolic Acid	209-230	IGAN1	Homo sapiens	112-116
15086925-1	2004	BACKGROUND: Because humoral immunity is believed to play a pivotal role in the pathogenesis of IgA nephropathy (IgAN), a prospective placebo-controlled randomized study was started in patients with IgAN using mycophenolate mofetil (MMF).	Mycophenolic Acid	209-230	IGAN1	Homo sapiens	198-202
15086925-1	2004	BACKGROUND: Because humoral immunity is believed to play a pivotal role in the pathogenesis of IgA nephropathy (IgAN), a prospective placebo-controlled randomized study was started in patients with IgAN using mycophenolate mofetil (MMF).	Mycophenolic Acid	232-235	IGAN1	Homo sapiens	198-202
15041382-7	2004	In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).	Mycophenolic Acid	63-66	interleukin 2	Homo sapiens	103-107
14550820-1	2003	BACKGROUND: The purpose of the study was to evaluate the effects of cyclosporine (CsA), FK 506 and mycophenolate mofetil (MMF) on graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) after cardiac transplantation in rats.	Mycophenolic Acid	122-125	Cd4 molecule	Rattus norvegicus	161-164
12970678-8	2004	In contrast to p21(Waf1/Cip1), a reduction in p27(Kip1) occurred in MPA-treated cells.	Mycophenolic Acid	68-71	interferon alpha inducible protein 27	Homo sapiens	46-49
12970678-8	2004	In contrast to p21(Waf1/Cip1), a reduction in p27(Kip1) occurred in MPA-treated cells.	Mycophenolic Acid	68-71	cyclin dependent kinase inhibitor 1B	Homo sapiens	50-54
14734128-11	2004	CONCLUSIONS: Changing immunosuppression from a standard AZA-based regimen to MMF resulted in a decrease in systemic inflammatory activity as indicated by levels of high-sensitive CRP.	Mycophenolic Acid	77-80	C-reactive protein	Homo sapiens	179-182
14671038-0	2004	Effects of mycophenolic acid on IL-6 expression of human renal proximal and distal tubular cells in vitro.	Mycophenolic Acid	11-28	interleukin 6	Homo sapiens	32-36
14671038-4	2004	Until now no data about the effect of the immunosuppressant drug mycophenolic acid (MPA) on IL-6 expression were available.	Mycophenolic Acid	65-82	interleukin 6	Homo sapiens	92-96
14671038-4	2004	Until now no data about the effect of the immunosuppressant drug mycophenolic acid (MPA) on IL-6 expression were available.	Mycophenolic Acid	84-87	interleukin 6	Homo sapiens	92-96
14688525-1	2003	BACKGROUND: The immunosuppressive drug mycophenolate mofetil (MMF) reduces expression of the heterophilic binding elements intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and thereby prevents attachment of alloactivated leukocytes to donor endothelium.	Mycophenolic Acid	39-60	vascular cell adhesion molecule 1	Homo sapiens	161-194
14688525-1	2003	BACKGROUND: The immunosuppressive drug mycophenolate mofetil (MMF) reduces expression of the heterophilic binding elements intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and thereby prevents attachment of alloactivated leukocytes to donor endothelium.	Mycophenolic Acid	62-65	vascular cell adhesion molecule 1	Homo sapiens	161-194
12879230-0	2003	Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.	Mycophenolic Acid	81-102	calcineurin binding protein 1	Homo sapiens	0-21
14578746-0	2003	A short course of mycophenolate immunosuppression inhibits rejection, but not tolerance, of rat liver allografts in association with inhibition of interleukin-4 and alloantibody responses.	Mycophenolic Acid	18-31	interleukin 4	Rattus norvegicus	147-160
14550820-1	2003	BACKGROUND: The purpose of the study was to evaluate the effects of cyclosporine (CsA), FK 506 and mycophenolate mofetil (MMF) on graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) after cardiac transplantation in rats.	Mycophenolic Acid	99-120	Cd4 molecule	Rattus norvegicus	161-164
14629285-0	2003	Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity.	Mycophenolic Acid	0-21	transforming growth factor, beta 1	Rattus norvegicus	63-95
14612104-0	2003	Low-dose sirolimus in combination with mycophenolate in calcineurin inhibitor elimination: the Kuwaiti experience.	Mycophenolic Acid	39-52	calcineurin binding protein 1	Homo sapiens	56-77
14550820-1	2003	BACKGROUND: The purpose of the study was to evaluate the effects of cyclosporine (CsA), FK 506 and mycophenolate mofetil (MMF) on graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) after cardiac transplantation in rats.	Mycophenolic Acid	122-125	CD8a molecule	Homo sapiens	166-169
14550820-1	2003	BACKGROUND: The purpose of the study was to evaluate the effects of cyclosporine (CsA), FK 506 and mycophenolate mofetil (MMF) on graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) after cardiac transplantation in rats.	Mycophenolic Acid	122-125	integrin subunit alpha L	Homo sapiens	171-176
14550820-1	2003	BACKGROUND: The purpose of the study was to evaluate the effects of cyclosporine (CsA), FK 506 and mycophenolate mofetil (MMF) on graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) after cardiac transplantation in rats.	Mycophenolic Acid	122-125	integrin subunit beta 2	Rattus norvegicus	178-182
12795679-0	2003	Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts.	Mycophenolic Acid	57-77	CD55 molecule (Cromer blood group)	Homo sapiens	142-146
12907250-5	2003	Notably, IL-18 BPa:Fc (200 ng/mL) further reinforced dexamethasone (5 nM)- or mycophenolic acid (2 microM)-mediated reduction of LPS/IL-12-induced IFNgamma production by an additional 50.5 or 49.9%, respectively.	Mycophenolic Acid	78-95	interleukin 18 binding protein	Homo sapiens	9-18
12907250-5	2003	Notably, IL-18 BPa:Fc (200 ng/mL) further reinforced dexamethasone (5 nM)- or mycophenolic acid (2 microM)-mediated reduction of LPS/IL-12-induced IFNgamma production by an additional 50.5 or 49.9%, respectively.	Mycophenolic Acid	78-95	interferon gamma	Homo sapiens	147-155
12972617-3	2003	BUR1 mutants are sensitive to the drugs 6-azauracil and mycophenolic acid and interact genetically with the elongation factors Ctk1 and Spt5.	Mycophenolic Acid	56-73	cyclin-dependent serine/threonine protein kinase SGV1	Saccharomyces cerevisiae S288C	0-4
12780674-2	2003	We examined the hypothesis that using anti-CD25 monoclonal antibody induction and mycophenolate mofetil (MMF) would allow the lowering of target pre-dose blood concentrations of tacrolimus immediately after transplantation and subsequently stopping steroids at 5 months.	Mycophenolic Acid	105-108	interleukin 2 receptor subunit alpha	Homo sapiens	43-47
12609835-4	2003	We have examined the induction of apoptosis by mycophenolic acid (MPA), a specific IMPDH inhibitor, in interleukin-3 (IL-3)-dependent murine hematopoietic cell lines.	Mycophenolic Acid	47-64	interleukin 3	Mus musculus	103-116
12609835-4	2003	We have examined the induction of apoptosis by mycophenolic acid (MPA), a specific IMPDH inhibitor, in interleukin-3 (IL-3)-dependent murine hematopoietic cell lines.	Mycophenolic Acid	47-64	interleukin 3	Mus musculus	118-122
12609835-4	2003	We have examined the induction of apoptosis by mycophenolic acid (MPA), a specific IMPDH inhibitor, in interleukin-3 (IL-3)-dependent murine hematopoietic cell lines.	Mycophenolic Acid	66-69	interleukin 3	Mus musculus	103-116
12609835-4	2003	We have examined the induction of apoptosis by mycophenolic acid (MPA), a specific IMPDH inhibitor, in interleukin-3 (IL-3)-dependent murine hematopoietic cell lines.	Mycophenolic Acid	66-69	interleukin 3	Mus musculus	118-122
12826215-13	2003	CONCLUSIONS: Conversion from AZA to MMF after CSA reduction improves creatinine clearance in HTX recipients and reduces serum creatinine.	Mycophenolic Acid	36-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	46-49
12699411-3	2003	We here investigated the effect of bioactive MMF compound mycophenolic acid (MPA) on iNOS-mediated NO synthesis in fibroblasts, which are important source of NO in rheumatoid arthritis and during rejection of solid organ transplants.	Mycophenolic Acid	45-48	nitric oxide synthase 2, inducible	Mus musculus	85-89
12813890-6	2003	Although IMPDH is evolutionarily conserved, the bacterial enzyme is orders of magnitude more resistant to the toxic effect of the drug mycophenolic acid, which is an IMPDH inhibitor.	Mycophenolic Acid	135-152	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	9-14
12813890-6	2003	Although IMPDH is evolutionarily conserved, the bacterial enzyme is orders of magnitude more resistant to the toxic effect of the drug mycophenolic acid, which is an IMPDH inhibitor.	Mycophenolic Acid	135-152	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	166-171
12813890-7	2003	We have demonstrated that transfection of human, monkey or Chinese hamster cell lines with an expression vector containing bacterial IMPDH and mycophenolic acid treatment resulted in the selection of colonies with a strikingly increased resistance to mycophenolic acid toxicity.	Mycophenolic Acid	251-268	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	133-138
12813890-9	2003	As a proof of principle, we showed that mammalian cell transfection with a bicistronic IMPDH/GFP expression vector and mycophenolic acid treatment can be used to successfully select transfectants that express the fluorescent protein.	Mycophenolic Acid	119-136	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	87-92
12699411-3	2003	We here investigated the effect of bioactive MMF compound mycophenolic acid (MPA) on iNOS-mediated NO synthesis in fibroblasts, which are important source of NO in rheumatoid arthritis and during rejection of solid organ transplants.	Mycophenolic Acid	58-75	nitric oxide synthase 2, inducible	Mus musculus	85-89
12699411-3	2003	We here investigated the effect of bioactive MMF compound mycophenolic acid (MPA) on iNOS-mediated NO synthesis in fibroblasts, which are important source of NO in rheumatoid arthritis and during rejection of solid organ transplants.	Mycophenolic Acid	77-80	nitric oxide synthase 2, inducible	Mus musculus	85-89
12709024-0	2003	Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor- and tumour necrosis factor-receptor superfamily costimulatory molecules.	Mycophenolic Acid	0-17	tumor necrosis factor	Homo sapiens	61-83
12709024-0	2003	Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor- and tumour necrosis factor-receptor superfamily costimulatory molecules.	Mycophenolic Acid	0-17	tumor necrosis factor	Homo sapiens	89-111
12947887-0	2003	Mycophenolate mofetil in stable liver transplant patients with calcineurin inhibitor-induced renal impairment: single-center experience.	Mycophenolic Acid	0-21	calcineurin binding protein 1	Homo sapiens	63-84
12698082-12	2003	CONCLUSIONS: ABO-incompatible living donor kidney transplants can achieve an acceptable 1-year graft survival rate using an immunosuppressive regimen consisting of Thymoglobulin induction, tacrolimus, mycophenolate mofetil, and prednisone combined with pretransplant plasmapheresis, intravenous immunoglobulin, and splenectomy.	Mycophenolic Acid	201-222	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	13-16
12773967-6	2003	The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone.	Mycophenolic Acid	258-279	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
12773967-6	2003	The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone.	Mycophenolic Acid	281-284	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
12773967-6	2003	The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone.	Mycophenolic Acid	336-339	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
12235158-7	2002	The high resolution crystal structures of the protozoan parasite Tritrichomonas foetus IMPDH complexed with the inhibitor ribavirin monophosphate as well as monophosphate together with a second inhibitor, mycophenolic acid, are presented here.	Mycophenolic Acid	205-222	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	87-92
12591533-0	2003	Mycophenolic acid-induced apoptotic signal transduction in MOLT-4 T-cell.	Mycophenolic Acid	0-17	transmembrane protein 132D	Homo sapiens	59-63
12181421-3	2002	We studied the effect of an inosine-5"-monophosphate dehydrogenase (IMPDH) inhibitor, mycophenolic acid (MPA), on constitutive and IL-1beta-induced expression of ICAM-1 in human umbilical vein endothelial cells (HUVECs).	Mycophenolic Acid	86-103	interleukin 1 beta	Homo sapiens	131-139
12460238-0	2002	Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells.	Mycophenolic Acid	76-97	TNF receptor superfamily member 4	Homo sapiens	128-132
12460238-0	2002	Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells.	Mycophenolic Acid	76-97	CD4 molecule	Homo sapiens	134-137
12460238-2	2002	OX40+CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF).	Mycophenolic Acid	321-342	TNF receptor superfamily member 4	Homo sapiens	0-4
12460238-2	2002	OX40+CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF).	Mycophenolic Acid	321-342	CD4 molecule	Homo sapiens	5-8
12460238-2	2002	OX40+CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF).	Mycophenolic Acid	321-342	CD4 molecule	Homo sapiens	98-101
12460238-2	2002	OX40+CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF).	Mycophenolic Acid	344-347	TNF receptor superfamily member 4	Homo sapiens	0-4
12460238-2	2002	OX40+CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF).	Mycophenolic Acid	344-347	CD4 molecule	Homo sapiens	5-8
12460238-2	2002	OX40+CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF).	Mycophenolic Acid	344-347	CD4 molecule	Homo sapiens	98-101
12431671-0	2002	Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue.	Mycophenolic Acid	37-58	negative elongation factor complex member C/D	Homo sapiens	97-100
12438969-0	2002	Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity.	Mycophenolic Acid	0-21	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	117-120
12203391-0	2002	Mycophenolic acid downregulates inducible nitric oxide synthase induction in astrocytes.	Mycophenolic Acid	0-17	nitric oxide synthase 2	Homo sapiens	32-63
12203391-2	2002	Mycophenolic acid (MPA), a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibited interferon-gamma (IFN-gamma) + lipopolysaccharide (LPS)-induced NO production dose-dependently in astrocytes, but not in macrophages.	Mycophenolic Acid	0-17	interferon gamma	Homo sapiens	105-121
12203391-2	2002	Mycophenolic acid (MPA), a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibited interferon-gamma (IFN-gamma) + lipopolysaccharide (LPS)-induced NO production dose-dependently in astrocytes, but not in macrophages.	Mycophenolic Acid	0-17	interferon gamma	Homo sapiens	123-132
12203391-2	2002	Mycophenolic acid (MPA), a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibited interferon-gamma (IFN-gamma) + lipopolysaccharide (LPS)-induced NO production dose-dependently in astrocytes, but not in macrophages.	Mycophenolic Acid	19-22	interferon gamma	Homo sapiens	105-121
12203391-2	2002	Mycophenolic acid (MPA), a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibited interferon-gamma (IFN-gamma) + lipopolysaccharide (LPS)-induced NO production dose-dependently in astrocytes, but not in macrophages.	Mycophenolic Acid	19-22	interferon gamma	Homo sapiens	123-132
12386643-13	2002	However, the "newer" immunosuppressive agents tacrolimus and mycophenolate mofetil seemed to have fewer unfavorable effects on platelet CD62 expression and PAC1 expression and aggregation.	Mycophenolic Acid	61-82	selectin P	Homo sapiens	136-140
12386643-13	2002	However, the "newer" immunosuppressive agents tacrolimus and mycophenolate mofetil seemed to have fewer unfavorable effects on platelet CD62 expression and PAC1 expression and aggregation.	Mycophenolic Acid	61-82	ADCYAP receptor type I	Homo sapiens	156-160
12395202-5	2002	In contrast, the resistance of paf1 Delta cells to the transcription elongation inhibitors 6-azauracil and mycophenolic acid correlates with its ability to derepress the IMD2 transcript.	Mycophenolic Acid	107-124	Paf1p	Saccharomyces cerevisiae S288C	31-35
12395202-5	2002	In contrast, the resistance of paf1 Delta cells to the transcription elongation inhibitors 6-azauracil and mycophenolic acid correlates with its ability to derepress the IMD2 transcript.	Mycophenolic Acid	107-124	IMP dehydrogenase IMD2	Saccharomyces cerevisiae S288C	170-174
12193749-0	2002	Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.	Mycophenolic Acid	0-17	interleukin 2	Homo sapiens	27-31
12181421-3	2002	We studied the effect of an inosine-5"-monophosphate dehydrogenase (IMPDH) inhibitor, mycophenolic acid (MPA), on constitutive and IL-1beta-induced expression of ICAM-1 in human umbilical vein endothelial cells (HUVECs).	Mycophenolic Acid	86-103	intercellular adhesion molecule 1	Homo sapiens	162-168
12181421-3	2002	We studied the effect of an inosine-5"-monophosphate dehydrogenase (IMPDH) inhibitor, mycophenolic acid (MPA), on constitutive and IL-1beta-induced expression of ICAM-1 in human umbilical vein endothelial cells (HUVECs).	Mycophenolic Acid	105-108	interleukin 1 beta	Homo sapiens	131-139
12181421-3	2002	We studied the effect of an inosine-5"-monophosphate dehydrogenase (IMPDH) inhibitor, mycophenolic acid (MPA), on constitutive and IL-1beta-induced expression of ICAM-1 in human umbilical vein endothelial cells (HUVECs).	Mycophenolic Acid	105-108	intercellular adhesion molecule 1	Homo sapiens	162-168
12270371-0	2002	Mig, IP-10, and CXCR3 gene expression is predictive for the individual response of children with chronic allograft nephropathy to mycophenolate mofetil.	Mycophenolic Acid	130-151	C-X-C motif chemokine ligand 9	Homo sapiens	0-3
12270371-0	2002	Mig, IP-10, and CXCR3 gene expression is predictive for the individual response of children with chronic allograft nephropathy to mycophenolate mofetil.	Mycophenolic Acid	130-151	C-X-C motif chemokine ligand 10	Homo sapiens	5-10
12270371-0	2002	Mig, IP-10, and CXCR3 gene expression is predictive for the individual response of children with chronic allograft nephropathy to mycophenolate mofetil.	Mycophenolic Acid	130-151	C-X-C motif chemokine receptor 3	Homo sapiens	16-21
12297111-0	2002	Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.	Mycophenolic Acid	35-52	interleukin 6	Mus musculus	72-76
12297111-1	2002	Mycophenolic acid (MPA) and A77 1726, the active components of the immunosuppressants mycophenolate mophetil and leflunomide, respectively, in a dose-dependent manner inhibited interferon (IFN)-gamma/LPS-induced interleukin (IL)-6 release in confluent cultures of mouse L929 fibrosarcoma cells.	Mycophenolic Acid	0-17	interferon gamma	Mus musculus	177-199
12297111-1	2002	Mycophenolic acid (MPA) and A77 1726, the active components of the immunosuppressants mycophenolate mophetil and leflunomide, respectively, in a dose-dependent manner inhibited interferon (IFN)-gamma/LPS-induced interleukin (IL)-6 release in confluent cultures of mouse L929 fibrosarcoma cells.	Mycophenolic Acid	19-22	interferon gamma	Mus musculus	177-199
12297111-1	2002	Mycophenolic acid (MPA) and A77 1726, the active components of the immunosuppressants mycophenolate mophetil and leflunomide, respectively, in a dose-dependent manner inhibited interferon (IFN)-gamma/LPS-induced interleukin (IL)-6 release in confluent cultures of mouse L929 fibrosarcoma cells.	Mycophenolic Acid	86-99	interferon gamma	Mus musculus	177-199
12193059-0	2002	The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells.	Mycophenolic Acid	27-44	endothelin 1	Homo sapiens	53-65
12193059-2	2002	This study aimed to investigate whether the new immunosuppressive drug mycophenolic acid (MPA), which in contrast with CsA and tacrolimus lacks nephrotoxic side effects, modulates ET-1 synthesis in endothelial cells and renal epithelial cells.	Mycophenolic Acid	71-88	endothelin 1	Homo sapiens	180-184
12193059-2	2002	This study aimed to investigate whether the new immunosuppressive drug mycophenolic acid (MPA), which in contrast with CsA and tacrolimus lacks nephrotoxic side effects, modulates ET-1 synthesis in endothelial cells and renal epithelial cells.	Mycophenolic Acid	90-93	endothelin 1	Homo sapiens	180-184
11981085-7	2002	There was an association between symptoms and increased levels of mycophenolic acid (MPA) acyl glucuronide and serum interleukin-6, suggesting the induction of inflammatory cytokines by MPA acyl glucuronide as the cause of the syndrome.	Mycophenolic Acid	66-83	interleukin 6	Homo sapiens	117-130
12100761-0	2002	Inhibition of mycophenolic acid on NF-kappaB activity in human endothelial cells.	Mycophenolic Acid	14-31	nuclear factor kappa B subunit 1	Homo sapiens	35-44
12100761-1	2002	AIM: To examine the effect of mycophenolic acid (MPA) on the activity of nuclear factor-kappaB (NF-kappaB) and its inhibitor (IkappaBalpha) in 4-phorbal-12-myristate-13-acetate (PMA) stimulated and non-stimulated human umbilical vein endothelial cells (HUVEC).	Mycophenolic Acid	30-47	nuclear factor kappa B subunit 1	Homo sapiens	73-94
12100761-1	2002	AIM: To examine the effect of mycophenolic acid (MPA) on the activity of nuclear factor-kappaB (NF-kappaB) and its inhibitor (IkappaBalpha) in 4-phorbal-12-myristate-13-acetate (PMA) stimulated and non-stimulated human umbilical vein endothelial cells (HUVEC).	Mycophenolic Acid	30-47	nuclear factor kappa B subunit 1	Homo sapiens	96-105
12100761-1	2002	AIM: To examine the effect of mycophenolic acid (MPA) on the activity of nuclear factor-kappaB (NF-kappaB) and its inhibitor (IkappaBalpha) in 4-phorbal-12-myristate-13-acetate (PMA) stimulated and non-stimulated human umbilical vein endothelial cells (HUVEC).	Mycophenolic Acid	30-47	NFKB inhibitor alpha	Homo sapiens	126-138
12100761-1	2002	AIM: To examine the effect of mycophenolic acid (MPA) on the activity of nuclear factor-kappaB (NF-kappaB) and its inhibitor (IkappaBalpha) in 4-phorbal-12-myristate-13-acetate (PMA) stimulated and non-stimulated human umbilical vein endothelial cells (HUVEC).	Mycophenolic Acid	49-52	nuclear factor kappa B subunit 1	Homo sapiens	73-94
12100761-1	2002	AIM: To examine the effect of mycophenolic acid (MPA) on the activity of nuclear factor-kappaB (NF-kappaB) and its inhibitor (IkappaBalpha) in 4-phorbal-12-myristate-13-acetate (PMA) stimulated and non-stimulated human umbilical vein endothelial cells (HUVEC).	Mycophenolic Acid	49-52	nuclear factor kappa B subunit 1	Homo sapiens	96-105
12100761-1	2002	AIM: To examine the effect of mycophenolic acid (MPA) on the activity of nuclear factor-kappaB (NF-kappaB) and its inhibitor (IkappaBalpha) in 4-phorbal-12-myristate-13-acetate (PMA) stimulated and non-stimulated human umbilical vein endothelial cells (HUVEC).	Mycophenolic Acid	49-52	NFKB inhibitor alpha	Homo sapiens	126-138
12231370-6	2002	RESULTS: Exposure to cyclosporine and mycophenolate mofetil was associated with a dose-dependent decrease in endothelium-dependent relaxations to serotonin (an agonist that binds to 5-HT1D receptors coupled to Gi-protein) but no impairment of relaxations to bradykinin (an agonist that binds to B2 receptors coupled to Gq-proteins).	Mycophenolic Acid	38-59	5-hydroxytryptamine receptor 1D	Homo sapiens	182-188
12231370-6	2002	RESULTS: Exposure to cyclosporine and mycophenolate mofetil was associated with a dose-dependent decrease in endothelium-dependent relaxations to serotonin (an agonist that binds to 5-HT1D receptors coupled to Gi-protein) but no impairment of relaxations to bradykinin (an agonist that binds to B2 receptors coupled to Gq-proteins).	Mycophenolic Acid	38-59	kininogen 1	Homo sapiens	258-268
12182469-6	2002	By flowcytometry and limiting dilution analysis, the IL-2R complex was analyzed in peripheral blood samples from renal allograft recipients (n = 29) who received basiliximab (20 mg IV bolus on day 0 and 4), cyclosporin and mycophenolate mofetil.	Mycophenolic Acid	223-244	interleukin 2 receptor subunit alpha	Homo sapiens	53-58
11884930-7	2002	Insulin secretion from Wistar rat islets was reduced by 0% and 48% after exposure to mycophenolate (P<0.001) and 20% and 31% after exposure to tacrolimus (P<0.05).	Mycophenolic Acid	85-98	insulin	Mesocricetus auratus	0-7
11966438-11	2002	Several other IMPDH inhibitors (TR, mycophenolic acid, and ribavirin) exhibit similar PARP inhibitory activity.	Mycophenolic Acid	36-53	poly(ADP-ribose) polymerase 1	Homo sapiens	86-90
11834357-3	2002	The results demonstrate that patients taking MMF instead of azathioprine generated significantly fewer de novo anti-vimentin antibodies.	Mycophenolic Acid	45-48	vimentin	Homo sapiens	116-124
11675402-1	2001	Rats that are administered angiotensin II (AngII) for 2 wk develop persistent salt-sensitive hypertension, which can be prevented by the immunosuppressor mycophenolate mofetil (MMF) given during the AngII infusion.	Mycophenolic Acid	177-180	angiotensinogen	Rattus norvegicus	43-48
11742267-0	2001	The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients.	Mycophenolic Acid	42-63	interleukin 5	Homo sapiens	134-138
11742267-1	2001	We have used an optimized, physiologically relevant in vitro assay system to show that in a concentration-dependent fashion the immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin), as well as the glucocorticoid dexamethasone, inhibit allergen-driven T-cell proliferation and IL-5 production in PBMCs from allergen-sensitized atopic asthmatic individuals at physiologic concentrations.	Mycophenolic Acid	166-187	interleukin 5	Homo sapiens	310-314
11733621-0	2001	Influence of hepatocyte growth factor, epidermal growth factor, and mycophenolic acid on endothelin-1 synthesis in human endothelial cells.	Mycophenolic Acid	68-85	endothelin 1	Homo sapiens	89-101
11733621-4	2001	In addition, we have investigated whether mycophenolic acid (MPA), a new immunosuppressive drug, which in contrast to CsA and tacrolimus lacks nephrotoxic side effects, modulates ET-1 synthesis in endothelial cells.	Mycophenolic Acid	42-59	endothelin 1	Homo sapiens	179-183
11733621-4	2001	In addition, we have investigated whether mycophenolic acid (MPA), a new immunosuppressive drug, which in contrast to CsA and tacrolimus lacks nephrotoxic side effects, modulates ET-1 synthesis in endothelial cells.	Mycophenolic Acid	61-64	endothelin 1	Homo sapiens	179-183
11819181-5	2002	METHOD: Eighteen HIV-positive outpatients, given MMF (500 mg po bid) on a compassionate basis as part of their salvage therapy, were monitored for adverse effects.	Mycophenolic Acid	49-52	BH3 interacting domain death agonist	Homo sapiens	64-67
11778698-8	2001	Although PCR analysis clearly indicated the presence of the correctly targeted M118L deletion mutants in mixed recombinant virus plaques selected with mycophenolic acid (MPA), repeated passages and plaquing failed to segregate the pure M118L deletion mutant from either single crossover recombinants or regenerated wild type parental viruses.	Mycophenolic Acid	151-168	IMV membrane protein	Myxoma virus	79-84
11778698-8	2001	Although PCR analysis clearly indicated the presence of the correctly targeted M118L deletion mutants in mixed recombinant virus plaques selected with mycophenolic acid (MPA), repeated passages and plaquing failed to segregate the pure M118L deletion mutant from either single crossover recombinants or regenerated wild type parental viruses.	Mycophenolic Acid	170-173	IMV membrane protein	Myxoma virus	79-84
11675402-1	2001	Rats that are administered angiotensin II (AngII) for 2 wk develop persistent salt-sensitive hypertension, which can be prevented by the immunosuppressor mycophenolate mofetil (MMF) given during the AngII infusion.	Mycophenolic Acid	177-180	angiotensinogen	Rattus norvegicus	27-41
11675402-1	2001	Rats that are administered angiotensin II (AngII) for 2 wk develop persistent salt-sensitive hypertension, which can be prevented by the immunosuppressor mycophenolate mofetil (MMF) given during the AngII infusion.	Mycophenolic Acid	177-180	angiotensinogen	Rattus norvegicus	199-204
11513333-4	2001	However, it has been recently observed that drugs like cyclosporin A, FK506, leflunomide, mycophenolate mofetil, pentoxifylline, and linomide can directly modulate cytokine and/or LPS-induced NO production in various cell types in vitro, probably by interfering with iNOS gene transcription or catalytic activity of iNOS enzyme.	Mycophenolic Acid	90-111	nitric oxide synthase 2	Homo sapiens	267-271
11750393-0	2001	Effects of mycophenolate mofetil and azathioprine on the erythropoietin production in renal transplant recipients.	Mycophenolic Acid	11-32	erythropoietin	Homo sapiens	57-71
11675402-1	2001	Rats that are administered angiotensin II (AngII) for 2 wk develop persistent salt-sensitive hypertension, which can be prevented by the immunosuppressor mycophenolate mofetil (MMF) given during the AngII infusion.	Mycophenolic Acid	154-175	angiotensinogen	Rattus norvegicus	27-41
11675402-1	2001	Rats that are administered angiotensin II (AngII) for 2 wk develop persistent salt-sensitive hypertension, which can be prevented by the immunosuppressor mycophenolate mofetil (MMF) given during the AngII infusion.	Mycophenolic Acid	154-175	angiotensinogen	Rattus norvegicus	43-48
11675402-1	2001	Rats that are administered angiotensin II (AngII) for 2 wk develop persistent salt-sensitive hypertension, which can be prevented by the immunosuppressor mycophenolate mofetil (MMF) given during the AngII infusion.	Mycophenolic Acid	154-175	angiotensinogen	Rattus norvegicus	199-204
11513333-4	2001	However, it has been recently observed that drugs like cyclosporin A, FK506, leflunomide, mycophenolate mofetil, pentoxifylline, and linomide can directly modulate cytokine and/or LPS-induced NO production in various cell types in vitro, probably by interfering with iNOS gene transcription or catalytic activity of iNOS enzyme.	Mycophenolic Acid	90-111	nitric oxide synthase 2	Homo sapiens	316-320
11404327-4	2001	First, defects in CCR4-NOT components as well as overexpression of the NOT4 gene elicited 6-azauracil (6AU) and mycophenolic acid sensitivities, hallmarks of transcriptional elongation defects.	Mycophenolic Acid	112-129	CCR4-NOT core ubiquitin-protein ligase subunit MOT2	Saccharomyces cerevisiae S288C	71-75
11489974-8	2001	These results demonstrate that a short treatment with immunosuppressive agents, such as 1alpha,25-dihydroxyvitamin D3/mycophenolate mofetil, induces tolerance to islet allografts associated with an increased frequency of CD4+CD25+ regulatory cells that can adoptively transfer transplantation tolerance.	Mycophenolic Acid	118-139	CD4 antigen	Mus musculus	221-224
11433230-0	2001	Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.	Mycophenolic Acid	0-21	nitric oxide synthase 2, inducible	Mus musculus	45-76
11544444-1	2001	AIM: To study the efficacy of mycophenolate mofetil (MMF) as renal rescue in paediatric liver transplant recipients with calcineurin-inhibitor- (CI) related nephrotoxicity.	Mycophenolic Acid	30-51	calcineurin binding protein 1	Homo sapiens	121-142
11544444-1	2001	AIM: To study the efficacy of mycophenolate mofetil (MMF) as renal rescue in paediatric liver transplant recipients with calcineurin-inhibitor- (CI) related nephrotoxicity.	Mycophenolic Acid	53-56	calcineurin binding protein 1	Homo sapiens	121-142
11328741-0	2001	CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis.	Mycophenolic Acid	88-109	CD69 molecule	Homo sapiens	0-4
11390035-9	2001	Additionally, alteration of insulin release from PIC cultured with PBMC or plastic-adherent cells was abolished dose-dependently (p < 0.0001 and p < 0.04, respectively) by gadolinium chloride (which inhibits macrophages), but not modified by cyclosporin A or mycophenolate mofetil which did not alter insulin release from PIC but blocked the proliferation of PBMC against PIC.	Mycophenolic Acid	265-286	insulin	Homo sapiens	28-35
11380825-0	2001	Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure.	Mycophenolic Acid	0-21	angiotensinogen	Rattus norvegicus	74-88
11380825-11	2001	Ang II-producing cells were present in the renal tubulointerstitium of rats with SSHTN (60 +/- 30 Ang II-positive cells/mm(2) at 8 weeks) and were reduced by two thirds in the MMF-treated group.	Mycophenolic Acid	176-179	angiotensinogen	Rattus norvegicus	0-6
11328741-0	2001	CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis.	Mycophenolic Acid	88-109	CD4 molecule	Homo sapiens	30-33
11328741-5	2001	Of all patients receiving MMF therapy, only patients with moderate to severe uveitis activity in the pre-MMF treatment group (n = 5; 15.5% +/- 5.0%, P = 0.004) had increased frequency of CD69-positive CD4 T cells compared with healthy volunteers.	Mycophenolic Acid	26-29	CD69 molecule	Homo sapiens	187-191
11264639-6	2001	As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).	Mycophenolic Acid	167-188	interleukin 2 receptor subunit alpha	Homo sapiens	73-77
11377468-0	2001	Mycophenolate mofetil interferes with interferon gamma production in T-cell activation models.	Mycophenolic Acid	0-21	interferon gamma	Homo sapiens	38-54
11264639-10	2001	The average duration of CD25 saturation was prolonged by 39 and 64% in the presence of azathioprine and mycophenolate mofetil, respectively.	Mycophenolic Acid	104-125	interleukin 2 receptor subunit alpha	Homo sapiens	24-28
11240978-10	2001	In addition, a slight but significant enhancement of hypoxanthine-guanine phosphoribosyltransferase activity was seen in the mycophenolate mofetil group.	Mycophenolic Acid	125-146	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	53-99
11328549-13	2001	Both ABO donor-recipient mismatch patients were started on tacrolimus/MMF as primary therapy and had no significant episodes of rejection.	Mycophenolic Acid	70-73	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	5-8
11292296-13	2001	Plasmapheresis and tacrolimus-mycophenolate mofetil rescue reversed rejection in 9 of 10 recipients with refractory AHR.	Mycophenolic Acid	30-51	aryl hydrocarbon receptor	Homo sapiens	116-119
11211184-9	2001	RESULTS: After mycophenolate mofetil was administered, the serum alanine aminotransferase level increased in two patients, did not change in one, and decreased in one.	Mycophenolic Acid	15-36	glutamic--pyruvic transaminase	Homo sapiens	65-89
11250452-0	2001	Membrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in MDCK and MDR1-MDCK cell monolayers.	Mycophenolic Acid	22-43	ATP binding cassette subfamily B member 1	Canis lupus familiaris	101-105
11014804-8	2000	We also show that a deletion of RTF1 causes sensitivity to 6-azauracil and mycophenolic acid, phenotypes correlated with a transcription elongation defect.	Mycophenolic Acid	75-92	Rtf1p	Saccharomyces cerevisiae S288C	32-36
11267268-0	2001	Treatment of calcineurin inhibitor toxicity by dose reduction plus introduction of mycophenolate mofetil.	Mycophenolic Acid	83-104	calcineurin binding protein 1	Homo sapiens	13-34
11165712-5	2001	Granulysin was studied in phytohemagglutinin (PHA) stimulated cell lines (donor PBL and CD45RO(+) T cells) by FACS, Western blotting, and RT-PCR after pretreating with cyclosporine A (CSA), azathioprine, mycophenolic acid, and steroids.	Mycophenolic Acid	204-221	granulysin	Homo sapiens	0-10
11165712-9	2001	Granulysin levels were unchanged after azathioprine and mycophenolic acid treatment, decreased after treating activated PBL with steroids and cyclosporine A (CSA), and paradoxically, increased (p < 0.05) after treating CD45RO(+) CTL with CSA.	Mycophenolic Acid	56-73	granulysin	Homo sapiens	0-10
11127307-0	2000	A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.	Mycophenolic Acid	56-77	calcineurin binding protein 1	Homo sapiens	2-23
11558493-2	2001	We did a randomised controlled trial of mycophenolate mofetil monotherapy in liver transplant patients who developed renal failure associated with calcineurin-inhibitor (ciclosporin or tacrolimus) immunosuppressive therapy.	Mycophenolic Acid	40-61	calcineurin binding protein 1	Homo sapiens	147-168
10915175-0	2000	Acceptance of an ABO-incompatible mismatched (AB(+) to O(+)) liver allograft with the use of daclizumab and mycophenolate mofetil.	Mycophenolic Acid	108-129	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	17-20
10978780-7	2000	The fresh leukemia cells responding to mycophenolate mofetil revealed significant higher positivity to CD11b, CD14, and NBT before treatment and significantly reduced intracellular GTP levels after treatment compared to the non-responding cells.	Mycophenolic Acid	39-60	integrin subunit alpha M	Homo sapiens	103-108
10978780-7	2000	The fresh leukemia cells responding to mycophenolate mofetil revealed significant higher positivity to CD11b, CD14, and NBT before treatment and significantly reduced intracellular GTP levels after treatment compared to the non-responding cells.	Mycophenolic Acid	39-60	CD14 molecule	Homo sapiens	110-114
10949181-0	2000	Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction.	Mycophenolic Acid	60-73	CD40 ligand	Mus musculus	92-97
10915175-11	2000	We are unaware of previous reports of the use of daclizumab and mycophenolate mofetil as part of an immunosuppressive protocol aimed to induce acceptance of ABO-incompatible mismatched liver allografts.	Mycophenolic Acid	64-85	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	157-160
11035376-1	2000	Instead of donor T cell depletion, we used CTLA4 and TJU103 (a small organic compound believed to block CD4 binding to MHC II molecule of APC) to block donor T lymphocyte activation in vitro before infusion, and mycophenolate mofetil to control the activity of lymphocytes of the recipient.	Mycophenolic Acid	212-233	CD4 molecule	Homo sapiens	104-107
10693638-0	2000	A longitudinal study of TGF-beta1 protein levels in renal allograft recipients converted from CsA to MMF or AZA.	Mycophenolic Acid	101-104	transforming growth factor beta 1	Homo sapiens	24-33
10729746-5	2000	Mycophenolate mofetil significantly reduced the production of autoantibodies against gp330 in rats with Heymann nephritis.	Mycophenolic Acid	0-21	LDL receptor related protein 2	Rattus norvegicus	85-90
10501627-0	1999	Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release.	Mycophenolic Acid	31-52	tumor necrosis factor	Mus musculus	90-99
10648663-4	2000	Therefore the aim of this study was to evaluate the effect of the antiproliferative and immunosuppressive agent mycophenolic acid (MPA) on cell growth and cytokine-induced expression of RANTES, HLA-DR and ICAM-1 of highly purified proximal (PTC) and distal tubular cells (DTC) from human kidney.	Mycophenolic Acid	112-129	C-C motif chemokine ligand 5	Homo sapiens	186-192
10648663-4	2000	Therefore the aim of this study was to evaluate the effect of the antiproliferative and immunosuppressive agent mycophenolic acid (MPA) on cell growth and cytokine-induced expression of RANTES, HLA-DR and ICAM-1 of highly purified proximal (PTC) and distal tubular cells (DTC) from human kidney.	Mycophenolic Acid	112-129	intercellular adhesion molecule 1	Homo sapiens	205-211
10648663-4	2000	Therefore the aim of this study was to evaluate the effect of the antiproliferative and immunosuppressive agent mycophenolic acid (MPA) on cell growth and cytokine-induced expression of RANTES, HLA-DR and ICAM-1 of highly purified proximal (PTC) and distal tubular cells (DTC) from human kidney.	Mycophenolic Acid	131-134	C-C motif chemokine ligand 5	Homo sapiens	186-192
10648663-4	2000	Therefore the aim of this study was to evaluate the effect of the antiproliferative and immunosuppressive agent mycophenolic acid (MPA) on cell growth and cytokine-induced expression of RANTES, HLA-DR and ICAM-1 of highly purified proximal (PTC) and distal tubular cells (DTC) from human kidney.	Mycophenolic Acid	131-134	intercellular adhesion molecule 1	Homo sapiens	205-211
10688250-4	2000	Two UDP glucuronosyltransferase forms, UGT1A8 and UGT1A10, were active in the glucuronidation of mycophenolic acid.	Mycophenolic Acid	97-114	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	39-45
10688250-4	2000	Two UDP glucuronosyltransferase forms, UGT1A8 and UGT1A10, were active in the glucuronidation of mycophenolic acid.	Mycophenolic Acid	97-114	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	50-57
10688250-6	2000	The identities of the UDP glucuronosyltransferase forms that are mainly responsible for the glucuronidation of mycophenolic acid in the liver and kidney remain unknown; however, UGT1A9 may be important in this respect as the cDNA-expressed enzyme has some capacity to glucuronidate mycophenolic acid.	Mycophenolic Acid	111-128	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	178-184
10688250-6	2000	The identities of the UDP glucuronosyltransferase forms that are mainly responsible for the glucuronidation of mycophenolic acid in the liver and kidney remain unknown; however, UGT1A9 may be important in this respect as the cDNA-expressed enzyme has some capacity to glucuronidate mycophenolic acid.	Mycophenolic Acid	282-299	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	178-184
10501627-0	1999	Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release.	Mycophenolic Acid	31-52	interleukin 10	Mus musculus	120-125
10405210-6	1999	Combined treatment with ACE inhibitor and a specific antilymphocyte agent, mycophenolate mofetil, dramatically attenuated macrophage and T cell infiltration, MHC-class II overexpression, dendritic cells, and all manifestations of the disease.	Mycophenolic Acid	75-96	angiotensin I converting enzyme	Homo sapiens	24-27
9809157-4	1998	In the area of therapeutics, recombinant growth hormone was shown to improve statural growth of children with chronic renal failure; in addition, renal transplantation benefits from new immunosuppressants as tacrolimus and mycophenolate mofetil.	Mycophenolic Acid	223-244	growth hormone 1	Homo sapiens	41-55
10688409-7	1999	Furtherly, with the knowledge of molecular immunology the better understanding of the cellular and molecular mechanisms that underlie the immunological response to transplanted organs, led to the discovery of new immunosuppressive agents, such as tacrolimus, rapamycin, interleukin-2 monoclonal antibodies, and mycophenolate mofetil.	Mycophenolic Acid	311-332	interleukin 2	Homo sapiens	270-283
10320576-4	1999	The SAP2P-FLP fusion was integrated into one of the SAP2 alleles in a strain that contained a deletable marker that conferred resistance to mycophenolic acid and was flanked by direct repeats of the FLP recognition target (FRT).	Mycophenolic Acid	140-157	stromal antigen 2	Mus musculus	4-8
10353469-0	1999	Alterations of endothelial nucleotide levels by mycophenolic acid result in changes of membrane glycosylation and E-selectin expression.	Mycophenolic Acid	48-65	selectin E	Homo sapiens	114-124
10353469-7	1999	The pronounced reduction of E-selectin surface expression on endothelial cells accompanied by changes of endothelial cell fucosylation, a prerequisite for the contact with lymphocytic L-selectin, indicates an inhibitory effect of mycophenolic acid in the rolling phase of leukocyte recruitment and strongly implies a new and additional immunosuppressive mechanism of this agent.	Mycophenolic Acid	230-247	selectin E	Homo sapiens	28-38
10353469-7	1999	The pronounced reduction of E-selectin surface expression on endothelial cells accompanied by changes of endothelial cell fucosylation, a prerequisite for the contact with lymphocytic L-selectin, indicates an inhibitory effect of mycophenolic acid in the rolling phase of leukocyte recruitment and strongly implies a new and additional immunosuppressive mechanism of this agent.	Mycophenolic Acid	230-247	selectin L	Homo sapiens	184-194
10051052-2	1999	This finding was accompanied by a corresponding reduction of the inactive glucuronide metabolite of MPA (MPAG) in patients, suggesting that tacrolimus may effect the conversion of MPA to MPAG by the enzyme UDP-glucuronosyltransferase (UDPGT).	Mycophenolic Acid	100-103	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	206-233
10051052-2	1999	This finding was accompanied by a corresponding reduction of the inactive glucuronide metabolite of MPA (MPAG) in patients, suggesting that tacrolimus may effect the conversion of MPA to MPAG by the enzyme UDP-glucuronosyltransferase (UDPGT).	Mycophenolic Acid	100-103	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	235-240
10353468-0	1999	Mycophenolic acid influences T helper 2 (Th2) cytokine induced expression of intercellular cell adhesion molecule-1 (ICAM-1) on human endothelial cells.	Mycophenolic Acid	0-17	intercellular adhesion molecule 1	Homo sapiens	77-115
10353468-0	1999	Mycophenolic acid influences T helper 2 (Th2) cytokine induced expression of intercellular cell adhesion molecule-1 (ICAM-1) on human endothelial cells.	Mycophenolic Acid	0-17	intercellular adhesion molecule 1	Homo sapiens	117-123
10069195-1	1999	BACKGROUND: Several multinational controlled clinical trials have shown that triple therapy immunosuppressive regimens which include mycophenolate mofetil (MMF), cyclosporin A (CSA) and steroids (S) are superior compared with conventional regimens which include azathioprine (AZA), CSA and S, mainly because MMF reduces the rate of acute rejection episodes in the first 6 months after kidney transplantation.	Mycophenolic Acid	133-154	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	282-285
10083525-0	1999	Mycophenolic acid inhibits PDGF-induced osteopontin expression in rat mesangial cells.	Mycophenolic Acid	0-17	secreted phosphoprotein 1	Rattus norvegicus	40-51
10083559-0	1999	Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells.	Mycophenolic Acid	0-21	CD4 molecule	Homo sapiens	71-74
10083559-0	1999	Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells.	Mycophenolic Acid	0-21	CD8a molecule	Homo sapiens	79-82
9869086-14	1998	CONCLUSIONS: Our findings suggest that a therapeutic approach combining PE and tacrolimus-mycophenolate mofetil rescue has the potential to improve the outcome of AHR.	Mycophenolic Acid	90-111	aryl hydrocarbon receptor	Homo sapiens	163-166
9794567-17	1998	CONCLUSIONS: These preliminary results suggest that in low-immunological-risk patients who receive a suboptimal renal allograft or at risk of delayed graft function, the combination of MMF, ATG, and steroids is an efficient immunosuppressive regime that may avoid the use of CsA in 70% of the recipients.	Mycophenolic Acid	185-188	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	275-278
8632430-0	1996	Nuclear magnetic resonance and molecular modeling study on mycophenolic acid: implications for binding to inosine monophosphate dehydrogenase.	Mycophenolic Acid	59-76	inosine monophosphate dehydrogenase 1	Homo sapiens	106-141
9593124-8	1998	The fact that the phosphorylation of D-CdG was stimulated by mycophenolic acid and was not affected by deoxycytidine suggested that 5"-nucleotidase was the enzyme primarily responsible for its metabolism in virally infected cells.	Mycophenolic Acid	61-78	5'-nucleotidase ecto	Homo sapiens	132-147
9598106-0	1998	IMP-dehydrogenase (IMPDH), hypoxanthine-guanine phosphoribosyltransferase (HGPRT), and phosphodiesterases (PDEs) expression during mycophenolic acid (MPA)-induced differentiation in human neuroblastoma cell lines.	Mycophenolic Acid	131-148	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	75-80
9598129-0	1998	Mycophenolic acid influences the expression of ICAM-1 on human endothelial cells.	Mycophenolic Acid	0-17	intercellular adhesion molecule 1	Homo sapiens	47-53
9325166-0	1997	The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid.	Mycophenolic Acid	63-80	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	39-46
9325166-3	1997	The enzyme synthesized in UGT1A10 cDNA-transfected COS-7 cells has a relative molecular mass of 56 kDa and is very active in the glucuronidation of mycophenolic acid (apparent Km of 34 microM and Vmax of 0.6 nmoles/min/mg protein).	Mycophenolic Acid	148-165	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	26-33
9299166-10	1997	Mycophenolic acid (50 microM, 2-h treatment) caused partial translocation of RH-II/Gu; this effect was slowly reversed upon drug removal and was inhibited by 100 microM guanosine, in a manner similar to the effects of mycophenolic acid on the localization of nucleophosmin/B23.	Mycophenolic Acid	0-17	DExD-box helicase 21	Homo sapiens	77-85
9299166-10	1997	Mycophenolic acid (50 microM, 2-h treatment) caused partial translocation of RH-II/Gu; this effect was slowly reversed upon drug removal and was inhibited by 100 microM guanosine, in a manner similar to the effects of mycophenolic acid on the localization of nucleophosmin/B23.	Mycophenolic Acid	0-17	nucleophosmin 1	Homo sapiens	259-272
9299166-10	1997	Mycophenolic acid (50 microM, 2-h treatment) caused partial translocation of RH-II/Gu; this effect was slowly reversed upon drug removal and was inhibited by 100 microM guanosine, in a manner similar to the effects of mycophenolic acid on the localization of nucleophosmin/B23.	Mycophenolic Acid	0-17	nucleophosmin 1	Homo sapiens	273-276
8725879-2	1996	Unlike other genes tested to date in brain tumor models, the Escherichia coli gpt gene is unique in that it not only sensitizes cells to the prodrug 6-thioxanthine (6TX) but also encodes resistance to a different regimen (mycophenolic acid, xanthine, and hypoxanthine), thus providing a means to select for gpt-positive cells.	Mycophenolic Acid	222-239	glutamic--pyruvic transaminase	Rattus norvegicus	78-81
9698512-1	1998	BACKGROUND: Recent multicenter reports have demonstrated improved outcome in recipients of cadaveric renal transplants treated with mycophenolate mofetil (MMF) versus azathioprine (AZA) in combination with cyclosporine A (CSA) and prednisone.	Mycophenolic Acid	132-153	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	222-225
9698512-1	1998	BACKGROUND: Recent multicenter reports have demonstrated improved outcome in recipients of cadaveric renal transplants treated with mycophenolate mofetil (MMF) versus azathioprine (AZA) in combination with cyclosporine A (CSA) and prednisone.	Mycophenolic Acid	155-158	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	222-225
9565100-8	1998	Low pharmacologic concentrations of tacrolimus/cyclosporine (CsA) and mycophenolic acid (MPA) singly or in combination had no effect on the spontaneous proliferation of DBMC and had significantly less inhibitory activity on MLC responses of DBMC and its purified CD3+ or CD34+ subpopulations, compared with the responses of spleen cells.	Mycophenolic Acid	70-87	CD34 molecule	Homo sapiens	271-275
9565100-8	1998	Low pharmacologic concentrations of tacrolimus/cyclosporine (CsA) and mycophenolic acid (MPA) singly or in combination had no effect on the spontaneous proliferation of DBMC and had significantly less inhibitory activity on MLC responses of DBMC and its purified CD3+ or CD34+ subpopulations, compared with the responses of spleen cells.	Mycophenolic Acid	89-92	CD34 molecule	Homo sapiens	271-275
9421277-0	1997	Effect of mycophenolic acid on TNF alpha-induced expression of cell adhesion molecules in human venous endothelial cells in vitro.	Mycophenolic Acid	10-27	tumor necrosis factor	Homo sapiens	31-40
8762015-9	1996	In addition, the number of cells positive for MHC class II and LFA-1 was reduced in the MMF-treated animals.	Mycophenolic Acid	88-91	integrin subunit alpha L	Rattus norvegicus	63-68
8568826-2	1996	The derivatives with a methyl group or hydrogen at C-4 and lacking the lactone moiety were much less cytotoxic than mycophenolic acid.	Mycophenolic Acid	116-133	complement C4A (Rodgers blood group)	Homo sapiens	51-54
8568826-3	1996	The monocyclic analogues with a C-4 chloro group did show some activity, albeit much less than mycophenolic acid.	Mycophenolic Acid	95-112	complement C4A (Rodgers blood group)	Homo sapiens	32-35
8632430-1	1996	The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from 1D DIFNOE and 2D ROESY experiments in water and molecular dynamics (MD) is described.	Mycophenolic Acid	39-56	inosine monophosphate dehydrogenase 1	Homo sapiens	86-121
8632430-1	1996	The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from 1D DIFNOE and 2D ROESY experiments in water and molecular dynamics (MD) is described.	Mycophenolic Acid	39-56	inosine monophosphate dehydrogenase 1	Homo sapiens	123-127
8632430-1	1996	The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from 1D DIFNOE and 2D ROESY experiments in water and molecular dynamics (MD) is described.	Mycophenolic Acid	58-61	inosine monophosphate dehydrogenase 1	Homo sapiens	86-121
8632430-1	1996	The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from 1D DIFNOE and 2D ROESY experiments in water and molecular dynamics (MD) is described.	Mycophenolic Acid	58-61	inosine monophosphate dehydrogenase 1	Homo sapiens	123-127
8549684-1	1995	Mycophenolate mofetil (MM), an inhibitor of purine metabolism, was found to effectively inhibit the development of experimental autoimmune uveoretinitis (EAU) induced by S-antigen (SAg) in Lewis rats.	Mycophenolic Acid	0-21	S-antigen visual arrestin	Rattus norvegicus	170-179
8549684-1	1995	Mycophenolate mofetil (MM), an inhibitor of purine metabolism, was found to effectively inhibit the development of experimental autoimmune uveoretinitis (EAU) induced by S-antigen (SAg) in Lewis rats.	Mycophenolic Acid	0-21	S-antigen visual arrestin	Rattus norvegicus	181-184
8549684-1	1995	Mycophenolate mofetil (MM), an inhibitor of purine metabolism, was found to effectively inhibit the development of experimental autoimmune uveoretinitis (EAU) induced by S-antigen (SAg) in Lewis rats.	Mycophenolic Acid	23-25	S-antigen visual arrestin	Rattus norvegicus	170-179
8549684-1	1995	Mycophenolate mofetil (MM), an inhibitor of purine metabolism, was found to effectively inhibit the development of experimental autoimmune uveoretinitis (EAU) induced by S-antigen (SAg) in Lewis rats.	Mycophenolic Acid	23-25	S-antigen visual arrestin	Rattus norvegicus	181-184
7544050-1	1995	Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase, shows strong anti-HIV activity in vitro in both human peripheral blood CD4+ lymphocytes and macrophages, as well as established human cell lines.	Mycophenolic Acid	0-17	CD4 molecule	Homo sapiens	149-152
8554903-2	1995	Treatment of Rev-expressing cells with mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, resulted in a redistribution of Rev from the nucleoli to the nucleoplasm and cytoplasm.	Mycophenolic Acid	39-56	Rev	Human immunodeficiency virus 1	13-16
8554903-2	1995	Treatment of Rev-expressing cells with mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, resulted in a redistribution of Rev from the nucleoli to the nucleoplasm and cytoplasm.	Mycophenolic Acid	39-56	Rev	Human immunodeficiency virus 1	143-146
7655019-4	1995	Bcl-XL expression dramatically reduces the cytotoxicity of bleomycin, cisplatin, etoposide, vincristine, hygromycin B, and mycophenolic acid for up to 4 days in culture.	Mycophenolic Acid	123-140	BCL2 like 1	Homo sapiens	0-6
7544050-1	1995	Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase, shows strong anti-HIV activity in vitro in both human peripheral blood CD4+ lymphocytes and macrophages, as well as established human cell lines.	Mycophenolic Acid	19-22	CD4 molecule	Homo sapiens	149-152
7600680-0	1995	Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics.	Mycophenolic Acid	0-17	albumin	Homo sapiens	35-48
7565647-3	1995	Cells were first depleted of GTP with the IMP dehydrogenase inhibitor, mycophenolic acid (MA), to induce translocation of NPM from the nucleoli to the nucleoplasm.	Mycophenolic Acid	71-88	nucleophosmin 1	Homo sapiens	122-125
7604443-1	1995	This is an initial study of the immunosuppressive efficacy of CAM, a derivative of mycophenolic acid, in a rat heart allograft model when the major histocompatibility complex was fully incompatible, and its effect in improving heart allograft survival compared with mycophenolate mofetil (MMF, RS-61443).	Mycophenolic Acid	83-100	calmodulin 1	Rattus norvegicus	62-65
7604443-1	1995	This is an initial study of the immunosuppressive efficacy of CAM, a derivative of mycophenolic acid, in a rat heart allograft model when the major histocompatibility complex was fully incompatible, and its effect in improving heart allograft survival compared with mycophenolate mofetil (MMF, RS-61443).	Mycophenolic Acid	266-287	calmodulin 1	Rattus norvegicus	62-65
7604443-1	1995	This is an initial study of the immunosuppressive efficacy of CAM, a derivative of mycophenolic acid, in a rat heart allograft model when the major histocompatibility complex was fully incompatible, and its effect in improving heart allograft survival compared with mycophenolate mofetil (MMF, RS-61443).	Mycophenolic Acid	289-292	calmodulin 1	Rattus norvegicus	62-65
7878746-13	1995	In contrast, recipient treatment with RS61443 (both Gp 1 and Gp 2) allowed the allografts to function normally throughout follow-up period.	Mycophenolic Acid	38-45	glycoprotein 2	Rattus norvegicus	52-65
8440321-0	1993	Regulated expression of the MRP8 and MRP14 genes in human promyelocyticleukemic HL-60 cells treated with the differentiation-inducing agents mycophenolic acid and 1 alpha,25-dihydroxyvitamin D3.	Mycophenolic Acid	141-158	ATP binding cassette subfamily C member 11	Homo sapiens	28-32
7963539-2	1994	Mycophenolic acid-treated long-term bone marrow cultures were charged with stromally depleted bone marrow cells along with 10 to 500 U/ml recombinant human TNF-alpha, and assayed each week for 5 wk for the presence of primitive (CFU-S and high proliferative potential colony-forming cell) and mature (CFU-C) colony-forming units.	Mycophenolic Acid	0-17	tumor necrosis factor	Homo sapiens	156-165
7521360-6	1994	Our results show that when CsA is used as the primary ISD, further proliferation can be inhibited by rapamycin, mycophenolic acid, or suramin.	Mycophenolic Acid	112-129	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	27-30
8324935-4	1993	Treatment with mycophenolate mofetil reduces rheumatoid factor titres, immunoglobulin (IgG, IgM, and IgA) levels, and the total number of T cells (CD2) in RA patient peripheral blood; in addition, lymphocyte mitogen responses are inhibited and delayed hypersensitivity skin test reactivity is decreased.	Mycophenolic Acid	15-36	CD2 molecule	Homo sapiens	147-150
7506264-3	1994	Toxin (doxorubicin or mycophenolic acid) was attached to synthetic AcMBP(1-14)Ala4 peptide, an analog of the natural acetylated NH2-terminal segment, AcMBP(1-14), of rat myelin basic protein (MBP).	Mycophenolic Acid	22-39	myelin basic protein	Rattus norvegicus	69-72
7509129-0	1993	Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro.	Mycophenolic Acid	18-35	interleukin 4	Homo sapiens	83-97
7509129-0	1993	Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro.	Mycophenolic Acid	18-35	immunoglobulin heavy constant epsilon	Homo sapiens	121-124
7509129-1	1993	We investigated the effect of cyclosporin A (CsA), mycophenolic acid (MPA), and brequinar sodium (BQ) on human IgG4 and IgE synthesis induced by IL-4 or IL-13.	Mycophenolic Acid	70-73	immunoglobulin heavy constant epsilon	Homo sapiens	120-123
7509129-1	1993	We investigated the effect of cyclosporin A (CsA), mycophenolic acid (MPA), and brequinar sodium (BQ) on human IgG4 and IgE synthesis induced by IL-4 or IL-13.	Mycophenolic Acid	70-73	interleukin 4	Homo sapiens	145-149
8109827-0	1993	Mycophenolic acid and some antioxidants induce differentiation of monocytic lineage cells and augment production of the IL-1 receptor antagonist.	Mycophenolic Acid	0-17	interleukin 1 receptor antagonist	Homo sapiens	120-144
8280797-6	1993	In vitro, gpt-positive K3T3 clones could be selected on the basis of resistance to a regimen containing mycophenolic acid and xanthine; the same clones were 18 to 86 times as sensitive to 6-thioxanthine (6TX) as their gpt-negative counterparts.	Mycophenolic Acid	104-121	glutamic pyruvic transaminase, soluble	Mus musculus	10-13
8440321-0	1993	Regulated expression of the MRP8 and MRP14 genes in human promyelocyticleukemic HL-60 cells treated with the differentiation-inducing agents mycophenolic acid and 1 alpha,25-dihydroxyvitamin D3.	Mycophenolic Acid	141-158	S100 calcium binding protein A9	Homo sapiens	37-42
8440321-2	1993	We determined the levels of a protein complex (PC) containing MRP8 and MRP14 and investigated the mechanism by which the genes encoding these proteins are regulated in HL-60 cells treated with the differentiation-inducing agent mycophenolic acid (MPA).	Mycophenolic Acid	228-245	ATP binding cassette subfamily C member 11	Homo sapiens	62-66
1627163-0	1992	E. coli gpt gene expression effects on K562 human leukemia cell proliferation and erythroid differentiation altered by mycophenolic acid.	Mycophenolic Acid	119-136	glutamic--pyruvic transaminase	Homo sapiens	8-11
1418979-3	1992	Primers based on the sequence of the target gene enable amplification of flanking arms and their subsequent attachment to the gpt cassette that confers resistance to mycophenolic acid.	Mycophenolic Acid	166-183	glutamic--pyruvic transaminase	Homo sapiens	126-129
8020339-2	1993	Inhibitors of the de novo purinergic synthesis pathways for AMP, GMP and IMP by hadacidin, mycophenolic acid and azaserine, respectively, or adenosine, guanosine or inosine alone or in combination were given every 4 or 6 hours in vivo.	Mycophenolic Acid	91-108	5'-nucleotidase, cytosolic II	Homo sapiens	65-68
8020339-4	1993	Hadacidin lowered AMP (p < or = 0.01) and azaserine tended to lower IMP and the GMP: AMP ratio (p < or = 01) while mycophenolic acid tended to lower the GMP:AMP ratio (p < or = 0.1) in luteal tissue.	Mycophenolic Acid	121-138	5'-nucleotidase, cytosolic II	Homo sapiens	159-162
1677450-3	1991	In the present in vitro study, the formation in human T cells (MOLT-4, ATH8, and CCRF-CEM) of the pharmacologically active metabolite of ddIno and ddAdo, 2",3"-dideoxyadenosine-5"-triphosphate (ddATP), was found to be stimulated 2-4-fold by appropriate concentrations of inosinate dehydrogenase (IMPD) inhibitors such as ribavirin, tiazofurin, and mycophenolic acid.	Mycophenolic Acid	348-365	inosine monophosphate dehydrogenase 1	Homo sapiens	296-300
1826574-0	1991	Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1.	Mycophenolic Acid	36-53	SH2 domain containing 3A	Homo sapiens	118-122
1980599-4	1990	A detailed analysis of the HO and SK-MEL-131 cell lines indicated that mycophenolic acid and tiazofurin caused a time- and dose-dependent increase in the expression of a series of other maturation markers, including formation of dendrite-like structures, tyrosinase activity, and reactivity with the CF21 monoclonal antibody.	Mycophenolic Acid	71-88	tyrosinase	Homo sapiens	255-265
1989387-2	1991	A plasmid containing E. coli gpt inserted within a large deletion in the DNA ligase gene was transfected into vaccinia virus-infected cells and recombinant viruses selected by three cycles of plaque purification in the presence of mycophenolic acid (MPA).	Mycophenolic Acid	231-248	glutamic--pyruvic transaminase	Homo sapiens	29-32
2119478-3	1990	To examine the expression of genes containing the immunoglobulin heavy chain gene (IgH) enhancer in stably transfected non-B cells, we used a vector with two selectable markers, one of which (gpt providing resistance to mycophenolic acid) either lacks an enhancer or contains the IgH enhancer, the other (neo providing resistance to G418) contains an SV40 enhancer.	Mycophenolic Acid	220-237	glutamic pyruvic transaminase, soluble	Mus musculus	192-195
2119478-5	1990	When the IgH enhancer is positioned 3" to the gpt gene, transfected J558L are mycophenolic acid resistant whereas stably transfected L-cells are mycophenolic acid sensitive.	Mycophenolic Acid	78-95	immunoglobulin heavy chain complex	Mus musculus	9-12
2119478-5	1990	When the IgH enhancer is positioned 3" to the gpt gene, transfected J558L are mycophenolic acid resistant whereas stably transfected L-cells are mycophenolic acid sensitive.	Mycophenolic Acid	78-95	glutamic pyruvic transaminase, soluble	Mus musculus	46-49
2119478-5	1990	When the IgH enhancer is positioned 3" to the gpt gene, transfected J558L are mycophenolic acid resistant whereas stably transfected L-cells are mycophenolic acid sensitive.	Mycophenolic Acid	145-162	immunoglobulin heavy chain complex	Mus musculus	9-12
2119478-5	1990	When the IgH enhancer is positioned 3" to the gpt gene, transfected J558L are mycophenolic acid resistant whereas stably transfected L-cells are mycophenolic acid sensitive.	Mycophenolic Acid	145-162	glutamic pyruvic transaminase, soluble	Mus musculus	46-49
2119478-8	1990	In both cases, in the mycophenolic acid resistant subclones, increased accumulation of gpt and neo mRNA is seen.	Mycophenolic Acid	22-39	glutamic pyruvic transaminase, soluble	Mus musculus	87-90
34725108-3	2022	Results: In MPA-treated R+ KTR, both alphabeta and gammadelta T-cells displayed a more dysfunctional phenotype (PD-1+, CD85j+) at day 0 of transplantation in the 16 KTR with severe CMV infection when compared to the 17 KTR without or with spontaneously resolving CMV infection.	Mycophenolic Acid	12-15	leukocyte immunoglobulin like receptor B1	Homo sapiens	119-124
34922024-9	2022	In terms of the predictors of GI symptoms, it was determined that mycophenolate mofetil (MMF) was effective in the development of reflux and diarrhoea, cyclosporine in the development of diarrhoea and constipation, and tacrolimus in the development of indigestion, which are (p < 0.05).	Mycophenolic Acid	66-87	G protein subunit alpha i1	Homo sapiens	30-32
34922024-9	2022	In terms of the predictors of GI symptoms, it was determined that mycophenolate mofetil (MMF) was effective in the development of reflux and diarrhoea, cyclosporine in the development of diarrhoea and constipation, and tacrolimus in the development of indigestion, which are (p < 0.05).	Mycophenolic Acid	89-92	G protein subunit alpha i1	Homo sapiens	30-32
33774745-4	2021	CASE-DIAGNOSIS/TREATMENT: We report on two children, diagnosed with mildly severe aHUS due to anti-CFH antibodies, who were treated with the association eculizumab-mycophenolate mofetil (MMF).	Mycophenolic Acid	164-185	complement factor H	Homo sapiens	99-102
33767058-4	2021	A multicentre study supported the use of mycophenolate mofetil (MMF) in C3G even after a propensity matching analysis.	Mycophenolic Acid	41-62	Rap guanine nucleotide exchange factor 1	Homo sapiens	72-75
33767058-4	2021	A multicentre study supported the use of mycophenolate mofetil (MMF) in C3G even after a propensity matching analysis.	Mycophenolic Acid	64-67	Rap guanine nucleotide exchange factor 1	Homo sapiens	72-75
27011912-1	2016	Tacrolimus (Prograf( ), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil, corticosteroids, with or without basiliximab induction.	Mycophenolic Acid	231-252	BH3 interacting domain death agonist	Homo sapiens	103-106
34967072-7	2022	G-CSF use was associated with transplant center, induction immunosuppression, steroid-free maintenance immunosuppression, hospitalization, and decreases in mycophenolate mofetil, valganciclovir, and trimethoprim-sulfamethoxazole dosing.	Mycophenolic Acid	156-177	colony stimulating factor 3	Homo sapiens	0-5
34654723-7	2021	Mycophenolic acid, the active metabolite of FDA-approved drug mycophenolate mofetil, was identified as an HNF4alpha antagonist exhibiting anti-IMA activities in vitro and in vivo.	Mycophenolic Acid	0-17	hepatocyte nuclear factor 4 alpha	Homo sapiens	106-115
34537545-0	2021	The important role of RPS14, RPL5 and MDM2 in TP53-associated ribosome stress in mycophenolic acid-induced microtia.	Mycophenolic Acid	81-98	ribosomal protein S14	Homo sapiens	22-27
34537545-0	2021	The important role of RPS14, RPL5 and MDM2 in TP53-associated ribosome stress in mycophenolic acid-induced microtia.	Mycophenolic Acid	81-98	ribosomal protein L5	Homo sapiens	29-33
34537545-0	2021	The important role of RPS14, RPL5 and MDM2 in TP53-associated ribosome stress in mycophenolic acid-induced microtia.	Mycophenolic Acid	81-98	MDM2 proto-oncogene	Homo sapiens	38-42
34537545-0	2021	The important role of RPS14, RPL5 and MDM2 in TP53-associated ribosome stress in mycophenolic acid-induced microtia.	Mycophenolic Acid	81-98	tumor protein p53	Homo sapiens	46-50
34166800-3	2021	METHODS: This retrospective study included 77 patients with CS treated with prednisone monotherapy (n=32) or a combination with mycophenolate mofetil (MMF) (n=45) between 2003 and 2018.	Mycophenolic Acid	128-149	citrate synthase	Homo sapiens	60-62
34169529-0	2021	Association of ABCC2 Haplotypes to Mycophenolic Acid Pharmacokinetics in Stable Kidney Transplant Recipients.	Mycophenolic Acid	35-52	ATP binding cassette subfamily C member 2	Homo sapiens	15-20
34169529-8	2021	There were significant associations of pharmacokinetic parameters with ABCC2 haplotypes for mycophenolic acid clearance (L/hr), mycophenolic acid AUC0-12h (mg hr/L) and the ratio of mycophenolic acid glucuronide to mycophenolic acid AUC0-12h .	Mycophenolic Acid	92-109	ATP binding cassette subfamily C member 2	Homo sapiens	71-76
34169529-8	2021	There were significant associations of pharmacokinetic parameters with ABCC2 haplotypes for mycophenolic acid clearance (L/hr), mycophenolic acid AUC0-12h (mg hr/L) and the ratio of mycophenolic acid glucuronide to mycophenolic acid AUC0-12h .	Mycophenolic Acid	128-145	ATP binding cassette subfamily C member 2	Homo sapiens	71-76
34169529-8	2021	There were significant associations of pharmacokinetic parameters with ABCC2 haplotypes for mycophenolic acid clearance (L/hr), mycophenolic acid AUC0-12h (mg hr/L) and the ratio of mycophenolic acid glucuronide to mycophenolic acid AUC0-12h .	Mycophenolic Acid	182-199	ATP binding cassette subfamily C member 2	Homo sapiens	71-76
34169529-8	2021	There were significant associations of pharmacokinetic parameters with ABCC2 haplotypes for mycophenolic acid clearance (L/hr), mycophenolic acid AUC0-12h (mg hr/L) and the ratio of mycophenolic acid glucuronide to mycophenolic acid AUC0-12h .	Mycophenolic Acid	215-232	ATP binding cassette subfamily C member 2	Homo sapiens	71-76
34169529-9	2021	The wildtype haplotype ABCC2 CGC had greater mycophenolic acid AUC0-12h (P = 0.017), slower clearance (P = 0.013) and lower mycophenolic acid glucuronide to mycophenolic acid AUC0-12h ratio (P = 0.047) compared to the reduced function ABCC2 haplotype, CGT.	Mycophenolic Acid	45-62	ATP binding cassette subfamily C member 2	Homo sapiens	23-28
34169529-9	2021	The wildtype haplotype ABCC2 CGC had greater mycophenolic acid AUC0-12h (P = 0.017), slower clearance (P = 0.013) and lower mycophenolic acid glucuronide to mycophenolic acid AUC0-12h ratio (P = 0.047) compared to the reduced function ABCC2 haplotype, CGT.	Mycophenolic Acid	124-141	ATP binding cassette subfamily C member 2	Homo sapiens	23-28
34284043-1	2021	The most frequently used immunosuppressive treatment in kidney transplant recipients is the combination therapy of a calcineurin inhibitor and mycophenolate mofetil (MMF), with or without corticosteroids.	Mycophenolic Acid	166-169	calcineurin binding protein 1	Homo sapiens	117-138
34654723-7	2021	Mycophenolic acid, the active metabolite of FDA-approved drug mycophenolate mofetil, was identified as an HNF4alpha antagonist exhibiting anti-IMA activities in vitro and in vivo.	Mycophenolic Acid	62-83	hepatocyte nuclear factor 4 alpha	Homo sapiens	106-115
34169529-9	2021	The wildtype haplotype ABCC2 CGC had greater mycophenolic acid AUC0-12h (P = 0.017), slower clearance (P = 0.013) and lower mycophenolic acid glucuronide to mycophenolic acid AUC0-12h ratio (P = 0.047) compared to the reduced function ABCC2 haplotype, CGT.	Mycophenolic Acid	157-174	ATP binding cassette subfamily C member 2	Homo sapiens	23-28
34169529-12	2021	Variation in ABCC2 haplotypes contributes to sub-therapeutic mycophenolic acid exposures and influences interpatient variability in pharmacokinetic phenotypes based upon the concurrent calcineurin inhibitor treatment.	Mycophenolic Acid	61-78	ATP binding cassette subfamily C member 2	Homo sapiens	13-18
34312870-8	2021	The post-transplant time, serum albumin, and creatinine clearance were identified as significant covariates affecting the PK of MPA and MPAG, which should be considered in the clinical use of mycophenolate mofetil.	Mycophenolic Acid	128-131	albumin	Homo sapiens	32-39
34166800-3	2021	METHODS: This retrospective study included 77 patients with CS treated with prednisone monotherapy (n=32) or a combination with mycophenolate mofetil (MMF) (n=45) between 2003 and 2018.	Mycophenolic Acid	151-154	citrate synthase	Homo sapiens	60-62
34105062-9	2021	Heterozygous carriers of the UGT1A9 -275T>A polymorphism were observed to have a significantly lower MPA exposure than wild-type individuals.	Mycophenolic Acid	101-104	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	29-35
34779909-0	2022	Serum albumin level is associated with mycophenolic acid concentration in children with idiopathic nephrotic syndrome.	Mycophenolic Acid	39-56	albumin	Homo sapiens	6-13
34779909-4	2022	However, few studies have focused on the association between serum concentrations of MPA and albumin.	Mycophenolic Acid	85-88	albumin	Homo sapiens	93-100
34779909-5	2022	This retrospective observational study aimed to evaluate the relationship between the serum concentrations of MPA and albumin in INS children.	Mycophenolic Acid	110-113	albumin	Homo sapiens	118-125
34779909-11	2022	Furthermore, MPA AUC0-12 levels positively correlated with sAlb concentrations (p < 0.001) and were inversely correlated with eGFR values (p = 0.005) but not with CsA AUC0-12 (p = 0.24) and age (p = 0.65).Conclusion: Serum albumin concentration was strongly associated with total MPA concentration compared with kidney function or CsA values.	Mycophenolic Acid	280-283	albumin	Homo sapiens	223-230
34779909-14	2022	Kidney function, cyclosporin concentrations, or serum albumin concentrations influence serum mycophenolic acid levels.	Mycophenolic Acid	93-110	albumin	Homo sapiens	48-61
34779909-15	2022	What is New:   Serum albumin concentration is more strongly associated with total mycophenolic acid concentration than kidney function or cyclosporin values.	Mycophenolic Acid	82-99	albumin	Homo sapiens	21-28
34390491-9	2021	Significant correlation between abundance and activity (measured by mycophenolic acid clearance) was observed for UGT1A9 (Rs=0.65, p=0.004) and UGT2B7 (Rs=0.70, p=0.023).	Mycophenolic Acid	68-85	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	114-120
34390491-9	2021	Significant correlation between abundance and activity (measured by mycophenolic acid clearance) was observed for UGT1A9 (Rs=0.65, p=0.004) and UGT2B7 (Rs=0.70, p=0.023).	Mycophenolic Acid	68-85	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	144-150
34581204-0	2021	Effect of UGT polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patients.	Mycophenolic Acid	73-90	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	10-13
34581204-3	2021	Although, many studies have focused on the relationship between UGT polymorphisms and pharmacokinetics and adverse reactions of MPA, the conclusion are controversial.	Mycophenolic Acid	128-131	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	64-67
34797551-14	2022	CONCLUSIONS: RTX, AZA, and MMF therapies efficiently lowered the relapse frequency and disability in both of the AQP4-Ab seropositive or seronegative patients with NMO.	Mycophenolic Acid	27-30	aquaporin 4	Homo sapiens	113-117
34694439-11	2021	Within the SSc cohort, mycophenolate intake was associated with lower T helper cells and lower NK cells (CD56+/CD3-).	Mycophenolic Acid	23-36	neural cell adhesion molecule 1	Homo sapiens	105-109
34077831-0	2021	Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders.	Mycophenolic Acid	25-46	myelin oligodendrocyte glycoprotein	Homo sapiens	72-107
34188518-0	2021	Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 -106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients.	Mycophenolic Acid	87-104	inosine monophosphate dehydrogenase 1	Homo sapiens	47-53
34296353-6	2022	SLE treatment using mycophenolate mofetil (1500 mg/day) was initiated, and serum complements levels increased as FGF-23 level increased.	Mycophenolic Acid	20-41	fibroblast growth factor 23	Homo sapiens	113-119
34124077-5	2021	We report here that IMPDH2 cytoophidium forms in vivo in the growing oocytes naturally and in vitro in the cumulus-enclosed oocytes treated with IMPDH inhibitor mycophenolic acid (MPA).	Mycophenolic Acid	161-178	inosine monophosphate dehydrogenase 2	Mus musculus	20-26
34075374-7	2021	We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction.	Mycophenolic Acid	131-148	inosine monophosphate dehydrogenase 2	Homo sapiens	23-29
34075374-7	2021	We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction.	Mycophenolic Acid	131-148	nuclear factor kappa B subunit 1	Homo sapiens	180-189
34075374-7	2021	We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction.	Mycophenolic Acid	150-153	inosine monophosphate dehydrogenase 2	Homo sapiens	23-29
34075374-7	2021	We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction.	Mycophenolic Acid	150-153	nuclear factor kappa B subunit 1	Homo sapiens	180-189
34522770-0	2021	Mycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies.	Mycophenolic Acid	0-21	insulin	Homo sapiens	72-79
34522770-0	2021	Mycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies.	Mycophenolic Acid	0-21	insulin	Homo sapiens	101-108
34570631-4	2021	In contrast, treatment with tacrolimus or mycophenolate led to reduced expression of functional molecule GITR in CB-Tregs, impaired their viability, proliferation and mitochondrial metabolism.	Mycophenolic Acid	42-55	TNF receptor superfamily member 18	Homo sapiens	105-109
34201974-0	2021	A Novel Curcumin-Mycophenolic Acid Conjugate Inhibited Hyperproliferation of Tumor Necrosis Factor-Alpha-Induced Human Keratinocyte Cells.	Mycophenolic Acid	17-34	tumor necrosis factor	Homo sapiens	77-104
35143644-2	2022	We performed a prospective randomized, multicenter, phase III trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse free survival (GRFS) as compared to the combination of CsA and mycophenolic acid (MPA) after non-myeloablative (NMA) matched related and unrelated peripheral blood alloHSCT.	Mycophenolic Acid	322-339	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	173-176
35143644-2	2022	We performed a prospective randomized, multicenter, phase III trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse free survival (GRFS) as compared to the combination of CsA and mycophenolic acid (MPA) after non-myeloablative (NMA) matched related and unrelated peripheral blood alloHSCT.	Mycophenolic Acid	341-344	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	173-176
34124077-5	2021	We report here that IMPDH2 cytoophidium forms in vivo in the growing oocytes naturally and in vitro in the cumulus-enclosed oocytes treated with IMPDH inhibitor mycophenolic acid (MPA).	Mycophenolic Acid	180-183	inosine monophosphate dehydrogenase 2	Mus musculus	20-26
34124077-8	2021	In cultured COCs, MPA-treatment causes the simultaneous formation of IMPDH cytoopidium in cumulus cells and the resumption of meiosis in oocytes, which is mediated by the MTOR pathway and is prevented by guanosine supplementation.	Mycophenolic Acid	18-21	mechanistic target of rapamycin kinase	Mus musculus	171-175
35064793-13	2022	The combined effects of myeloperoxidase concentration and renal function resulted in a sixfold range of MPA dose.	Mycophenolic Acid	104-107	myeloperoxidase	Homo sapiens	24-39
35143644-5	2022	The cumulative incidence of grade II-IV acute GVHD at six months was 48% in recipients of CsA/MPA versus 30% following PT-Cy/CsA (Hazard ratio (HR): 0.48, 95% confidence interval (CI): 0.29-0.82, p=0.007).	Mycophenolic Acid	94-97	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	90-93
35524809-1	2022	PURPOSE: To investigate the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid (MPA).	Mycophenolic Acid	129-146	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	54-60
35524809-1	2022	PURPOSE: To investigate the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid (MPA).	Mycophenolic Acid	148-151	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	54-60
35524809-2	2022	METHODS: PubMed, Web of Science, Embase, Cochrane Library, Wanfang Data, and the China Academic Journal Network Publishing Database were systematically searched for studies investigating the associations of IMPDH1, IMPDH2, and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking MPA.	Mycophenolic Acid	302-305	inosine monophosphate dehydrogenase 1	Homo sapiens	207-213
35524809-2	2022	METHODS: PubMed, Web of Science, Embase, Cochrane Library, Wanfang Data, and the China Academic Journal Network Publishing Database were systematically searched for studies investigating the associations of IMPDH1, IMPDH2, and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking MPA.	Mycophenolic Acid	302-305	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	227-233
35524809-8	2022	CONCLUSIONS: IMPDH1, IMPDH2, and UGT1A9 polymorphisms were associated with rejection in kidney transplant recipients, and the genetic backgrounds of patients should be considered when using MPA.	Mycophenolic Acid	190-193	inosine monophosphate dehydrogenase 1	Homo sapiens	13-19
35524809-8	2022	CONCLUSIONS: IMPDH1, IMPDH2, and UGT1A9 polymorphisms were associated with rejection in kidney transplant recipients, and the genetic backgrounds of patients should be considered when using MPA.	Mycophenolic Acid	190-193	inosine monophosphate dehydrogenase 2	Homo sapiens	21-27
35524809-8	2022	CONCLUSIONS: IMPDH1, IMPDH2, and UGT1A9 polymorphisms were associated with rejection in kidney transplant recipients, and the genetic backgrounds of patients should be considered when using MPA.	Mycophenolic Acid	190-193	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	33-39
35508891-9	2022	Although urine beta2-microglobulin significantly decreased following 2 months of treatment with all medications, efficacy was greater with tacrolimus than with cyclophosphamide and MMF (P < 0.001).	Mycophenolic Acid	181-184	beta-2-microglobulin	Homo sapiens	15-34
34995765-12	2022	Mycophenolate, azathioprine, calcineurin inhibitors and steroids associated with a lower risk of POF compared to CYC.	Mycophenolic Acid	0-13	POF1B actin binding protein	Homo sapiens	97-100
35411376-7	2022	Antibody levels were significantly lower in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or bucillamine or CNI (p<0.01).	Mycophenolic Acid	125-146	tumor necrosis factor	Homo sapiens	68-71
35411376-7	2022	Antibody levels were significantly lower in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or bucillamine or CNI (p<0.01).	Mycophenolic Acid	148-151	tumor necrosis factor	Homo sapiens	68-71
35411376-7	2022	Antibody levels were significantly lower in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or bucillamine or CNI (p<0.01).	Mycophenolic Acid	154-157	calcineurin binding protein 1	Homo sapiens	196-217
35411376-7	2022	Antibody levels were significantly lower in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or bucillamine or CNI (p<0.01).	Mycophenolic Acid	173-176	tumor necrosis factor	Homo sapiens	68-71
35411376-7	2022	Antibody levels were significantly lower in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or bucillamine or CNI (p<0.01).	Mycophenolic Acid	173-176	calcineurin binding protein 1	Homo sapiens	196-217
35398950-12	2022	CONCLUSION: We provide Class III evidence that reduced dose of RTX is superior to AZA and MMF as initial treatment to reduce the risk of relapse and is better tolerated than AZA in Chinese patients with AQP4-antibody-positive NMOSD.	Mycophenolic Acid	90-93	aquaporin 4	Homo sapiens	203-207
35393481-6	2022	Univariate logistic regression analysis revealed that age > 53 years, rituximab use, mycophenolate mofetil use, and KT vintage < 7 years were negatively associated with the rate of anti-SARS-CoV-2 S IgG >= 15 U/mL in KT recipients.	Mycophenolic Acid	85-106	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	197-198
35062878-10	2022	RESULTS: Four potential ligands for UGT2B10 namely acetaminophen, lorazepam, mycophenolic acid and voriconazole n-oxide intermediate were identified.	Mycophenolic Acid	77-94	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	36-43
35168373-8	2022	Data suggest that adding this newly approved calcineurin inhibitor to a regimen of mycophenolate mofetil and corticosteroids produces promising therapeutic results.	Mycophenolic Acid	83-104	calcineurin binding protein 1	Homo sapiens	45-66
35155485-8	2021	Regarding the treatments, significant differences were found (p 0.011) in the treatment with anti-TNF-alpha agents with OR 3.422 (1.322-8.858) and a trend to significance (p 0.094) was observed in patients receiving mycophenolate treatment (OR 2.016 (0.996-4-081)).	Mycophenolic Acid	216-229	tumor necrosis factor	Homo sapiens	98-107
35571122-9	2022	Both mycophenolic acid and rapamycin inhibited inflammatory and fibrotic processes induced by TGF-beta1 or IL-6 by downregulating mTOR and ERK phosphorylation.	Mycophenolic Acid	5-22	transforming growth factor beta 1	Homo sapiens	94-103
35571122-9	2022	Both mycophenolic acid and rapamycin inhibited inflammatory and fibrotic processes induced by TGF-beta1 or IL-6 by downregulating mTOR and ERK phosphorylation.	Mycophenolic Acid	5-22	interleukin 6	Homo sapiens	107-111
35571122-9	2022	Both mycophenolic acid and rapamycin inhibited inflammatory and fibrotic processes induced by TGF-beta1 or IL-6 by downregulating mTOR and ERK phosphorylation.	Mycophenolic Acid	5-22	mechanistic target of rapamycin kinase	Homo sapiens	130-134
35571122-9	2022	Both mycophenolic acid and rapamycin inhibited inflammatory and fibrotic processes induced by TGF-beta1 or IL-6 by downregulating mTOR and ERK phosphorylation.	Mycophenolic Acid	5-22	mitogen-activated protein kinase 1	Homo sapiens	139-142
35571122-10	2022	Conclusions: Our findings indicate that combined mycophenolate and rapamycin, at reduced dose, improves kidney fibrosis in murine lupus nephritis through their distinct effect on mTOR and ERK signaling in mesangial cells.	Mycophenolic Acid	49-62	mechanistic target of rapamycin kinase	Mus musculus	179-183
35571122-10	2022	Conclusions: Our findings indicate that combined mycophenolate and rapamycin, at reduced dose, improves kidney fibrosis in murine lupus nephritis through their distinct effect on mTOR and ERK signaling in mesangial cells.	Mycophenolic Acid	49-62	mitogen-activated protein kinase 1	Mus musculus	188-191
35182318-11	2022	Based on Spearman analysis, significant control correlations supporting the validity of our dataset were observed between total MPA trough concentration (C0) and total MPAG C0 (correlation coefficient (R) = 0.39), ratio of total MPAG C0-to-total MPA C0 and post-transplant time (R = - 0.56), total MPAG C0 and eGFR (R = - 0.35), and p-cresol sulfate concentration and eGFR (R = - 0.70).	Mycophenolic Acid	128-131	epidermal growth factor receptor	Homo sapiens	310-314
35182318-11	2022	Based on Spearman analysis, significant control correlations supporting the validity of our dataset were observed between total MPA trough concentration (C0) and total MPAG C0 (correlation coefficient (R) = 0.39), ratio of total MPAG C0-to-total MPA C0 and post-transplant time (R = - 0.56), total MPAG C0 and eGFR (R = - 0.35), and p-cresol sulfate concentration and eGFR (R = - 0.70).	Mycophenolic Acid	128-131	epidermal growth factor receptor	Homo sapiens	368-372
34651654-4	2022	Treatment with prednisolone (PSL), mycophenolate mofetil (MMF), and tacrolimus (TAC) resulted in improved SLE activity and glucose intolerance with the reduction of anti-insulin receptor autoantibodies.	Mycophenolic Acid	35-56	insulin receptor	Homo sapiens	170-186
35126949-1	2022	In this paper, numerous effects of immunosuppressive regimen of mycophenolate mofetil (MMF) on CNI-related renal damage after lung transplantation are evaluated thoroughly.	Mycophenolic Acid	64-85	5'-nucleotidase, cytosolic IA	Homo sapiens	95-98
35126949-1	2022	In this paper, numerous effects of immunosuppressive regimen of mycophenolate mofetil (MMF) on CNI-related renal damage after lung transplantation are evaluated thoroughly.	Mycophenolic Acid	87-90	5'-nucleotidase, cytosolic IA	Homo sapiens	95-98
35048572-6	2022	We summarize here the findings of two studies published in 2021, one reporting the benefits of combining GC with mycophenolate mofetil in immune thrombocytopenia, the other suggesting that blockage of interleukin-6 may decrease disease progression in systemic sclerosis with lung involvement.	Mycophenolic Acid	113-134	interleukin 6	Homo sapiens	201-214
34651654-4	2022	Treatment with prednisolone (PSL), mycophenolate mofetil (MMF), and tacrolimus (TAC) resulted in improved SLE activity and glucose intolerance with the reduction of anti-insulin receptor autoantibodies.	Mycophenolic Acid	58-61	insulin receptor	Homo sapiens	170-186
2525148-3	1989	We report that incubating RBL-2H3 cells for 4 h with 10 microM mycophenolic acid (MPA), an inhibitor of de novo GTP synthesis, reduces GTP levels by over 60% and causes an average reduction of 50% in Ag-stimulated serotonin release.	Mycophenolic Acid	63-80	RB transcriptional corepressor like 2	Rattus norvegicus	26-31
35257064-1	2022	Introduction: Addition of a calcineurin inhibitor (CNI) to corticosteroids and mycophenolate increased the renal response rate in lupus nephritis (LN) because of proteinuria reduction, but there is little long-term efficacy and safety data on this triple immunosuppressive regimen.	Mycophenolic Acid	79-92	calcineurin binding protein 1	Homo sapiens	28-49
2541548-4	1989	Recombinant viruses containing the gpt insertion were isolated by selection for growth in the presence of mycophenolic acid.	Mycophenolic Acid	106-123	glutamic--pyruvic transaminase	Homo sapiens	35-38
3050492-4	1988	These cells with a genotype of hgprt-/Ecogpt+ can grow in medium containing mycophenolic acid and xanthine (MX medium) but not in medium containing 6-thioguanine (6-TG).	Mycophenolic Acid	76-93	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	31-36
2525148-3	1989	We report that incubating RBL-2H3 cells for 4 h with 10 microM mycophenolic acid (MPA), an inhibitor of de novo GTP synthesis, reduces GTP levels by over 60% and causes an average reduction of 50% in Ag-stimulated serotonin release.	Mycophenolic Acid	82-85	RB transcriptional corepressor like 2	Rattus norvegicus	26-31
2828350-4	1988	Selection and analysis of cell clones resistant to hypoxanthine/aminopterin/thymidine and mycophenolic acid showed that the apoA-I gene is expressed in L6E9 but not in HeLa cells.	Mycophenolic Acid	90-107	apolipoprotein A1	Rattus norvegicus	124-130
3129297-3	1988	Transfection of mouse C127 cells with a recombinant vector containing the Tangier apoA-I gene (pSV2-gpt apoA-I) allowed selection of stable clones resistant to aminopterin and mycophenolic acid.	Mycophenolic Acid	176-193	apolipoprotein A-I	Mus musculus	82-88
3129297-3	1988	Transfection of mouse C127 cells with a recombinant vector containing the Tangier apoA-I gene (pSV2-gpt apoA-I) allowed selection of stable clones resistant to aminopterin and mycophenolic acid.	Mycophenolic Acid	176-193	apolipoprotein A-I	Mus musculus	104-110
2444981-2	1987	High-level expression of antisense MYC RNA was obtained by selecting cells resistant to progressively higher levels of mycophenolic acid over a period of greater than 6 months.	Mycophenolic Acid	119-136	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	35-38
3284209-3	1988	The genes used were the neo gene and gpt gene which conferred resistance to the drugs G418 and mycophenolic acid, respectively.	Mycophenolic Acid	95-112	glutamic pyruvic transaminase, soluble	Mus musculus	37-40
2890214-1	1987	We isolated four mycophenolic acid (MA) -resistant clones (MA0.4, MA2, MA5, MA20) of murine leukemia (L1210) cells which were 2- to 125-fold more resistant than the parent cells to MA and had a 4- to 50-fold increase in the activity of the enzyme inosine monophosphate dehydrogenase (IMPDase).	Mycophenolic Acid	17-34	PNMA family member 2	Homo sapiens	66-69
2890214-1	1987	We isolated four mycophenolic acid (MA) -resistant clones (MA0.4, MA2, MA5, MA20) of murine leukemia (L1210) cells which were 2- to 125-fold more resistant than the parent cells to MA and had a 4- to 50-fold increase in the activity of the enzyme inosine monophosphate dehydrogenase (IMPDase).	Mycophenolic Acid	17-34	PNMA family member 3	Homo sapiens	71-74
3304619-2	1987	Treatment of cells with an inhibitor of guanine nucleotide biosynthesis, mycophenolic acid, enhanced detection of GFAP by indirect immunofluorescence microscopy.	Mycophenolic Acid	73-90	glial fibrillary acidic protein	Homo sapiens	114-118
2890098-0	1987	Amplification of the IMP dehydrogenase gene in Chinese hamster cells resistant to mycophenolic acid.	Mycophenolic Acid	82-99	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	21-38
2890098-1	1987	The regulation of IMP dehydrogenase (IMPDH) was analyzed in Chinese hamster V79 cell variants that exhibit different degrees of resistance to the cytotoxic effect of mycophenolic acid, a specific inhibitor of IMPDH.	Mycophenolic Acid	166-183	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	18-35
2890098-1	1987	The regulation of IMP dehydrogenase (IMPDH) was analyzed in Chinese hamster V79 cell variants that exhibit different degrees of resistance to the cytotoxic effect of mycophenolic acid, a specific inhibitor of IMPDH.	Mycophenolic Acid	166-183	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	37-42
2890098-1	1987	The regulation of IMP dehydrogenase (IMPDH) was analyzed in Chinese hamster V79 cell variants that exhibit different degrees of resistance to the cytotoxic effect of mycophenolic acid, a specific inhibitor of IMPDH.	Mycophenolic Acid	166-183	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	209-214
2890098-2	1987	Western blot (immunoblot) analysis with an IMPDH antiserum revealed a 14- to 27-fold increase in the amount of enzyme in the mycophenolic acid-resistant cells.	Mycophenolic Acid	125-142	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	43-48
2890098-5	1987	Southern blotting with the probe indicated an amplification of the IMPDH gene in the mycophenolic acid-resistant cells.	Mycophenolic Acid	85-102	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	67-72
2890098-6	1987	Our findings suggest that the acquired mycophenolic acid resistance of the V79 cell variants is associated with increases in the amount and activity of IMPDH and the number of IMPDH gene copies.	Mycophenolic Acid	39-56	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	152-157
2890098-6	1987	Our findings suggest that the acquired mycophenolic acid resistance of the V79 cell variants is associated with increases in the amount and activity of IMPDH and the number of IMPDH gene copies.	Mycophenolic Acid	39-56	inosine-5'-monophosphate dehydrogenase 2	Cricetulus griseus	176-181
3260256-9	1988	CM from mycophenolic acid- treated adherent layers exposed for 24 h to 50 U/ml of IL-1 was added at volume concentrations of 5, 10, and 25% to MBMC at the time of transfer to lymphoid bone marrow culture conditions and at each feeding thereafter.	Mycophenolic Acid	8-25	interleukin 1 complex	Mus musculus	82-86
921901-0	1977	Cutaneous beta-glucuronidase: cleavage of mycophenolic acid by preparations of mouse skin.	Mycophenolic Acid	42-59	glucuronidase, beta	Mus musculus	10-28
3104085-3	1987	When T cells are selectively depleted of guanine nucleotides by treatment with mycophenolic acid, the early mitogen-induced activation of ODC is completely inhibited.	Mycophenolic Acid	79-96	ornithine decarboxylase 1	Homo sapiens	138-141
4073927-1	1985	Ethyl-O-[N-(p-carboxyphenyl) carbamoyl]-mycophenolate (CAM), a mycophenolic acid (MPA) derivative, has been evaluated in terms of influence of treatment schedule and route of administration on antitumor activity in mice bearing L 1210 leukemia and cross-resistance to 6-MP was studied.	Mycophenolic Acid	82-85	calmodulin 2	Mus musculus	55-58
6520700-9	1984	The metabolites of CAM were only mycophenolic acid (MPA) and its glucuronic acid conjugate (MPA-G) in all tested animals.	Mycophenolic Acid	33-50	calmodulin 2	Mus musculus	19-22
6131740-4	1983	Xanthine monophosphate formation was linear for at least 40 min and was inhibited by greater than 95% in the presence of mycophenolic acid, a specific IMPD inhibitor.	Mycophenolic Acid	121-138	inosine monophosphate dehydrogenase 2	Mus musculus	151-155
7274650-1	1981	A newly synthesized mycophenolic acid (MPA) derivative, ethyl O-[N-(p-carboxyphenyl)-carbamoyl]-mycophenolate (CAM, NSC-297879D) was tested for antitumor activity, when given orally, against transplantable murine tumors.	Mycophenolic Acid	20-37	calmodulin 2	Mus musculus	62-109
7274650-1	1981	A newly synthesized mycophenolic acid (MPA) derivative, ethyl O-[N-(p-carboxyphenyl)-carbamoyl]-mycophenolate (CAM, NSC-297879D) was tested for antitumor activity, when given orally, against transplantable murine tumors.	Mycophenolic Acid	39-42	calmodulin 2	Mus musculus	62-109
3985993-4	1985	Treatment with tiazofurin, selenazofurin, or mycophenolic acid decreased guanylate pools and caused an accumulation of IMP in WIL2 human lymphoma cells.	Mycophenolic Acid	45-62	inositol monophosphatase 1	Homo sapiens	119-122
6355764-8	1983	Mycophenolic acid (MPA), an inhibitor of de novo guanine nucleotide synthesis, inhibits the growth of hpt1 and hpt1+.	Mycophenolic Acid	0-17	hypoxanthine phosphoribosyltransferase	Saccharomyces cerevisiae S288C	102-106
6355764-8	1983	Mycophenolic acid (MPA), an inhibitor of de novo guanine nucleotide synthesis, inhibits the growth of hpt1 and hpt1+.	Mycophenolic Acid	0-17	hypoxanthine phosphoribosyltransferase	Saccharomyces cerevisiae S288C	111-115
6355764-8	1983	Mycophenolic acid (MPA), an inhibitor of de novo guanine nucleotide synthesis, inhibits the growth of hpt1 and hpt1+.	Mycophenolic Acid	19-22	hypoxanthine phosphoribosyltransferase	Saccharomyces cerevisiae S288C	102-106
6355764-8	1983	Mycophenolic acid (MPA), an inhibitor of de novo guanine nucleotide synthesis, inhibits the growth of hpt1 and hpt1+.	Mycophenolic Acid	19-22	hypoxanthine phosphoribosyltransferase	Saccharomyces cerevisiae S288C	111-115
6818555-3	1982	Cells expressing the gpt gene were selected by growth in medium containing mycophenolic acid.	Mycophenolic Acid	75-92	glutamic pyruvic transaminase, soluble	Mus musculus	21-24
6108130-9	1980	Inhibition of IMP dehydrogenase activity by mycophenolic acid caused a 12- and 3-fold increase in the rate of production of labelled base and nucleoside in the parent and HGPRT- cells respectively.	Mycophenolic Acid	44-61	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	171-176
6243274-2	1980	Addition of mycophenolic acid to pituitary cell cultures decreased basal and GnRH-induced cGMP production to undetectable levels, but did not reduce basal or GnRH-stimulated luteinizing hormone (LH) release.	Mycophenolic Acid	12-29	gonadotropin releasing hormone 1	Homo sapiens	77-81
198444-5	1977	The inhibition of proliferation of cells by mycophenolic acid then does not include the inhibition of synthesis of c-GMP, but apparently resides solely in limiting the guanylate necessary for nucleic acid synthesis.	Mycophenolic Acid	44-61	5'-nucleotidase, cytosolic II	Homo sapiens	117-120
33855339-9	2021	Targeting the ARLI3B-IMPDH2 circuit can be achieved using the Food and Drug Administration-approved drug, mycophenolate mofetil, which can block IMPDH2 activity and enhance the therapeutic efficacy of temozolomide.	Mycophenolic Acid	106-127	inosine monophosphate dehydrogenase 2	Homo sapiens	21-27
33855339-9	2021	Targeting the ARLI3B-IMPDH2 circuit can be achieved using the Food and Drug Administration-approved drug, mycophenolate mofetil, which can block IMPDH2 activity and enhance the therapeutic efficacy of temozolomide.	Mycophenolic Acid	106-127	inosine monophosphate dehydrogenase 2	Homo sapiens	145-151
33967795-16	2021	Conclusions: These results support that CYP3A5 and UGT1A9 genotyping in pediatric recipients might be useful and advisable to guide TAC and MPA dosing and monitoring in children that undergo kidney transplantation.	Mycophenolic Acid	140-143	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	40-46
34032749-0	2021	The important role of MDM2, RPL5, and TP53 in mycophenolic acid-induced cleft lip and palate.	Mycophenolic Acid	46-63	MDM2 proto-oncogene	Homo sapiens	22-26
34032749-0	2021	The important role of MDM2, RPL5, and TP53 in mycophenolic acid-induced cleft lip and palate.	Mycophenolic Acid	46-63	ribosomal protein L5	Homo sapiens	28-32
34032749-0	2021	The important role of MDM2, RPL5, and TP53 in mycophenolic acid-induced cleft lip and palate.	Mycophenolic Acid	46-63	tumor protein p53	Homo sapiens	38-42
34032749-7	2021	The genes most relevant to MPA-induced CLP included ABCB1, COL1A1, Rac1, TGFbeta1, EDN1, and TP53, as well as the TP53-associated genes MDM2 and RPL5.	Mycophenolic Acid	27-30	ATP binding cassette subfamily B member 1	Homo sapiens	52-57
34032749-7	2021	The genes most relevant to MPA-induced CLP included ABCB1, COL1A1, Rac1, TGFbeta1, EDN1, and TP53, as well as the TP53-associated genes MDM2 and RPL5.	Mycophenolic Acid	27-30	collagen type I alpha 1 chain	Homo sapiens	59-65
34032749-7	2021	The genes most relevant to MPA-induced CLP included ABCB1, COL1A1, Rac1, TGFbeta1, EDN1, and TP53, as well as the TP53-associated genes MDM2 and RPL5.	Mycophenolic Acid	27-30	Rac family small GTPase 1	Homo sapiens	67-71
34032749-7	2021	The genes most relevant to MPA-induced CLP included ABCB1, COL1A1, Rac1, TGFbeta1, EDN1, and TP53, as well as the TP53-associated genes MDM2 and RPL5.	Mycophenolic Acid	27-30	transforming growth factor beta 1	Homo sapiens	73-81
34032749-7	2021	The genes most relevant to MPA-induced CLP included ABCB1, COL1A1, Rac1, TGFbeta1, EDN1, and TP53, as well as the TP53-associated genes MDM2 and RPL5.	Mycophenolic Acid	27-30	endothelin 1	Homo sapiens	83-87
34032749-7	2021	The genes most relevant to MPA-induced CLP included ABCB1, COL1A1, Rac1, TGFbeta1, EDN1, and TP53, as well as the TP53-associated genes MDM2 and RPL5.	Mycophenolic Acid	27-30	tumor protein p53	Homo sapiens	93-97
34032749-7	2021	The genes most relevant to MPA-induced CLP included ABCB1, COL1A1, Rac1, TGFbeta1, EDN1, and TP53, as well as the TP53-associated genes MDM2 and RPL5.	Mycophenolic Acid	27-30	ribosomal protein L5	Homo sapiens	145-149
34032749-9	2021	KEGG analysis demonstrated gene enrichment in such pathways as the HIF-1 signaling pathway, glycosylphosphatidylinositol-anchor biosynthesis, the TNF signaling pathway, and hematopoietic stem cell development.Bioinformatic analysis was performed on the genes currently known to be associated with MPA-induced CLP pathogenesis.	Mycophenolic Acid	297-300	hypoxia inducible factor 1 subunit alpha	Homo sapiens	67-72
33967795-16	2021	Conclusions: These results support that CYP3A5 and UGT1A9 genotyping in pediatric recipients might be useful and advisable to guide TAC and MPA dosing and monitoring in children that undergo kidney transplantation.	Mycophenolic Acid	140-143	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	51-57
33863547-1	2021	PURPOSE: This study assessed the long-term (10-year) tolerability and efficacy of a low-dose corticosteroid combined with mycophenolate mofetil (CS + MMF) in the treatment of immunoglobulin A nephropathy (IgAN) with stage 3/4 chronic kidney disease and proteinuria in clinical practice in China.	Mycophenolic Acid	122-143	citrate synthase	Homo sapiens	145-147
33539910-0	2021	Evaluation of the therapeutic effects of mycophenolate mofetil targeting Nrf-2 and NLRP3 inflammasome in acetic acid induced ulcerative colitis in rats.	Mycophenolic Acid	41-62	NFE2 like bZIP transcription factor 2	Rattus norvegicus	73-78
33539910-8	2021	MMF significantly decreased oxidative stress as indicated by the decreased malondialdehyde concentration and the increased total antioxidant capacity, glutathione, catalase, and superoxide dismutase concentrations in colon tissues.	Mycophenolic Acid	0-3	catalase	Rattus norvegicus	164-172
33609620-7	2021	Finally, we demonstrated that MPA-TG was significantly more effective than MPA at inhibiting CD4+ and CD8+ T cell proliferation in the MLN of mice in response to an oral ovalbumin antigen challenge.	Mycophenolic Acid	30-33	CD4 antigen	Mus musculus	93-96
33279598-0	2021	Mycophenolate mofetil preconditioning protects mouse liver against ischemia/reperfusion injury in wild type and toll-like receptor 4 knockout and mice.	Mycophenolic Acid	0-21	toll-like receptor 4	Mus musculus	112-132
33150434-9	2021	Relative risk (RR) of death from any cause was increased among patients who had received anti-TNF therapy [2.09 (1.1-4.0)] P =0.03, while RR was lower in those treated with rituximab [0.52(0.1-2.1)] or mycophenolate [0.65 (0.2-2.0)].	Mycophenolic Acid	202-215	tumor necrosis factor	Homo sapiens	94-97
33524926-2	2021	This research investigated the association between the gene polymorphism of inosine monophosphate dehydrogenase-1 and effectiveness of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorder patients.	Mycophenolic Acid	135-156	inosine monophosphate dehydrogenase 1	Homo sapiens	76-113
33524926-0	2021	Effect of inosine monophosphate dehydrogenase-1 gene polymorphisms on mycophenolate mofetil effectiveness in neuromyelitis optica spectrum disorder patients.	Mycophenolic Acid	70-91	inosine monophosphate dehydrogenase 1	Homo sapiens	10-47
33524926-1	2021	BACKGROUND: Inosine monophosphate dehydrogenase-1 is the target of mycophenolate mofetil.	Mycophenolic Acid	67-88	inosine monophosphate dehydrogenase 1	Homo sapiens	12-49
33279598-4	2021	METHODS: Male wild type (WT) and TLR4 knockout (KO) mice were injected intraperitoneally with MMF or normal saline.	Mycophenolic Acid	94-97	toll-like receptor 4	Mus musculus	33-37
33279598-9	2021	MMF administration also significantly inhibited the activation of the NF-kappaB pathway and the expression of pro-inflammatory cytokines.	Mycophenolic Acid	0-3	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	70-79
33279598-11	2021	MMF treatment inhibited hepatocyte apoptosis, as indicated by reduced TUNEL staining, and reduced the accumulation of cleaved caspase-3.	Mycophenolic Acid	0-3	caspase 3	Mus musculus	126-135
33279598-13	2021	The induction of autophagy by MMF treatment may be related to TLR4 activation.	Mycophenolic Acid	30-33	toll-like receptor 4	Mus musculus	62-66
33016111-3	2021	He was found to have anti-insulin antibodies and responded clinically to plasmapheresis and immunosuppression with mycophenolate mofetil (MMF)and prednisolone.	Mycophenolic Acid	115-136	insulin	Homo sapiens	26-33
33016111-3	2021	He was found to have anti-insulin antibodies and responded clinically to plasmapheresis and immunosuppression with mycophenolate mofetil (MMF)and prednisolone.	Mycophenolic Acid	138-141	insulin	Homo sapiens	26-33
33663060-8	2021	RESULTS: This network meta-analysis of 37 RCTs involving 3012 participants found that Mycophenolate mofetil (MMF) combined with corticosteroids (CS) was superior to other interventions in end point events and proteinuria.	Mycophenolic Acid	86-107	citrate synthase	Homo sapiens	145-147
33791812-9	2021	In vitro microsomal assays indicated that intestinal metabolism of mycophenolate mofetil (MMF, a known CES1 substrate) was more extensive at ZT6 than at ZT18.	Mycophenolic Acid	67-88	carboxylesterase 1G	Mus musculus	103-107
33791812-9	2021	In vitro microsomal assays indicated that intestinal metabolism of mycophenolate mofetil (MMF, a known CES1 substrate) was more extensive at ZT6 than at ZT18.	Mycophenolic Acid	90-93	carboxylesterase 1G	Mus musculus	103-107
32811369-0	2021	A Case of Anti-MDA5 Antibody-positive Dermatomyositis Developing Reversible Cerebral Vasospasm Syndrome Successfully Treated by Multi-Immunosuppressant Combination Including Mycophenolate Mofetil.	Mycophenolic Acid	174-195	interferon induced with helicase C domain 1	Homo sapiens	15-19
33274857-2	2021	We aimed to assess the effect of rituximab +- mycophenolate mofetil (MMF) compared with MMF on pulmonary function and prednisone dosage in patients with CTD-related ILD (CTD-ILD).	Mycophenolic Acid	69-72	CTD	Homo sapiens	153-156
33035395-2	2021	Specifically, we identify highly potent and selective photoswitchable inhibitors of the drug-metabolizing enzymes carboxylesterases 1 and 2 and demonstrate the pharmacological application of our compounds by optically controlling the metabolism of the immunosuppressant drug mycophenolate mofetil.	Mycophenolic Acid	275-296	carboxylesterase 1	Homo sapiens	114-139
33539328-8	2021	The patient had several FSGS relapses that were treated by different combinations of plasmapheresis, pulse steroid, mycophenolic acid, tacrolimus, prednisolone, IVIG, and IV rituximab.	Mycophenolic Acid	116-133	actinin alpha 4	Homo sapiens	24-28
33430741-4	2021	METHODS: Aqueous MPA eye drops were prepared by nanoencapsulation of MPA using Nanomerics MET (N-palamitoylN-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan) at a MET, MPA ratio of 7.5: 1 g g-1 in the presence of glycerol (2.75% w/w).	Mycophenolic Acid	17-20	SAFB like transcription modulator	Homo sapiens	0-3
33360369-10	2021	In mDCs, the mRNA levels of ICAM-1, CD40 and CD83 were enhanced in MPA-treated mDCs with an increase in the expression of CD83 and ICAM-1 near the Golgi compared to non-treated mDCs.	Mycophenolic Acid	67-70	intercellular adhesion molecule 1	Homo sapiens	28-34
33360369-10	2021	In mDCs, the mRNA levels of ICAM-1, CD40 and CD83 were enhanced in MPA-treated mDCs with an increase in the expression of CD83 and ICAM-1 near the Golgi compared to non-treated mDCs.	Mycophenolic Acid	67-70	CD40 molecule	Homo sapiens	36-40
33360369-10	2021	In mDCs, the mRNA levels of ICAM-1, CD40 and CD83 were enhanced in MPA-treated mDCs with an increase in the expression of CD83 and ICAM-1 near the Golgi compared to non-treated mDCs.	Mycophenolic Acid	67-70	CD83 molecule	Homo sapiens	45-49
33360369-10	2021	In mDCs, the mRNA levels of ICAM-1, CD40 and CD83 were enhanced in MPA-treated mDCs with an increase in the expression of CD83 and ICAM-1 near the Golgi compared to non-treated mDCs.	Mycophenolic Acid	67-70	CD83 molecule	Homo sapiens	122-126
33360369-10	2021	In mDCs, the mRNA levels of ICAM-1, CD40 and CD83 were enhanced in MPA-treated mDCs with an increase in the expression of CD83 and ICAM-1 near the Golgi compared to non-treated mDCs.	Mycophenolic Acid	67-70	intercellular adhesion molecule 1	Homo sapiens	131-137
33360369-11	2021	In contrast, mRNA levels of CD86 were diminished after MPA treatment.	Mycophenolic Acid	55-58	CD86 molecule	Homo sapiens	28-32
33430741-4	2021	METHODS: Aqueous MPA eye drops were prepared by nanoencapsulation of MPA using Nanomerics MET (N-palamitoylN-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan) at a MET, MPA ratio of 7.5: 1 g g-1 in the presence of glycerol (2.75% w/w).	Mycophenolic Acid	17-20	SAFB like transcription modulator	Homo sapiens	90-93
32949604-2	2020	Recent advances in the role of the type II isoform of inosine-5"-monophosphate dehydrogenase (IMPDH2) in the tumorigenesis of various types of cancer have called for a second look of MPA, the first IMPDH2 inhibitor discovered a hundred years ago, to be repurposed as an anticancer agent.	Mycophenolic Acid	183-186	inosine monophosphate dehydrogenase 2	Homo sapiens	94-100
32820679-0	2021	MRP4 is responsible for the efflux transport of mycophenolic acid beta-d glucuronide (MPAG) from hepatocytes to blood.	Mycophenolic Acid	48-65	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
33370992-0	2020	Mycophenolate mofetil-induced liver injury in a patient with aquaporin-4 antibody positive transverse myelitis.	Mycophenolic Acid	0-21	aquaporin 4	Homo sapiens	61-72
33370992-1	2020	We present a case of a 49-year-old woman diagnosed with aquaporin-4 antibody-positive transverse myelitis, who developed a significant transaminitis 2 months after commencing mycophenolate mofetil (MMF) as a steroid-sparing agent.	Mycophenolic Acid	175-196	aquaporin 4	Homo sapiens	56-67
33370992-1	2020	We present a case of a 49-year-old woman diagnosed with aquaporin-4 antibody-positive transverse myelitis, who developed a significant transaminitis 2 months after commencing mycophenolate mofetil (MMF) as a steroid-sparing agent.	Mycophenolic Acid	198-201	aquaporin 4	Homo sapiens	56-67
33025511-9	2020	CONCLUSION: This population pharmacokinetic model demonstrated the intracellular accumulation of MPA, the efflux of MPA out of the cells being dependent on P-glycoprotein transporters.	Mycophenolic Acid	97-100	ATP binding cassette subfamily B member 1	Homo sapiens	156-170
33025511-9	2020	CONCLUSION: This population pharmacokinetic model demonstrated the intracellular accumulation of MPA, the efflux of MPA out of the cells being dependent on P-glycoprotein transporters.	Mycophenolic Acid	116-119	ATP binding cassette subfamily B member 1	Homo sapiens	156-170
33185905-1	2021	We read with great interest Poli et al"s case report describing a post-Liver Transplantation (LT) Sinusoidal Obstruction Syndrome (SOS) induced by Mycophenolate Mofetil (MMF).	Mycophenolic Acid	147-168	DNA polymerase iota	Homo sapiens	28-32
33185905-1	2021	We read with great interest Poli et al"s case report describing a post-Liver Transplantation (LT) Sinusoidal Obstruction Syndrome (SOS) induced by Mycophenolate Mofetil (MMF).	Mycophenolic Acid	170-173	DNA polymerase iota	Homo sapiens	28-32
33206751-1	2020	OBJECTIVES: Here, we aimed to compare the clinical effects of mycophenolate mofetil combined with either tacrolimus or with cyclophosphamide on lupus nephritis (LN) and to analyze their influence on the expression of cystatin C and on transforming growth factor-1 (TGF-beta1).	Mycophenolic Acid	62-83	cystatin C	Homo sapiens	217-227
33206751-1	2020	OBJECTIVES: Here, we aimed to compare the clinical effects of mycophenolate mofetil combined with either tacrolimus or with cyclophosphamide on lupus nephritis (LN) and to analyze their influence on the expression of cystatin C and on transforming growth factor-1 (TGF-beta1).	Mycophenolic Acid	62-83	transforming growth factor beta 1	Homo sapiens	265-274
33206751-8	2020	Moreover, the drug combination of mycophenolate mofetil and tacrolimus greatly reduced the expression levels of serum TGF-beta1 and cystatin C.	Mycophenolic Acid	34-55	transforming growth factor beta 1	Homo sapiens	118-127
33206751-8	2020	Moreover, the drug combination of mycophenolate mofetil and tacrolimus greatly reduced the expression levels of serum TGF-beta1 and cystatin C.	Mycophenolic Acid	34-55	cystatin C	Homo sapiens	132-142
33168076-0	2020	Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells.	Mycophenolic Acid	0-17	interferon regulatory factor 7	Homo sapiens	77-81
33168076-0	2020	Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells.	Mycophenolic Acid	38-59	interferon regulatory factor 7	Homo sapiens	77-81
33168076-7	2020	Additionally, we cultured pDCs with serum from SLE patients in the presence or absence of MPA and then examined the inhibitory function of MPA on SLE serum-induced IFN-alpha production.	Mycophenolic Acid	139-142	interferon alpha 1	Homo sapiens	164-173
33168076-8	2020	RESULTS: We found that treatment with 1-10 muM of MPA (covering the clinical trough plasma concentration range) dose-dependently downregulated the expression of CD80 and CD86 on mDCs (but not pDCs) without inducing apoptosis, in response to R848 or CpG-ODN, respectively.	Mycophenolic Acid	50-53	CD80 molecule	Homo sapiens	161-165
33168076-8	2020	RESULTS: We found that treatment with 1-10 muM of MPA (covering the clinical trough plasma concentration range) dose-dependently downregulated the expression of CD80 and CD86 on mDCs (but not pDCs) without inducing apoptosis, in response to R848 or CpG-ODN, respectively.	Mycophenolic Acid	50-53	CD86 molecule	Homo sapiens	170-174
33168076-10	2020	In addition, MPA inhibited IL-12 production with STAT4 expression in mDCs.	Mycophenolic Acid	13-16	signal transducer and activator of transcription 4	Homo sapiens	49-54
33168076-11	2020	We further identified that MPA had an inhibitory effect on SLE serum-induced IFN-alpha production by pDCs.	Mycophenolic Acid	27-30	interferon alpha 1	Homo sapiens	77-86
32415749-4	2020	We sought to identify contributors to interindividual variability in MPA response, hypothesizing that the HPRT1 salvage guanosine synthesis contributes to variability.	Mycophenolic Acid	69-72	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	106-111
33029882-0	2020	Mycophenolate mofetil treatment of an H syndrome patient with a SLC29A3 mutation.	Mycophenolic Acid	0-21	solute carrier family 29 member 3	Homo sapiens	64-71
32415749-14	2020	The degree of lymphocyte stimulation, HPRT1, KLF2, and LTB expression may serve as markers of MPA efficacy.	Mycophenolic Acid	94-97	lymphotoxin beta	Homo sapiens	55-58
32998908-0	2020	MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin.	Mycophenolic Acid	128-149	interferon induced with helicase C domain 1	Homo sapiens	0-5
32687927-11	2020	RESULTS: GDNF significantly prolonged mean survival times of HolTg/Tg mice, Ednrbs-l//s-l mice, and male TashTTg/Tg mice, compared with control mice, but not Ret9/- mice (which had mycophenolate toxicity).	Mycophenolic Acid	181-194	glial cell line derived neurotrophic factor	Mus musculus	9-13
32805303-4	2020	Blocking viral entry through various mechanisms and the potential application of the FDA approved immunosuppressant agent, mycophenolic acid, as inducer of IFITM3 are among those discussed.	Mycophenolic Acid	123-140	interferon induced transmembrane protein 3	Homo sapiens	156-162
32906032-1	2020	OBJECTIVE: To investigate the prevalence of the MUC5B promoter variant rs35705950 in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) and whether its presence predicts response to immunosuppression with cyclophosphamide (CYC) and mycophenolate (MMF).	Mycophenolic Acid	250-263	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	48-53
32906032-1	2020	OBJECTIVE: To investigate the prevalence of the MUC5B promoter variant rs35705950 in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) and whether its presence predicts response to immunosuppression with cyclophosphamide (CYC) and mycophenolate (MMF).	Mycophenolic Acid	265-268	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	48-53
32998908-7	2020	Our case provides evidence for early and aggressive treatment of MDA-5 dermatomyositis with a combination of weight-based prednisone, MMF and IVIg.	Mycophenolic Acid	134-137	interferon induced with helicase C domain 1	Homo sapiens	65-70
32732827-0	2020	Can Mammalian Target of Rapamycin Inhibitors Replace Mycophenolate in Hypersensitized Kidney Transplant Recipients?	Mycophenolic Acid	53-66	mechanistic target of rapamycin kinase	Homo sapiens	4-33
32871981-7	2020	MMF induction significantly improved CR and TR vs cyclophosphamide (relative risk 1.34, 95% confidence interval: 1.13-1.58; P < .001; relative risk 1.16, 95% confidence interval: 1.02-1.33; P = .03), and was associated with significantly lower risks of infection (P < .001), amenorrhea (P < .001), leukopenia, and alopecia.	Mycophenolic Acid	0-3	coagulation factor II thrombin receptor	Homo sapiens	44-46
32159236-6	2020	Complementing this result, treatment with mycophenolic acid (MPA), an inhibitor of GTP production, dissociates TIF-90 from Pol I and hence abolishes AKT-increased rRNA synthesis by way of TIF-90 activation.	Mycophenolic Acid	42-59	TYRO3 protein tyrosine kinase	Homo sapiens	111-114
32159236-6	2020	Complementing this result, treatment with mycophenolic acid (MPA), an inhibitor of GTP production, dissociates TIF-90 from Pol I and hence abolishes AKT-increased rRNA synthesis by way of TIF-90 activation.	Mycophenolic Acid	42-59	AKT serine/threonine kinase 1	Homo sapiens	149-152
32159236-6	2020	Complementing this result, treatment with mycophenolic acid (MPA), an inhibitor of GTP production, dissociates TIF-90 from Pol I and hence abolishes AKT-increased rRNA synthesis by way of TIF-90 activation.	Mycophenolic Acid	61-64	TYRO3 protein tyrosine kinase	Homo sapiens	111-114
32159236-6	2020	Complementing this result, treatment with mycophenolic acid (MPA), an inhibitor of GTP production, dissociates TIF-90 from Pol I and hence abolishes AKT-increased rRNA synthesis by way of TIF-90 activation.	Mycophenolic Acid	61-64	AKT serine/threonine kinase 1	Homo sapiens	149-152
32458237-0	2020	Good response to mycophenolate mofetil on treatment of interstitial lung disease in polymyositis associated with antisynthetase syndrome positive for anti-EJ and anti-Ro52 antibodies.	Mycophenolic Acid	17-38	tripartite motif containing 21	Homo sapiens	167-171
32447506-5	2020	Treatment with glucocorticoids and mycophenolate mofetil has been shown to achieve remission of proteinuria in a significant proportion of C3G patients.	Mycophenolic Acid	35-56	Rap guanine nucleotide exchange factor 1	Homo sapiens	139-142
32983131-2	2020	Methods: To understand the biology of Tfr cells in kidney transplant patients treated with tacrolimus and mycophenolate mofetil (MMF) combination immunosuppression, we measured circulating (c)Tfh and cTfr cells in peripheral blood by flow cytometry in n = 211 kidney transplant recipients.	Mycophenolic Acid	106-127	transferrin receptor	Homo sapiens	38-41
32983131-2	2020	Methods: To understand the biology of Tfr cells in kidney transplant patients treated with tacrolimus and mycophenolate mofetil (MMF) combination immunosuppression, we measured circulating (c)Tfh and cTfr cells in peripheral blood by flow cytometry in n = 211 kidney transplant recipients.	Mycophenolic Acid	129-132	transferrin receptor	Homo sapiens	38-41
32779952-0	2022	Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.	Mycophenolic Acid	30-51	CD4 molecule	Homo sapiens	14-17
32779952-1	2022	PURPOSE: Sub-analysis of the FAST Trial comparing change in CD4 ( CD4) from baseline through 12 months in uveitis patients treated with mycophenolate mofetil (MMF) and methotrexate (MTX).	Mycophenolic Acid	136-157	CD4 molecule	Homo sapiens	60-63
32779952-1	2022	PURPOSE: Sub-analysis of the FAST Trial comparing change in CD4 ( CD4) from baseline through 12 months in uveitis patients treated with mycophenolate mofetil (MMF) and methotrexate (MTX).	Mycophenolic Acid	136-157	CD4 molecule	Homo sapiens	66-69
32534355-0	2020	Keratinocyte growth factor ameliorates mycophenolate mofetil-induced intestinal barrier disruption in mice.	Mycophenolic Acid	39-60	fibroblast growth factor 7	Mus musculus	0-26
32645052-0	2020	Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production.	Mycophenolic Acid	132-149	interleukin 6	Homo sapiens	166-170
32818204-15	2020	Patients with juvenile-onset SLE and elevated CD8 effector memory T-cell frequencies had more persistently active disease over time, as assessed by the SLE disease activity index 2000, and this was associated with increased treatment with mycophenolate mofetil and an increased prevalence of lupus nephritis.	Mycophenolic Acid	239-260	CD8a molecule	Homo sapiens	46-49
32083540-6	2020	POF was significantly associated with anti-Sm (p=0.0004), anti-RNP (p=0.02), anti-cardiolipin (p=0.0008), lupus anticoagulant (p=0.0002), treatment with cyclophosphamide (p=0.0001), azathioprine (p=0.0001), mycophenolate mofetil (p=0.0001), cyclosporine A (p=0.007).	Mycophenolic Acid	207-228	POF1B actin binding protein	Homo sapiens	0-3
32339343-1	2020	We write to express our concerns over the recently published paper by Chen et al, "Outcomes in kidney transplantation with mycophenolate mofetil-based maintenance immunosuppression in China: a large-sample retrospective analysis of a national database" and request details of the kidney procurement process in DCD or DCBD donors in relation to the short WIT" (Transplant International 2020, https://doi.org/10.1111/tri.13566).	Mycophenolic Acid	123-144	dermcidin	Homo sapiens	310-313
32477577-4	2020	We treated a head and neck cancer patient (a 50-year-old Japanese male) who suffered from corticosteroid-resistant hepatitis during treatment with nivolumab, an anti-PD-1 ICI, and that was recovered by mycophenolate mofetil salvage therapy.	Mycophenolic Acid	202-223	programmed cell death 1	Homo sapiens	166-170
31000815-0	2020	Anti-fibrotic effect of mycophenolate mofetil on Peyronie"s disease experimentally induced with TGF-beta.	Mycophenolic Acid	24-45	transforming growth factor alpha	Rattus norvegicus	96-104
32303208-11	2020	Mycophenolate mofetil was administered to manage proteinuria after 3 months of treatment with the steroid and angiotensin-converting enzyme inhibitor.	Mycophenolic Acid	0-21	angiotensin I converting enzyme	Homo sapiens	110-139
32265712-15	2020	We recommend monitoring uMPA instead of tMPA to optimize mycophenolate mofetil (MMF) dosing for patients with lower ALB levels.	Mycophenolic Acid	57-78	albumin	Homo sapiens	116-119
32265712-15	2020	We recommend monitoring uMPA instead of tMPA to optimize mycophenolate mofetil (MMF) dosing for patients with lower ALB levels.	Mycophenolic Acid	80-83	albumin	Homo sapiens	116-119
32170045-0	2020	Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study.	Mycophenolic Acid	22-43	myelin oligodendrocyte glycoprotein	Homo sapiens	47-82
32170045-1	2020	OBJECTIVE: To investigate whether the use of mycophenolate mofetil (MMF) could reduce the relapse risk in patients with myelin oligodendrocyte glycoprotein (MOG)-immunoglobulin G (IgG)-associated disorders (MOGADs).	Mycophenolic Acid	45-66	myelin oligodendrocyte glycoprotein	Homo sapiens	120-155
32170045-1	2020	OBJECTIVE: To investigate whether the use of mycophenolate mofetil (MMF) could reduce the relapse risk in patients with myelin oligodendrocyte glycoprotein (MOG)-immunoglobulin G (IgG)-associated disorders (MOGADs).	Mycophenolic Acid	68-71	myelin oligodendrocyte glycoprotein	Homo sapiens	120-155
31000815-1	2020	The aim of the present study was to evaluate the histological, histochemical, and stereological changes caused by mycophenolate mofetil (MMF) on the tunica albuginea of rat penises submitted to an injection of transforming growth factor beta (TGF-beta) for the induction of Peyronie"s disease (PD).	Mycophenolic Acid	114-135	transforming growth factor alpha	Rattus norvegicus	243-251
31000815-1	2020	The aim of the present study was to evaluate the histological, histochemical, and stereological changes caused by mycophenolate mofetil (MMF) on the tunica albuginea of rat penises submitted to an injection of transforming growth factor beta (TGF-beta) for the induction of Peyronie"s disease (PD).	Mycophenolic Acid	137-140	transforming growth factor alpha	Rattus norvegicus	243-251
31751564-0	2020	Enhanced anti-psoriatic activity of mycophenolic acid against the TNF-alpha-induced HaCaT cell proliferation by conjugated poloxamer micelles.	Mycophenolic Acid	36-53	tumor necrosis factor	Homo sapiens	66-75
30992538-0	2020	Impact of SLCO1B3 polymorphisms on clinical outcomes in lung allograft recipients receiving mycophenolic acid.	Mycophenolic Acid	92-109	solute carrier organic anion transporter family member 1B3	Homo sapiens	10-17
31742356-2	2020	The primary metabolic pathways of MPA are hepatic glucuronidation through UDP-glucuronosyltransferase (UGT) enzymes in the formation of MPA-glucuronide (MPAG, major pathway) and MPA-acyl glucuronide (AcMPAG).	Mycophenolic Acid	34-37	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	74-101
31742356-2	2020	The primary metabolic pathways of MPA are hepatic glucuronidation through UDP-glucuronosyltransferase (UGT) enzymes in the formation of MPA-glucuronide (MPAG, major pathway) and MPA-acyl glucuronide (AcMPAG).	Mycophenolic Acid	34-37	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	103-106
30992538-4	2020	Six SNPs known to regulate MPA exposure from the SLCO, UGT and MRP2 families were genotyped.	Mycophenolic Acid	27-30	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	55-58
30992538-4	2020	Six SNPs known to regulate MPA exposure from the SLCO, UGT and MRP2 families were genotyped.	Mycophenolic Acid	27-30	ATP binding cassette subfamily C member 2	Homo sapiens	63-67
30992538-11	2020	We conclude that hypofunctional SNPs in the SLCO1B3 gene are associated with an increased risk for acute rejection and allograft failure in lung transplant recipients treated with MPA.	Mycophenolic Acid	180-183	solute carrier organic anion transporter family member 1B3	Homo sapiens	44-51
30597187-0	2019	Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORgammat and T-bet expression in kidney transplantation.	Mycophenolic Acid	13-26	T-box transcription factor 21	Homo sapiens	175-180
31578207-5	2019	Further inhibition kinetic studies using HLMs suggested that ginsenoside Rc competitively and noncompetitively inhibited UGT1A9-mediated propofol and mycophenolic acid glucuronidation activities, with K i values of 2.83 and 3.31 muM, respectively.	Mycophenolic Acid	150-167	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	121-127
31385180-1	2019	PURPOSE: In large observational studies of adult kidney transplant recipients (KTRs) where older adults (65 years old and older) were not well represented, the mammalian target of rapamycin inhibitors (mTOR inhibitors) has poorer outcomes than the standard tacrolimus-mycophenolate-steroids (TAC-MPA-S) regimen.	Mycophenolic Acid	268-281	mechanistic target of rapamycin kinase	Homo sapiens	160-189
31385180-1	2019	PURPOSE: In large observational studies of adult kidney transplant recipients (KTRs) where older adults (65 years old and older) were not well represented, the mammalian target of rapamycin inhibitors (mTOR inhibitors) has poorer outcomes than the standard tacrolimus-mycophenolate-steroids (TAC-MPA-S) regimen.	Mycophenolic Acid	268-281	mechanistic target of rapamycin kinase	Homo sapiens	202-206
31325587-6	2019	Specifically, compared with cyclosporine/MMF as GVHD prophylaxis, the odds ratio (OR) for calcineurin inhibitor/methotrexate was .8 and for cyclosporine/prednisone .6.	Mycophenolic Acid	41-44	calcineurin binding protein 1	Homo sapiens	90-111
31408737-0	2019	Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus.	Mycophenolic Acid	66-83	TNF superfamily member 13b	Homo sapiens	93-97
31429348-3	2019	Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), in association with lipopolysaccharide (LPS), is able to promote the secretion of IL-18, but the mechanism remains unknown.	Mycophenolic Acid	50-71	interleukin 18	Homo sapiens	161-166
31429348-3	2019	Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), in association with lipopolysaccharide (LPS), is able to promote the secretion of IL-18, but the mechanism remains unknown.	Mycophenolic Acid	73-76	interleukin 18	Homo sapiens	161-166
31062373-0	2019	Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant.	Mycophenolic Acid	46-63	calcineurin binding protein 1	Homo sapiens	13-34
31651849-4	2019	The influence of mycophenolic acid (MPA) derivatives and prednisone on p70S6 kinase phosphorylation in CD4-positive cells was examined in liver transplant patients and healthy controls (HCs).	Mycophenolic Acid	17-34	CD4 molecule	Homo sapiens	103-106
31651849-4	2019	The influence of mycophenolic acid (MPA) derivatives and prednisone on p70S6 kinase phosphorylation in CD4-positive cells was examined in liver transplant patients and healthy controls (HCs).	Mycophenolic Acid	36-39	CD4 molecule	Homo sapiens	103-106
31377099-1	2019	The mammalian target of rapamycin (mTOR) inhibitor, everolimus, in combination with reduced-exposure calcineurin inhibitor (CNI), has been demonstrated in clinical trials to have comparable efficacy in low-to-moderate immunological risk kidney transplant recipients to the Standard of Care, mycophenolic acid (MPA) in combination with standard-exposure CNI.	Mycophenolic Acid	291-308	mechanistic target of rapamycin kinase	Homo sapiens	4-33
31377099-1	2019	The mammalian target of rapamycin (mTOR) inhibitor, everolimus, in combination with reduced-exposure calcineurin inhibitor (CNI), has been demonstrated in clinical trials to have comparable efficacy in low-to-moderate immunological risk kidney transplant recipients to the Standard of Care, mycophenolic acid (MPA) in combination with standard-exposure CNI.	Mycophenolic Acid	291-308	mechanistic target of rapamycin kinase	Homo sapiens	35-39
31377099-1	2019	The mammalian target of rapamycin (mTOR) inhibitor, everolimus, in combination with reduced-exposure calcineurin inhibitor (CNI), has been demonstrated in clinical trials to have comparable efficacy in low-to-moderate immunological risk kidney transplant recipients to the Standard of Care, mycophenolic acid (MPA) in combination with standard-exposure CNI.	Mycophenolic Acid	310-313	mechanistic target of rapamycin kinase	Homo sapiens	4-33
31377099-1	2019	The mammalian target of rapamycin (mTOR) inhibitor, everolimus, in combination with reduced-exposure calcineurin inhibitor (CNI), has been demonstrated in clinical trials to have comparable efficacy in low-to-moderate immunological risk kidney transplant recipients to the Standard of Care, mycophenolic acid (MPA) in combination with standard-exposure CNI.	Mycophenolic Acid	310-313	mechanistic target of rapamycin kinase	Homo sapiens	35-39
30993228-6	2019	Although the introduction of calcineurin inhibitors, mycophenolate mofetil and monoclonal antibodies (e.g., rituximab) has improved the outcome of children with FSGS, the reponse in Black children is less than optimal, with those having single gene mutations being universally unresponsive to all forms of immunosuppression.	Mycophenolic Acid	53-74	actinin alpha 4	Homo sapiens	161-165
31358596-8	2019	Both mycophenolate and rapamycin, especially the latter, decreased glomerular mTOR Ser2448 phosphorylation.	Mycophenolic Acid	5-18	mechanistic target of rapamycin kinase	Mus musculus	78-82
31358596-12	2019	Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1.	Mycophenolic Acid	0-13	mechanistic target of rapamycin kinase	Mus musculus	48-52
31358596-12	2019	Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1.	Mycophenolic Acid	0-13	mitogen-activated protein kinase 1	Homo sapiens	57-94
31358596-12	2019	Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1.	Mycophenolic Acid	0-13	mitogen-activated protein kinase 1	Homo sapiens	96-99
31358596-12	2019	Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1.	Mycophenolic Acid	0-13	transforming growth factor, beta 1	Mus musculus	215-224
30918194-5	2019	Corticosteroids and mycophenolate mofetil were administered as for ANCA vasculitis, and the serum creatinine, abnormal urinalysis and MPO-ANCA titer all gradually ameliorated.	Mycophenolic Acid	20-41	myeloperoxidase	Homo sapiens	134-137
30633591-5	2019	Results: It is found that percentages of CD3+, CD3+CD4+ and CD3+CD8+ T cells in FK506 group are lowered compared to the control group but they are elevated in FK506 + MMF group.	Mycophenolic Acid	167-170	CD8a molecule	Homo sapiens	64-67
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Mycophenolic Acid	102-105	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Mycophenolic Acid	102-105	programmed cell death 1	Homo sapiens	52-56
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Mycophenolic Acid	102-105	hepatitis A virus cellular receptor 2	Homo sapiens	58-63
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Mycophenolic Acid	102-105	lymphocyte activating 3	Homo sapiens	65-70
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Mycophenolic Acid	102-105	T cell immunoreceptor with Ig and ITIM domains	Homo sapiens	75-80
30995791-6	2019	The percentage of SOD1 immunopositive hepatocytes in rats treated with cyclosporine A, mycophenolate mofetil, everolimus, and glucocorticosteroid was significantly elevated above that of the control rats.	Mycophenolic Acid	87-108	superoxide dismutase 1	Rattus norvegicus	18-22
30604095-11	2019	Mycophenolate, the major pharmacologically active metabolite of MMF, is likely to inhibit the arginine:glycine amidinotransferase (AGAT), and to enhance arginase activity in leukocytes and other types of cell of MMF-treated children.	Mycophenolic Acid	0-13	glycine amidinotransferase	Homo sapiens	94-129
30976185-3	2019	The effect of pterostilbene on cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzyme activities were studied using the enzyme-selective substrates amodiaquine (CYP2C8), midazolam (CYP3A4), estradiol (UGT1A1), serotonin (UGT1A6) and mycophenolic acid (UGT1A8/9/10).	Mycophenolic Acid	245-262	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	86-89
31429348-0	2019	Mycophenolic acid enhanced lipopolysaccharide-induced interleukin-18 release in THP-1 cells via activation of the NLRP3 inflammasome.	Mycophenolic Acid	0-17	interleukin 18	Homo sapiens	54-68
31429348-0	2019	Mycophenolic acid enhanced lipopolysaccharide-induced interleukin-18 release in THP-1 cells via activation of the NLRP3 inflammasome.	Mycophenolic Acid	0-17	NLR family pyrin domain containing 3	Homo sapiens	114-119
31429348-3	2019	Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), in association with lipopolysaccharide (LPS), is able to promote the secretion of IL-18, but the mechanism remains unknown.	Mycophenolic Acid	0-17	interleukin 18	Homo sapiens	161-166
31429348-3	2019	Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), in association with lipopolysaccharide (LPS), is able to promote the secretion of IL-18, but the mechanism remains unknown.	Mycophenolic Acid	19-22	interleukin 18	Homo sapiens	161-166
31423655-0	2019	Pharmacokinetics of mycophenolic acid and its effect on CD4+ and CD8+ T cells after oral administration of mycophenolate mofetil to healthy cats.	Mycophenolic Acid	20-37	CD4 molecule	Felis catus	56-59
31457102-0	2019	Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial beta-glucuronidase activity.	Mycophenolic Acid	20-41	glucuronidase, beta	Mus musculus	105-123
31112757-0	2019	Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation.	Mycophenolic Acid	64-85	natural cytotoxicity triggering receptor 3	Homo sapiens	20-25
31112757-9	2019	In summary, our findings demonstrated that long-term MMF administration delayed the quality and quantity of NK cells, especially NKp30 subpopulations, which was associated with decreased EBV viremia post allogeneic HSCT.	Mycophenolic Acid	53-56	natural cytotoxicity triggering receptor 3	Homo sapiens	129-134
31253599-4	2019	The purpose of this study was to compare the efficacy and safety of mycophenolate mofetil versus cyclophosphamide for the induction treatment of nonlife-threatening relapses of proteinase 3-ANCA- and myeloperoxidase-ANCA-associated vasculitis.	Mycophenolic Acid	68-89	myeloperoxidase	Homo sapiens	177-215
30198840-1	2019	OBJECTIVES: Here, we report our 1-year follow-up data of stable ABO-incompatible kidney transplant recipients who converted from mycophenolate mofetil plus a standard dose of a calcineurin inhibitor to everolimus plus low exposure to calcineurin inhibitors.	Mycophenolic Acid	129-150	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	64-67
30674728-0	2019	Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients.	Mycophenolic Acid	0-21	signal transducer and activator of transcription 3	Homo sapiens	30-35
30636046-8	2019	Licoricidin showed a higher metabolic ratio and rapid metabolism with the recombinant human UGT1A9 than mycophenolic acid, a well-known UGT1A9 substrate.	Mycophenolic Acid	104-121	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	136-142
30610229-3	2019	Steroid therapy remains the first line therapy for moderate/severe and severe vision threatening TED The use of some traditional nonspecific immunosuppressant such as mycophenolate, cyclosporine and azathioprine seems useful in combination with steroid therapy to achieve stable results in the long term; methotrexate is useful as steroid-sparing medications and in steroid resistant or intolerant patients.	Mycophenolic Acid	167-180	NALCN channel auxiliary factor 2	Homo sapiens	97-100
30674728-8	2019	Further, healthy PBMCs treated with IL-6 revealed a reduction in p-STAT3 following the addition of mycophenolic acid (the active metabolite of MMF).	Mycophenolic Acid	99-116	interleukin 6	Homo sapiens	36-40
30674728-8	2019	Further, healthy PBMCs treated with IL-6 revealed a reduction in p-STAT3 following the addition of mycophenolic acid (the active metabolite of MMF).	Mycophenolic Acid	99-116	signal transducer and activator of transcription 3	Homo sapiens	67-72
30674728-8	2019	Further, healthy PBMCs treated with IL-6 revealed a reduction in p-STAT3 following the addition of mycophenolic acid (the active metabolite of MMF).	Mycophenolic Acid	143-146	interleukin 6	Homo sapiens	36-40
30674728-8	2019	Further, healthy PBMCs treated with IL-6 revealed a reduction in p-STAT3 following the addition of mycophenolic acid (the active metabolite of MMF).	Mycophenolic Acid	143-146	signal transducer and activator of transcription 3	Homo sapiens	67-72
31497276-2	2019	Objective: To evaluate M235T and T174M polymorphisms of angiotensinogen gene along with some demographic and clinical factors including age; sex; body mass index (BMI); model for end-stage liver disease (MELD) score; prednisolone, mycophenolate mofetil and tacrolimus dose; and serum level in NODAT among liver recipients.	Mycophenolic Acid	231-252	angiotensinogen	Homo sapiens	56-71
30243822-0	2019	Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1beta mediated PI3K/AKT/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy.	Mycophenolic Acid	0-21	AKT serine/threonine kinase 1	Rattus norvegicus	114-117
30243822-0	2019	Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1beta mediated PI3K/AKT/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy.	Mycophenolic Acid	0-21	mechanistic target of rapamycin kinase	Rattus norvegicus	118-122
30488399-0	2018	Increased Mucin Expression in Oral Mucosal Epithelial Cells in vitro: A Potential New Role of Mycophenolate Mofetil.	Mycophenolic Acid	94-115	LOC100508689	Homo sapiens	10-15
30488399-2	2018	Mycophenolate mofetil (MMF) has been found to upregulate the mucin production in conjunctival goblet cells in vitro.	Mycophenolic Acid	0-21	LOC100508689	Homo sapiens	61-66
30488399-2	2018	Mycophenolate mofetil (MMF) has been found to upregulate the mucin production in conjunctival goblet cells in vitro.	Mycophenolic Acid	23-26	LOC100508689	Homo sapiens	61-66
29923092-0	2019	Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).	Mycophenolic Acid	29-42	CLN3 lysosomal/endosomal transmembrane protein, battenin	Homo sapiens	64-68
30442353-0	2018	Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.	Mycophenolic Acid	125-146	inosine monophosphate dehydrogenase 2	Homo sapiens	17-23
30524720-2	2018	The aim of this study is to compare the carotid intima-media thickness (cIMT) between de novo tacrolimus/mycophenolate and tacrolimus/sirolimus at low doses.	Mycophenolic Acid	105-118	CIMT	Homo sapiens	72-76
30524720-9	2018	Conclusions: The use of sirolimus plus tacrolimus de novo in kidney transplantation is associated with a reduction in cIMT after 12 months, a decrease more significant than seen with the combination of mycophenolate plus tacrolimus.	Mycophenolic Acid	202-215	CIMT	Homo sapiens	118-122
30442353-0	2018	Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.	Mycophenolic Acid	125-146	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	25-31
30442353-0	2018	Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.	Mycophenolic Acid	125-146	carboxylesterase 2	Homo sapiens	37-41
30095739-0	2018	CXCR4 Antagonist Reduced the Incidence of Acute Rejection and Controlled Cardiac Allograft Vasculopathy in a Swine Heart Transplant Model Receiving a Mycophenolate-based Immunosuppressive Regimen.	Mycophenolic Acid	150-163	C-X-C motif chemokine receptor 4	Sus scrofa	0-5
30345879-0	2018	Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients.	Mycophenolic Acid	52-69	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	10-16
30193639-1	2018	In this study, for the first time a rapid, selective and highly sensitive method was developed for simultaneous determination of warfarin and mycophenolic acid using carbon paste electrode modified by beta-cyclodextrin/multi-walled carbon nanotubes/cobalt oxide nanoparticles (beta-CD/MWCNTs/Co3O4NPs/CPE).	Mycophenolic Acid	142-159	carboxypeptidase E	Homo sapiens	301-304
31384438-2	2019	An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west.	Mycophenolic Acid	28-49	Rap guanine nucleotide exchange factor 1	Homo sapiens	106-109
31384438-2	2019	An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west.	Mycophenolic Acid	51-54	Rap guanine nucleotide exchange factor 1	Homo sapiens	106-109
30345879-0	2018	Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients.	Mycophenolic Acid	52-69	ATP binding cassette subfamily C member 2	Homo sapiens	21-26
29025387-0	2018	In Vitro Study on Influences of UGT1A8 Gene Polymorphisms on Mycophenolate Mofetil Metabolism.	Mycophenolic Acid	61-82	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	32-38
30223117-8	2018	Most of the compounds exhibited higher cellular potency against cancer cell lines and notably lower toxicity towards NIH-3T3 cells compared to mycophenolic acid (MPA), a prototypical hIMPDH2 inhibitor.	Mycophenolic Acid	143-160	inosine monophosphate dehydrogenase 2	Homo sapiens	183-190
30177118-5	2018	PATIENTS AND METHODS: Kallistatin level was estimated in 131 heart transplant recipients on standard 3 drugs immunosuppressive regimens (calcineurin inhibitor, mycophenolate mofetil/mycophenolic acid, and steroids) in correlation to inflammation markers and blood pressure values.	Mycophenolic Acid	160-181	serpin family A member 4	Homo sapiens	22-33
30176946-3	2018	CASE PRESENTATION: Here, we report the successful treatment of a mycophenolate-resistant organizing pneumonia (OP) with infliximab in a patient with metastatic melanoma after PD-1 blockade.	Mycophenolic Acid	65-78	programmed cell death 1	Homo sapiens	175-179
30176946-8	2018	CONCLUSION: This case describes a not well-studied situation, in which a mycophenolate-resistant PD-1 blocker-associated pneumonitis was successfully treated with a TNFalpha neutralizing antibody.	Mycophenolic Acid	73-86	programmed cell death 1	Homo sapiens	97-101
30176946-8	2018	CONCLUSION: This case describes a not well-studied situation, in which a mycophenolate-resistant PD-1 blocker-associated pneumonitis was successfully treated with a TNFalpha neutralizing antibody.	Mycophenolic Acid	73-86	tumor necrosis factor	Homo sapiens	165-173
30186414-1	2018	The efficacy and safety of mycophenolate mofetil (MMF) for immunoglobulin A nephropathy (IgAN) remains debatable.	Mycophenolic Acid	27-48	IGAN1	Homo sapiens	89-93
30186414-1	2018	The efficacy and safety of mycophenolate mofetil (MMF) for immunoglobulin A nephropathy (IgAN) remains debatable.	Mycophenolic Acid	50-53	IGAN1	Homo sapiens	89-93
29025387-2	2018	The UDP glucuronosyltransferase enzyme is the key metabolic enzyme for mycophenolate mofetil, and UGT1A8 gene polymorphisms may affect the elimination of mycophenolate mofetil in patients.	Mycophenolic Acid	154-175	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	98-104
29025387-3	2018	Here, we conducted an in vitro study to explore the relation between UGT1A8 gene polymorphisms and mycophenolate mofetil metabolism.	Mycophenolic Acid	99-120	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	69-75
29455288-0	2018	Mycophenolate Mofetil Protects Septic Mice via the Dual Inhibition of Inflammatory Cytokines and PD-1.	Mycophenolic Acid	0-21	programmed cell death 1	Mus musculus	97-101
29025387-11	2018	CONCLUSIONS: Our results showed that UGT1A8 gene polymorphisms can affect the activity of UDP glucuronosyltransferase enzyme, which may influence the elimination of mycophenolate mofetil in different patients.	Mycophenolic Acid	165-186	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	37-43
29870138-10	2018	Daunorubicin, mycophenolic acid, and pyrvinium could potentially target the hub gene CHEK1 directly.	Mycophenolic Acid	14-31	checkpoint kinase 1	Homo sapiens	85-90
29996800-9	2018	At 6 months, serum creatinine (mg/dL) decreased from 1.73 to 0.96 in CYC and from 1.24 to 0.91 in the MMF group with improvement in eGFR (ml/min/1.73 m2) from 60.33 to 88.52 in CYC and from 64.42 to 89.09 in MMF group.	Mycophenolic Acid	102-105	epidermal growth factor receptor	Homo sapiens	132-136
29941706-0	2018	Mycophenolic Acid Synergizing with Lipopolysaccharide to Induce Interleukin-1beta Release via Activation of Caspase-1.	Mycophenolic Acid	0-17	caspase 1	Homo sapiens	108-117
29941706-11	2018	These findings suggested that patients immunosuppressed with mycophenolate mofetil may have overly activated caspase-1 during infection, which might contribute to a more sensitive host defense response to invading germs.	Mycophenolic Acid	61-82	caspase 1	Homo sapiens	109-118
29550576-10	2018	The clinical impact of CYP3A5 genetic differences may be small under the current immunosuppressive regimen consisting of mycophenolate mofetil, steroids, basiliximab, and lower target trough levels of tacrolimus with suitable TDM in a low immunological risk population.	Mycophenolic Acid	121-142	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	23-29
29970872-0	2018	Application of Docking Analysis in the Prediction and Biological Evaluation of the Lipoxygenase Inhibitory Action of Thiazolyl Derivatives of Mycophenolic Acid.	Mycophenolic Acid	142-159	linoleate 9S-lipoxygenase-4	Glycine max	83-95
29896275-0	2018	Mycophenolate Mofetil induces c-Jun-N-terminal kinase expression in 22Rv1 cells: an impact on androgen receptor signaling.	Mycophenolic Acid	0-21	androgen receptor	Homo sapiens	94-111
30056902-0	2018	Malnutrition Risk in Kidney Recipients Treated With Mycophenolate Mofetil Is Associated With IMPDH1 rs2278294 Polymorphism.	Mycophenolic Acid	52-73	inosine monophosphate dehydrogenase 1	Homo sapiens	93-99
29102373-6	2018	Specifically, combination therapy inhibited TLR7 expression in the kidneys of mice with lupus nephritis; combination of tacrolimus and mycophenolate mofetil led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities.	Mycophenolic Acid	135-156	ras homolog family member A	Mus musculus	257-261
29102373-6	2018	Specifically, combination therapy inhibited TLR7 expression in the kidneys of mice with lupus nephritis; combination of tacrolimus and mycophenolate mofetil led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities.	Mycophenolic Acid	135-156	Rac family small GTPase 1	Mus musculus	266-270
29778558-4	2018	We present the case of a young patient at high immunological risk, with atypical haemolytic uraemic syndrome due to factor H mutation, who underwent a successful kidney transplantation with eculizumab, thymoglobulin, belatacept, mycophenolate and steroids, to date preserving excellent graft function without disease recurrence.	Mycophenolic Acid	229-242	complement factor H	Homo sapiens	116-124
30056902-4	2018	STUDY DESIGN: In an observational longitudinal study of kidney transplant recipients treated with mycophenolate mofetil, genetic factors were IMPDH1 (rs2278294, rs2278293) and IMPDH2 (rs11706052) allelic variants, the main outcome was the time-dependent change in BMI, and secondary outcomes were occurrence of BMI below 18.5 or 20 kg/m2.	Mycophenolic Acid	98-119	inosine monophosphate dehydrogenase 1	Homo sapiens	142-148
30056902-4	2018	STUDY DESIGN: In an observational longitudinal study of kidney transplant recipients treated with mycophenolate mofetil, genetic factors were IMPDH1 (rs2278294, rs2278293) and IMPDH2 (rs11706052) allelic variants, the main outcome was the time-dependent change in BMI, and secondary outcomes were occurrence of BMI below 18.5 or 20 kg/m2.	Mycophenolic Acid	98-119	inosine monophosphate dehydrogenase 2	Homo sapiens	176-182
30056903-4	2018	MATERIALS AND METHODS: The level of serum endocan among 63 kidney transplant recipients on three immunosuppressives (calcineurin inhibitors, mycophenolate mofetil, steroids) in correlation with other markers of endothelial damage was estimated.	Mycophenolic Acid	141-162	endothelial cell specific molecule 1	Homo sapiens	42-49
29270163-9	2017	Finally, the silencing of sfk1 depleted the production of the main secondary metabolites of P. roqueforti, namely roquefortine C, andrastin A, and mycophenolic acid.	Mycophenolic Acid	147-164	Sfk1p	Saccharomyces cerevisiae S288C	26-30
29130236-6	2017	In addition, some immunosuppressive agents [such as calcium phosphatase inhibitor (CNI)] are carcinogenic and the use of anti-tumor combined with immunosuppressive drugs can be considered [such as mycophenolate mofetil (MMF), mammalian rapamycin target protein (mTOR) inhibitors].	Mycophenolic Acid	220-223	mechanistic target of rapamycin kinase	Homo sapiens	262-266
29308284-2	2017	A 52-year-old female with a history of anti-Jo1-associated ASS went into remission with glucocorticoids and mycophenolate mofetil.	Mycophenolic Acid	108-129	argininosuccinate synthase 1	Homo sapiens	59-62
29069774-6	2017	Further functional investigations carried out on PHOX2B mRNA levels and biological consequences, such as neuroblastoma cell apoptosis and growth, showed that chloroquine and mycophenolate mofetil are most promising agents for neuroblastoma therapy based on down-regulation of PHOX2B expression.	Mycophenolic Acid	174-195	paired like homeobox 2B	Homo sapiens	49-55
27616538-2	2017	The objective of this study was to examine the association of UGT1A9, SLCO, and ABCC polymorphisms with mycophenolic acid (MPA) pharmacokinetics in ABO blood type (ABO) incompatible patients with severe renal dysfunction pre-transplantation.	Mycophenolic Acid	104-121	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	164-167
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Mycophenolic Acid	194-211	ATP binding cassette subfamily C member 2	Homo sapiens	91-132
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Mycophenolic Acid	194-211	ATP binding cassette subfamily C member 2	Homo sapiens	134-138
28624888-1	2017	PURPOSE: The study aims to evaluate the impact of recipients" and donors" polymorphisms in multidrug resistance-associated protein 2 (MRP2) gene ABCC2 -24C&gt;T and 1249G&gt;A on disposition of mycophenolic acid (MPA) and their interaction with cyclosporine (CsA) (compared to tacrolimus, TAC) in stable de novo adult renal transplant patients of Croatian origin.	Mycophenolic Acid	194-211	ATP binding cassette subfamily C member 2	Homo sapiens	145-150
27885065-0	2017	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.	Mycophenolic Acid	17-38	aquaporin 4	Homo sapiens	64-68
27616538-2	2017	The objective of this study was to examine the association of UGT1A9, SLCO, and ABCC polymorphisms with mycophenolic acid (MPA) pharmacokinetics in ABO blood type (ABO) incompatible patients with severe renal dysfunction pre-transplantation.	Mycophenolic Acid	104-121	ATP binding cassette subfamily C member 1	Homo sapiens	80-84
27616538-2	2017	The objective of this study was to examine the association of UGT1A9, SLCO, and ABCC polymorphisms with mycophenolic acid (MPA) pharmacokinetics in ABO blood type (ABO) incompatible patients with severe renal dysfunction pre-transplantation.	Mycophenolic Acid	104-121	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	148-151
29069774-6	2017	Further functional investigations carried out on PHOX2B mRNA levels and biological consequences, such as neuroblastoma cell apoptosis and growth, showed that chloroquine and mycophenolate mofetil are most promising agents for neuroblastoma therapy based on down-regulation of PHOX2B expression.	Mycophenolic Acid	174-195	paired like homeobox 2B	Homo sapiens	276-282
27534951-3	2017	A recent open-label, single-arm, multicenter clinical study prospectively examined the efficacy and safety of rituximab/mycophenolate mofetil desensitization in ABO-incompatible kidney transplantation without splenectomy.	Mycophenolic Acid	120-141	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	161-164
28613375-0	2017	Study on the association of UGT1A9 gene c.98T&gt;C polymorphism and mycophenolic acid plasma levels in renal transplant patients.	Mycophenolic Acid	68-85	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	28-34
28724421-1	2017	BACKGROUND: The application of mycophenolate mofetil (MMF) in treating patients with immunoglobulin A nephropathy (IgAN) remains uncertain.	Mycophenolic Acid	31-52	IGAN1	Homo sapiens	115-119
28724421-1	2017	BACKGROUND: The application of mycophenolate mofetil (MMF) in treating patients with immunoglobulin A nephropathy (IgAN) remains uncertain.	Mycophenolic Acid	54-57	IGAN1	Homo sapiens	115-119
28747916-0	2017	Interferon-Gamma DNA Methylation Is Affected by Mycophenolic Acid but Not by Tacrolimus after T-Cell Activation.	Mycophenolic Acid	48-65	interferon gamma	Homo sapiens	0-16
28611384-9	2017	Enzyme assays showed that CYP3A5 and CYP17A1 exerted direct metabolic effects on tacrolimus and mycophenolate mofetil, respectively.	Mycophenolic Acid	96-117	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	26-32
28611384-9	2017	Enzyme assays showed that CYP3A5 and CYP17A1 exerted direct metabolic effects on tacrolimus and mycophenolate mofetil, respectively.	Mycophenolic Acid	96-117	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	37-44
28613375-5	2017	The objective of this study was to evaluate the effect of allelic variants of the UGT1A9 c.98T&gt;C polymorphism (rs72551330; g. 87289T&gt;C) on MMF metabolism in renal transplant patients.	Mycophenolic Acid	145-148	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	82-88
28316087-1	2017	STUDY OBJECTIVE: To investigate the influence of single nucleotide polymorphisms (SNPs) in genes encoding metabolizing enzymes (CYP2C8, CYP2J2, and UGT2B7) and transporters (ABCC2 and ABCG2) on dose and dose-adjusted trough blood concentrations (C:D ratio), clinical outcomes, and occurrence of adverse events of tacrolimus and mycophenolate sodium in Brazilian kidney transplant recipients.	Mycophenolic Acid	328-348	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	128-134
27549213-0	2017	Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis.	Mycophenolic Acid	31-48	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	55-61
27549213-7	2017	A significantly higher number of UGT1A9 polymorphisms was found in the group that did not respond to MPA treatment.	Mycophenolic Acid	101-104	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	33-39
27549213-8	2017	Of the patients that carried a UGT1A9 polymorphism, 85.7% were non-responsive to MPA treatment.	Mycophenolic Acid	81-84	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	31-37
28316087-11	2017	Further, CYP2C8*3 and CYP2J2 c.-76G&gt;T SNPs influenced the renal function of these patients and the occurrence of adverse events during treatment with tacrolimus and mycophenolate sodium.	Mycophenolic Acid	168-188	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	9-15
28353583-1	2017	The objective of the present study was to assess the effect of cyclosporine (CsA) on the pharmacokinetic parameters of mycophenolic acid (MPA), an active mycophenolate mofetil (MMF) metabolite, and to compare with the effect of everolimus (EVR).Anonymized medical records of 404 kidney recipients were reviewed.	Mycophenolic Acid	119-136	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	77-80
28316087-11	2017	Further, CYP2C8*3 and CYP2J2 c.-76G&gt;T SNPs influenced the renal function of these patients and the occurrence of adverse events during treatment with tacrolimus and mycophenolate sodium.	Mycophenolic Acid	168-188	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	22-28
28340819-15	2017	In patients with the CYP2C19*2/*2 genotype, the mean concentrations of MMF with lansoprazole were significantly lower than those with rabeprazole with MMF or without PPI (P &lt; .05).	Mycophenolic Acid	71-74	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	21-28
28353583-1	2017	The objective of the present study was to assess the effect of cyclosporine (CsA) on the pharmacokinetic parameters of mycophenolic acid (MPA), an active mycophenolate mofetil (MMF) metabolite, and to compare with the effect of everolimus (EVR).Anonymized medical records of 404 kidney recipients were reviewed.	Mycophenolic Acid	138-141	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	77-80
28353583-1	2017	The objective of the present study was to assess the effect of cyclosporine (CsA) on the pharmacokinetic parameters of mycophenolic acid (MPA), an active mycophenolate mofetil (MMF) metabolite, and to compare with the effect of everolimus (EVR).Anonymized medical records of 404 kidney recipients were reviewed.	Mycophenolic Acid	154-175	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	77-80
28173241-4	2017	Subsequently, mycophenolate mofetil (MMF) was administered at a dose of 2 g/d in addition to the corticosteroid, which resulted in aspartate aminotransferase and alanine aminotransferase levels gradually improving to grade 1, and the corticosteroid dose was successfully reduced to 0.5 mg/kg/d of oral prednisolone.	Mycophenolic Acid	14-35	glutamic--pyruvic transaminase	Homo sapiens	162-186
27416846-0	2017	Systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy treated with combination of mycophenolate mofetil, plasma exchange and steroid.	Mycophenolic Acid	117-138	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	34-42
28173241-4	2017	Subsequently, mycophenolate mofetil (MMF) was administered at a dose of 2 g/d in addition to the corticosteroid, which resulted in aspartate aminotransferase and alanine aminotransferase levels gradually improving to grade 1, and the corticosteroid dose was successfully reduced to 0.5 mg/kg/d of oral prednisolone.	Mycophenolic Acid	37-40	glutamic--pyruvic transaminase	Homo sapiens	162-186
28122021-0	2017	The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function.	Mycophenolic Acid	29-46	CD14 molecule	Homo sapiens	50-54
27876682-0	2017	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-alpha inhibitors and conventional immunosuppressants.	Mycophenolic Acid	0-21	tumor necrosis factor	Homo sapiens	97-106
28122021-10	2017	p-ERK was inhibited with a maximum of 15% after spiking with either tacrolimus or MPA.	Mycophenolic Acid	82-85	mitogen-activated protein kinase 1	Homo sapiens	2-5
27718019-0	2017	Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies.	Mycophenolic Acid	0-21	interferon induced with helicase C domain 1	Homo sapiens	111-116
28051798-0	2017	Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key.	Mycophenolic Acid	14-35	calcineurin binding protein 1	Homo sapiens	69-90
27754567-9	2017	Results from this study show comparable renal function between arms at Week 52, with fewer AEs leading to study discontinuation with prolonged-release tacrolimus plus MMF (Arm 1) versus lower dose prolonged-release tacrolimus plus sirolimus (Arm 2).	Mycophenolic Acid	167-170	ADRM1 26S proteasome ubiquitin receptor	Homo sapiens	172-177
28535523-5	2017	Due to immune-mediated pathogenic nature of IgAN, therapy with mycophenolate mofetil (MMF), a potent immunosuppressive agent, could be effective in patients at risk for progressive disease.	Mycophenolic Acid	63-84	IGAN1	Homo sapiens	44-48
28535523-5	2017	Due to immune-mediated pathogenic nature of IgAN, therapy with mycophenolate mofetil (MMF), a potent immunosuppressive agent, could be effective in patients at risk for progressive disease.	Mycophenolic Acid	86-89	IGAN1	Homo sapiens	44-48
28391339-2	2017	Mycophenolate mofetil (MMF) treatment is offered to patients presenting to the Imperial College Renal and Transplant Centre with IgAN and histological evidence of endocapillary hypercellularity.	Mycophenolic Acid	0-21	IGAN1	Homo sapiens	129-133
28391339-2	2017	Mycophenolate mofetil (MMF) treatment is offered to patients presenting to the Imperial College Renal and Transplant Centre with IgAN and histological evidence of endocapillary hypercellularity.	Mycophenolic Acid	23-26	IGAN1	Homo sapiens	129-133
27519278-0	2016	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.	Mycophenolic Acid	14-35	calcineurin binding protein 1	Homo sapiens	39-60
27651367-0	2016	Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.	Mycophenolic Acid	0-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
27651367-0	2016	Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.	Mycophenolic Acid	0-17	AKT serine/threonine kinase 1	Homo sapiens	116-119
27651367-0	2016	Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.	Mycophenolic Acid	0-17	forkhead box O1	Homo sapiens	120-125
27651367-0	2016	Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.	Mycophenolic Acid	0-17	Janus kinase 2	Homo sapiens	130-134
27651367-0	2016	Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.	Mycophenolic Acid	0-17	signal transducer and activator of transcription 3	Homo sapiens	135-140
27443993-2	2016	Immunosuppressive efficacies of glucocorticoids, calcineurin inhibitors, and mycophenolic acid are possibly affected by insulin after renal transplantation in these patients.	Mycophenolic Acid	77-94	insulin	Homo sapiens	120-127
27443993-4	2016	MATERIALS AND METHODS: Antiproliferative efficacies of prednisolone, hydrocortisone, cyclosporine, tacrolimus, and mycophenolic acid against concanavalin A-stimulated PBMCs were evaluated in the presence of physiological (5 muunits/mL) and super physiological (50 muunits/mL) concentrations of insulin.	Mycophenolic Acid	115-132	insulin	Homo sapiens	294-301
27443993-8	2016	The IC50 values of mycophenolic acid significantly increased by 50 muunits/mL insulin (p &lt; 0.01).	Mycophenolic Acid	19-36	insulin	Homo sapiens	78-85
27428762-5	2016	On the other hand, Mycophenolate mofetil induced GPX1 mRNA, although it suppressed mRNA level of UGT1A4/1A9/2B7/2B10, GSTA1/O1/T1, GSR and HMOX1 in HepG2 cells.	Mycophenolic Acid	19-40	glutathione peroxidase 1	Homo sapiens	49-53
27428762-5	2016	On the other hand, Mycophenolate mofetil induced GPX1 mRNA, although it suppressed mRNA level of UGT1A4/1A9/2B7/2B10, GSTA1/O1/T1, GSR and HMOX1 in HepG2 cells.	Mycophenolic Acid	19-40	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	97-103
27428762-5	2016	On the other hand, Mycophenolate mofetil induced GPX1 mRNA, although it suppressed mRNA level of UGT1A4/1A9/2B7/2B10, GSTA1/O1/T1, GSR and HMOX1 in HepG2 cells.	Mycophenolic Acid	19-40	glutathione S-transferase alpha 1	Homo sapiens	118-123
27428762-5	2016	On the other hand, Mycophenolate mofetil induced GPX1 mRNA, although it suppressed mRNA level of UGT1A4/1A9/2B7/2B10, GSTA1/O1/T1, GSR and HMOX1 in HepG2 cells.	Mycophenolic Acid	19-40	immunoglobulin kappa variable 2D-40	Homo sapiens	124-129
27428762-5	2016	On the other hand, Mycophenolate mofetil induced GPX1 mRNA, although it suppressed mRNA level of UGT1A4/1A9/2B7/2B10, GSTA1/O1/T1, GSR and HMOX1 in HepG2 cells.	Mycophenolic Acid	19-40	heme oxygenase 1	Homo sapiens	139-144
27496439-9	2016	Mofetil mycophenolate (MMF)contributed to the change of TLR4 expression in the CsA group but not in the Tac group.	Mycophenolic Acid	0-21	toll like receptor 4	Homo sapiens	56-60
27050624-0	2016	Mycophenolate mofetil and curcumin provide comparable therapeutic benefit in experimental chronic kidney disease: role of Nrf2-Keap1 and renal dopamine pathways.	Mycophenolic Acid	0-21	NFE2 like bZIP transcription factor 2	Homo sapiens	122-126
27050624-0	2016	Mycophenolate mofetil and curcumin provide comparable therapeutic benefit in experimental chronic kidney disease: role of Nrf2-Keap1 and renal dopamine pathways.	Mycophenolic Acid	0-21	kelch like ECH associated protein 1	Homo sapiens	127-132
27569951-5	2016	CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups.	Mycophenolic Acid	135-138	CD4 molecule	Homo sapiens	0-3
27569951-5	2016	CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups.	Mycophenolic Acid	149-152	CD4 molecule	Homo sapiens	0-3
27496439-9	2016	Mofetil mycophenolate (MMF)contributed to the change of TLR4 expression in the CsA group but not in the Tac group.	Mycophenolic Acid	23-26	toll like receptor 4	Homo sapiens	56-60
27496491-4	2016	METHODS: The level of serum endocan among 131 heart transplant recipients on 3-drug immunosuppression (calcineurin inhibitor, mycophenolate mofetil/mycophenolic acid, steroid) in correlation with other markers of endothelial damage was determined.	Mycophenolic Acid	126-147	endothelial cell specific molecule 1	Homo sapiens	28-35
27496491-4	2016	METHODS: The level of serum endocan among 131 heart transplant recipients on 3-drug immunosuppression (calcineurin inhibitor, mycophenolate mofetil/mycophenolic acid, steroid) in correlation with other markers of endothelial damage was determined.	Mycophenolic Acid	148-165	endothelial cell specific molecule 1	Homo sapiens	28-35
26274696-3	2016	METHODS: Twenty-four stable kidney transplant recipients receiving CSA, MPS, and corticosteroids were converted from CSA to EVR.	Mycophenolic Acid	72-75	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	117-120
27007325-8	2016	In cytokine assay, we noticed increasing levels of IL-17 with increasing doses of concanavalin A in control group and in group of dams treated with cyclosporine A, mycophenolate mofetil and prednisone.	Mycophenolic Acid	164-185	interleukin 17A	Rattus norvegicus	51-56
26882567-8	2016	Moreover, the identified HIF-1 inhibitors, such as mycophenolate mofetil, niclosamide, and trametinib, were able to suppress cancer cell proliferation and angiogenesis.	Mycophenolic Acid	51-72	hypoxia inducible factor 1 subunit alpha	Homo sapiens	25-30
27563474-6	2016	Based on the emergent evidence that both disorders share common immunopathogenic mechanisms involving Th1 and Th17 lymphocytes, our patient was given rituximab and mycophenolate mofetil to successfully suppress the haemolysis and sarcoid activity.	Mycophenolic Acid	164-185	negative elongation factor complex member C/D	Homo sapiens	102-105
26757303-4	2016	Her immunosuppression treatment was increased to 1,000 mg bid of mycophenolate and 20 mg of prednisone.	Mycophenolic Acid	65-78	BH3 interacting domain death agonist	Homo sapiens	58-61
26889216-11	2016	The present meta-analysis, which is based on IgAN patients, suggested that AZA, MMF, LET and CTX are effective in reducing proteinuria levels, with acceptable side effects.	Mycophenolic Acid	80-83	IGAN1	Homo sapiens	45-49
26548367-0	2016	Mycophenolic acid inhibits the phosphorylation of nuclear factor-kappaB and Akt in renal tubular epithelial cells.	Mycophenolic Acid	0-17	AKT serine/threonine kinase 1	Rattus norvegicus	76-79
25549254-0	2015	Relationship between the Peripheral Lymphocyte Response to Mycophenolic Acid in vitro and the Level of ATP in Peripheral CD4+ Lymphocytes before and after Renal Transplantation.	Mycophenolic Acid	59-76	CD4 molecule	Homo sapiens	121-124
26467706-0	2016	Differential Sensitivities of Fast- and Slow-Cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid.	Mycophenolic Acid	121-138	inosine monophosphate dehydrogenase 2	Homo sapiens	69-106
26561804-0	2015	Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn"s Disease Mouse Model.	Mycophenolic Acid	0-21	negative elongation factor complex member C/D, Th1l	Mus musculus	51-54
26561804-0	2015	Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn"s Disease Mouse Model.	Mycophenolic Acid	0-21	heart and neural crest derivatives expressed 2	Mus musculus	55-58
26561804-7	2015	Mycophenolic acid (MPA) also significantly decreased the percentages of splenic Th1 and Th2 cells in vitro.	Mycophenolic Acid	0-17	negative elongation factor complex member C/D, Th1l	Mus musculus	80-83
26561804-7	2015	Mycophenolic acid (MPA) also significantly decreased the percentages of splenic Th1 and Th2 cells in vitro.	Mycophenolic Acid	0-17	heart and neural crest derivatives expressed 2	Mus musculus	88-91
26561804-7	2015	Mycophenolic acid (MPA) also significantly decreased the percentages of splenic Th1 and Th2 cells in vitro.	Mycophenolic Acid	19-22	negative elongation factor complex member C/D, Th1l	Mus musculus	80-83
26561804-7	2015	Mycophenolic acid (MPA) also significantly decreased the percentages of splenic Th1 and Th2 cells in vitro.	Mycophenolic Acid	19-22	heart and neural crest derivatives expressed 2	Mus musculus	88-91
26093490-9	2015	In vivo, out of eight XET-inhibitors bioassayed, erythrosin (1 muM) inhibited cell expansion in Rosa and Zea cell-suspension cultures, and 40 muM mycophenolic acid and (-)-epigallocatechin gallate inhibited Zea culture growth.	Mycophenolic Acid	146-163	latexin	Homo sapiens	142-145
25808346-10	2015	An increased Bcl-2/Bax transcript ratio contributed to cellular proliferation, and this was maintained in the MPA-treated environment.	Mycophenolic Acid	110-113	B cell leukemia/lymphoma 2	Mus musculus	13-18
25808346-10	2015	An increased Bcl-2/Bax transcript ratio contributed to cellular proliferation, and this was maintained in the MPA-treated environment.	Mycophenolic Acid	110-113	BCL2-associated X protein	Mus musculus	19-22
26600786-3	2015	We report a case of a 73-year-old woman in severe immunosuppression due to treatment with mycophenolate mofetil, glucocorticosteroids and a tumor necrosis factor alpha inhibitor.	Mycophenolic Acid	90-111	tumor necrosis factor	Homo sapiens	140-167
26209543-1	2015	BACKGROUND: Previous randomized controlled trials evaluating the efficacy of mycophenolate mofetil (MMF) in patients with immunoglobulin A nephropathy (IgAN) have produced varying results.	Mycophenolic Acid	77-98	IGAN1	Homo sapiens	152-156
26209543-1	2015	BACKGROUND: Previous randomized controlled trials evaluating the efficacy of mycophenolate mofetil (MMF) in patients with immunoglobulin A nephropathy (IgAN) have produced varying results.	Mycophenolic Acid	100-103	IGAN1	Homo sapiens	152-156
26307985-3	2015	We evaluated SNPs in genes that have previously shown correlations in other kinds of solid organ transplantation, namely ABCB1 and CYP3A5 genes with tacrolimus (Tac) and ABCC2, UGT1A9 and SLCO1B1 genes with mycophenolic acid (MPA), during the first six months after lung transplantation (51 patients).	Mycophenolic Acid	226-229	ATP binding cassette subfamily B member 1	Homo sapiens	121-126
26449633-0	2015	Mycophenolic acid reverses TGF beta-induced cell motility, collagen matrix contraction and cell morphology in vitro.	Mycophenolic Acid	0-17	transforming growth factor beta 1	Homo sapiens	27-35
26080907-9	2015	In addition, the expression of epithelial mesenchymal transition indices, including alpha-SMA and TGF-beta1, in the renal tubule interstitium were significantly decreased in the benazepril- and MMF-treated groups compared with those of the diabetic group.	Mycophenolic Acid	194-197	actin gamma 2, smooth muscle	Rattus norvegicus	84-93
25661834-0	2015	Mycophenolic acid upregulates miR-142-3P/5P and miR-146a in lupus CD4+T cells.	Mycophenolic Acid	0-17	microRNA 142	Homo sapiens	30-37
26080907-9	2015	In addition, the expression of epithelial mesenchymal transition indices, including alpha-SMA and TGF-beta1, in the renal tubule interstitium were significantly decreased in the benazepril- and MMF-treated groups compared with those of the diabetic group.	Mycophenolic Acid	194-197	transforming growth factor, beta 1	Rattus norvegicus	98-107
26307985-3	2015	We evaluated SNPs in genes that have previously shown correlations in other kinds of solid organ transplantation, namely ABCB1 and CYP3A5 genes with tacrolimus (Tac) and ABCC2, UGT1A9 and SLCO1B1 genes with mycophenolic acid (MPA), during the first six months after lung transplantation (51 patients).	Mycophenolic Acid	207-224	ATP binding cassette subfamily B member 1	Homo sapiens	121-126
25661834-0	2015	Mycophenolic acid upregulates miR-142-3P/5P and miR-146a in lupus CD4+T cells.	Mycophenolic Acid	0-17	microRNA 146a	Homo sapiens	48-56
25661834-0	2015	Mycophenolic acid upregulates miR-142-3P/5P and miR-146a in lupus CD4+T cells.	Mycophenolic Acid	0-17	CD4 molecule	Homo sapiens	66-69
25929522-6	2015	Mycophenolate mofetil antagonized the effects of dexamethasone on GR but it potentiated the action of dioxin on AhR.	Mycophenolic Acid	0-21	aryl hydrocarbon receptor	Homo sapiens	112-115
25929522-7	2015	Induction of CYP1A1 mRNA in HepG2 cells by dioxin was modestly antagonized by mycophenolate mofetil, while the induction by benzo[a]pyren or S-omeprazole was significantly potentiated by this drug.	Mycophenolic Acid	78-99	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	13-19
25929522-9	2015	Nevertheless, mycophenolate mofetil is of possible concern and its combination with drugs, environmental pollutants or food constituents, which activate AhR, may represent a significant toxicological risk.	Mycophenolic Acid	14-35	aryl hydrocarbon receptor	Homo sapiens	153-156
25063424-12	2014	Indeed, the six patients who received both an induction therapy and a combined treatment with calcineurin inhibitors/mycophenolate exhibited a decrease of IgG4 anti-PLA2R1 activity and did not relapse, while the four patients who did not receive this strong immunosuppressive treatment association had persistently high IgG4 anti-PLA2R1 activity and relapsed.	Mycophenolic Acid	117-130	phospholipase A2 receptor 1	Homo sapiens	165-171
25557802-0	2015	Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.	Mycophenolic Acid	48-65	calcineurin binding protein 1	Homo sapiens	0-21
26126806-1	2015	BACKGROUND: A number of studies have provided information regarding the risks and benefits of mammalian target of rapamycin inhibitors (mTOR-I) combined with calcineurin inhibitors (CNI) versus mycophenolic acid (MPA).	Mycophenolic Acid	213-216	mechanistic target of rapamycin kinase	Homo sapiens	136-140
25773534-2	2015	The objective of our study was to investigate the efficacy of corticosteroids and mycophenolate mofetil (MMF) in treating childhood immunoglobulin A nephropathy (IgAN) with nephrotic syndrome.	Mycophenolic Acid	82-103	IGAN1	Homo sapiens	162-166
25773534-2	2015	The objective of our study was to investigate the efficacy of corticosteroids and mycophenolate mofetil (MMF) in treating childhood immunoglobulin A nephropathy (IgAN) with nephrotic syndrome.	Mycophenolic Acid	105-108	IGAN1	Homo sapiens	162-166
25979971-2	2015	However, use of IL2-RA remains controversial in LRT with tacrolimus (TAC)/mycophenolic acid (MPA) with or without steroids.	Mycophenolic Acid	74-91	interleukin 2 receptor subunit alpha	Homo sapiens	16-22
25979971-2	2015	However, use of IL2-RA remains controversial in LRT with tacrolimus (TAC)/mycophenolic acid (MPA) with or without steroids.	Mycophenolic Acid	93-96	interleukin 2 receptor subunit alpha	Homo sapiens	16-22
25828197-0	2015	Natural Killer Cell Activating Receptor NKG2D Is Involved in the Immunosuppressive Effects of Mycophenolate Mofetil and Hepatitis B Virus Infection.	Mycophenolic Acid	94-115	killer cell lectin like receptor K1	Homo sapiens	40-45
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	47-64	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	160-166
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	47-64	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	199-205
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	47-64	proliferation-associated 2G4	Homo sapiens	211-234
25413447-0	2015	Comment on "mycophenolic acid attenuates the tumour necrosis factor-a-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-kappaB and ROS pathways" by Olejarz et al.	Mycophenolic Acid	12-29	nuclear factor kappa B subunit 1	Homo sapiens	146-155
25841376-0	2015	Spectroscopy study and co-administration effect on the interaction of mycophenolic acid and human serum albumin.	Mycophenolic Acid	70-87	albumin	Homo sapiens	98-111
25841376-1	2015	Mycophenolic acid (MPA), an immunosuppressor, is always administered in combination with several drugs in clinical therapy, which may alter the binding of MPA to human serum albumin (HSA) and could influence its pharmacological activities.	Mycophenolic Acid	0-17	albumin	Homo sapiens	168-181
25841376-1	2015	Mycophenolic acid (MPA), an immunosuppressor, is always administered in combination with several drugs in clinical therapy, which may alter the binding of MPA to human serum albumin (HSA) and could influence its pharmacological activities.	Mycophenolic Acid	19-22	albumin	Homo sapiens	168-181
26293053-0	2015	WITHDRAWN: Natural Killer Cell Activating Receptor NKG2D Is Involved in the Immunosuppressant Effect of Mycophenolate Mofetil and Infection of Hepatitis B Virus.	Mycophenolic Acid	104-125	killer cell lectin like receptor K1	Homo sapiens	51-56
25869206-5	2015	We characterized two enzymes, PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and report increased efficacy of established anti-androgens in combination with a clinically approved IMPDH inhibitor, mycophenolic acid (MPA).	Mycophenolic Acid	222-239	phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase	Homo sapiens	30-35
25869206-5	2015	We characterized two enzymes, PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and report increased efficacy of established anti-androgens in combination with a clinically approved IMPDH inhibitor, mycophenolic acid (MPA).	Mycophenolic Acid	222-239	inosine monophosphate dehydrogenase 2	Homo sapiens	40-46
25869206-5	2015	We characterized two enzymes, PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and report increased efficacy of established anti-androgens in combination with a clinically approved IMPDH inhibitor, mycophenolic acid (MPA).	Mycophenolic Acid	241-244	phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase	Homo sapiens	30-35
25869206-5	2015	We characterized two enzymes, PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and report increased efficacy of established anti-androgens in combination with a clinically approved IMPDH inhibitor, mycophenolic acid (MPA).	Mycophenolic Acid	241-244	inosine monophosphate dehydrogenase 2	Homo sapiens	40-46
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	47-64	proliferation-associated 2G4	Homo sapiens	236-240
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	47-64	proliferating cell nuclear antigen	Homo sapiens	263-297
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	47-64	proliferating cell nuclear antigen	Homo sapiens	299-303
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	66-69	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	160-166
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	66-69	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	199-205
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	66-69	proliferation-associated 2G4	Homo sapiens	211-234
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	66-69	proliferation-associated 2G4	Homo sapiens	236-240
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	66-69	proliferating cell nuclear antigen	Homo sapiens	263-297
25883228-1	2015	In this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inhibits the function of transcription initiation factor I (TIF-IA) and impacts the interaction of TIF-IA with ErbB3-binding protein 1 (Ebp1), a key in regulating proliferating cell nuclear antigen (PCNA) expression and ribosomal RNA (rRNA) synthesis in T cells during activation.	Mycophenolic Acid	66-69	proliferating cell nuclear antigen	Homo sapiens	299-303
25673929-0	2015	Synergistic Inhibition of Tumor Necrosis Factor-Alpha-Stimulated Pro-Inflammatory Cytokine Expression in HaCaT Cells by a Combination of Rapamycin and Mycophenolic Acid.	Mycophenolic Acid	151-168	tumor necrosis factor	Homo sapiens	26-53
25455453-6	2015	For some of these compounds such as mycophenolic acid, leflunomide, and trifluridine, the observed interactions with PXR occurred at clinically significant concentrations and could provide potential mechanistic explanations for observed drug-to-drug interactions and drug-induced toxicity.	Mycophenolic Acid	36-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	117-120
26099989-9	2015	Results from in vitro experiments on human mesangial cells (HMC) showed that mycophenolic acid (MPA) was more effective than CTX in suppressing PKC-alpha activation and TGF-beta1 secretion induced by human polyclonal anti-dsDNA antibodies.	Mycophenolic Acid	77-94	protein kinase C alpha	Homo sapiens	144-153
26099989-9	2015	Results from in vitro experiments on human mesangial cells (HMC) showed that mycophenolic acid (MPA) was more effective than CTX in suppressing PKC-alpha activation and TGF-beta1 secretion induced by human polyclonal anti-dsDNA antibodies.	Mycophenolic Acid	77-94	transforming growth factor beta 1	Homo sapiens	169-178
26099989-9	2015	Results from in vitro experiments on human mesangial cells (HMC) showed that mycophenolic acid (MPA) was more effective than CTX in suppressing PKC-alpha activation and TGF-beta1 secretion induced by human polyclonal anti-dsDNA antibodies.	Mycophenolic Acid	96-99	protein kinase C alpha	Homo sapiens	144-153
26099989-9	2015	Results from in vitro experiments on human mesangial cells (HMC) showed that mycophenolic acid (MPA) was more effective than CTX in suppressing PKC-alpha activation and TGF-beta1 secretion induced by human polyclonal anti-dsDNA antibodies.	Mycophenolic Acid	96-99	transforming growth factor beta 1	Homo sapiens	169-178
26328657-5	2015	After switching from AZ to MMF, her symptoms of NPSLE completely resolved with marked improvement of the IL-6 level in her spinal fluid, suggesting that MMF was effective.	Mycophenolic Acid	27-30	interleukin 6	Homo sapiens	105-109
25540593-0	2014	Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms.	Mycophenolic Acid	0-17	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	117-123
25540593-0	2014	Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms.	Mycophenolic Acid	78-91	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	117-123
25063424-12	2014	Indeed, the six patients who received both an induction therapy and a combined treatment with calcineurin inhibitors/mycophenolate exhibited a decrease of IgG4 anti-PLA2R1 activity and did not relapse, while the four patients who did not receive this strong immunosuppressive treatment association had persistently high IgG4 anti-PLA2R1 activity and relapsed.	Mycophenolic Acid	117-130	phospholipase A2 receptor 1	Homo sapiens	330-336
24806448-0	2014	Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy.	Mycophenolic Acid	70-91	interleukin 2	Homo sapiens	0-13
25305313-6	2014	Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) cells from MSC-primed allograft mouse recipients resulted in a reduction of IL-17A production and an increase in the Foxp3(+) T(reg) cell fraction.	Mycophenolic Acid	18-39	interleukin 17A	Mus musculus	62-68
25305313-6	2014	Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) cells from MSC-primed allograft mouse recipients resulted in a reduction of IL-17A production and an increase in the Foxp3(+) T(reg) cell fraction.	Mycophenolic Acid	18-39	interleukin 17A	Mus musculus	148-154
25305313-6	2014	Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) cells from MSC-primed allograft mouse recipients resulted in a reduction of IL-17A production and an increase in the Foxp3(+) T(reg) cell fraction.	Mycophenolic Acid	18-39	forkhead box P3	Mus musculus	189-194
25985583-0	2014	Mycophenolate mofetil attenuates myocardial ischemia-reperfusion injury via regulation of the TLR4/NF-kappaB signaling pathway.	Mycophenolic Acid	0-21	toll-like receptor 4	Rattus norvegicus	94-98
24969967-0	2014	Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2.	Mycophenolic Acid	24-45	interleukin 2	Homo sapiens	136-149
25247578-0	2014	Mycophenolate antagonizes IFN-gamma-induced catagen-like changes via beta-catenin activation in human dermal papilla cells and hair follicles.	Mycophenolic Acid	0-13	interferon gamma	Homo sapiens	26-35
25247578-0	2014	Mycophenolate antagonizes IFN-gamma-induced catagen-like changes via beta-catenin activation in human dermal papilla cells and hair follicles.	Mycophenolic Acid	0-13	catenin beta 1	Homo sapiens	69-81
25247578-2	2014	In this study, we investigate the influence of mycophenolate (MPA), an immunosuppressant, on the proliferation of human dermal papilla cells (hDPCs) and on the growth of human hair follicles following catagen induction with interferon (IFN)-gamma.	Mycophenolic Acid	47-60	interferon gamma	Homo sapiens	224-246
24728488-8	2014	In particular, UGT1A1, UGT1A7, and UGT1B1 displayed good glucuronidation activities toward most phenolic aglycones (4-methylumbelliferone, 4-nitrophenol, 1-naphthol, bisphenol A, and mycophenolic acid) and the two carboxylic acids (bilirubin and diclofenac).	Mycophenolic Acid	183-200	UDP-glucuronosyltransferase 1-1	Danio rerio	15-21
24615849-0	2014	Inhibitory effect of ciprofloxacin on beta-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide.	Mycophenolic Acid	83-100	glucuronidase beta	Homo sapiens	38-56
24615849-4	2014	Ciprofloxacin and phenolphthalein-beta-d-glucuronide (PhePG), a typical beta-glucuronidase substrate, significantly decreased the production of MPA from MPAG in the beta-glucuronidase-mediated deconjugation system.	Mycophenolic Acid	144-147	glucuronidase beta	Homo sapiens	72-90
24615849-4	2014	Ciprofloxacin and phenolphthalein-beta-d-glucuronide (PhePG), a typical beta-glucuronidase substrate, significantly decreased the production of MPA from MPAG in the beta-glucuronidase-mediated deconjugation system.	Mycophenolic Acid	144-147	glucuronidase beta	Homo sapiens	165-183
24728488-8	2014	In particular, UGT1A1, UGT1A7, and UGT1B1 displayed good glucuronidation activities toward most phenolic aglycones (4-methylumbelliferone, 4-nitrophenol, 1-naphthol, bisphenol A, and mycophenolic acid) and the two carboxylic acids (bilirubin and diclofenac).	Mycophenolic Acid	183-200	UDP glucuronosyltransferase 1 family, polypeptide B1	Danio rerio	35-41
24728488-8	2014	In particular, UGT1A1, UGT1A7, and UGT1B1 displayed good glucuronidation activities toward most phenolic aglycones (4-methylumbelliferone, 4-nitrophenol, 1-naphthol, bisphenol A, and mycophenolic acid) and the two carboxylic acids (bilirubin and diclofenac).	Mycophenolic Acid	183-200	UDP glucuronosyltransferase 1 family, polypeptide A7	Danio rerio	23-29
23740036-9	2014	mTOR inhibitors, especially in combination with low-dose CNIs, can safely be used in children after kidney transplantation as de novo therapy or for conversion from CNI- and mycophenolate mofetil-based regimens.	Mycophenolic Acid	174-195	mechanistic target of rapamycin kinase	Homo sapiens	0-4
24486136-1	2014	Mycophenolic acid (MPA) is an immunosuppressant used in transplant rejection, often in combination with cyclosporine (CsA) and tacrolimus (Tac).	Mycophenolic Acid	0-17	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	118-121
24486136-1	2014	Mycophenolic acid (MPA) is an immunosuppressant used in transplant rejection, often in combination with cyclosporine (CsA) and tacrolimus (Tac).	Mycophenolic Acid	19-22	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	118-121
24491040-15	2014	CONCLUSION: Steroid-free de novo treatment and calcineurin-inhibitor weaning with mycophenolate monotherapy is feasible in first HLA-identical kidney transplantation from a living sibling.	Mycophenolic Acid	82-95	calcineurin binding protein 1	Homo sapiens	47-68
24703567-6	2014	Maintenance immunosuppressive therapy after an induction with CYC was preferentially MMF (58%), versus 14% for azathioprine (AZA) and 25% using either MMF or AZA without preference.	Mycophenolic Acid	85-88	cytochrome c, somatic	Homo sapiens	62-65
24369416-10	2014	Gastrointestinal manifestations were more common [combined IRR 1.68 (95% CI 1.06, 2.68)] and leucopoenia less frequent in the MMF group [combined IRR 0.14 (95% CI 0.05, 0.42)].	Mycophenolic Acid	126-129	insulin receptor related receptor	Homo sapiens	146-149
24509232-8	2014	Confocal immunofluorescence analysis showed redistribution of TJ proteins (ZO-1 and occludin) after MPA treatment.	Mycophenolic Acid	100-103	tight junction protein 1	Homo sapiens	75-92
24548980-12	2014	The relationships between transcript expression and patient-level data demonstrated; ABCC2 expression was different by race (1.26 +- 1.82 Caucasian versus 1.37 +- 0.86 non-Caucasian; p = 0.049) and CYP2B6 expression was different by treatment (2.07 +- 2.94 cyclophosphamide versus 0.45 +- 0.5 mycophenolate; p = 0.01).	Mycophenolic Acid	293-306	ATP binding cassette subfamily C member 2	Homo sapiens	85-90
24548980-12	2014	The relationships between transcript expression and patient-level data demonstrated; ABCC2 expression was different by race (1.26 +- 1.82 Caucasian versus 1.37 +- 0.86 non-Caucasian; p = 0.049) and CYP2B6 expression was different by treatment (2.07 +- 2.94 cyclophosphamide versus 0.45 +- 0.5 mycophenolate; p = 0.01).	Mycophenolic Acid	293-306	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	198-204
25340056-7	2014	Two relapsing MOG antibody-positive patients treated with mycophenolate mofetil remain in remission and have become MOG antibody seronegative.	Mycophenolic Acid	58-79	myelin oligodendrocyte glycoprotein	Homo sapiens	14-17
25340056-7	2014	Two relapsing MOG antibody-positive patients treated with mycophenolate mofetil remain in remission and have become MOG antibody seronegative.	Mycophenolic Acid	58-79	myelin oligodendrocyte glycoprotein	Homo sapiens	116-119
24307660-3	2014	She was unresponsive to cyclosporine A, methylprednisolone, intravenous immunoglobulin, and mycophenolate mofetil and the symptoms could only be controlled after plasma exchange and subsequent use of rituximab, in addition to cyclosporine A and mycophenolate mofetil maintenance.	Mycophenolic Acid	245-266	Src homology 2 domain containing E	Homo sapiens	0-3
24815167-0	2014	PRMT3: new binding molecule to RhoGDI-alpha during mycophenolic acid-induced beta-cell death.	Mycophenolic Acid	51-68	protein arginine methyltransferase 3	Rattus norvegicus	0-5
24815167-0	2014	PRMT3: new binding molecule to RhoGDI-alpha during mycophenolic acid-induced beta-cell death.	Mycophenolic Acid	51-68	Rho GDP dissociation inhibitor alpha	Rattus norvegicus	31-43
24782172-0	2014	Effects of mycophenolate mofetil on the expression of monocyte chemoattractant protein-1 and fibronectin in high glucose cultured human mesangial cells.	Mycophenolic Acid	11-32	C-C motif chemokine ligand 2	Homo sapiens	54-88
24782172-0	2014	Effects of mycophenolate mofetil on the expression of monocyte chemoattractant protein-1 and fibronectin in high glucose cultured human mesangial cells.	Mycophenolic Acid	11-32	fibronectin 1	Homo sapiens	93-104
24222014-0	2014	Mycophenolic acid-treated dendritic cells generate regulatory CD4+ T cells that suppress CD8+ T cells" allocytotoxicity.	Mycophenolic Acid	0-17	CD4 molecule	Homo sapiens	62-65
24222014-0	2014	Mycophenolic acid-treated dendritic cells generate regulatory CD4+ T cells that suppress CD8+ T cells" allocytotoxicity.	Mycophenolic Acid	0-17	CD8a molecule	Homo sapiens	89-92
24222014-4	2014	CD8(+) T cells are major agents in the rejection of allografts; the aim of this study is to investigate the effects exerted on CD8(+) T cells by human CD4(+) iTreg induced by mycophenolic acid-treated dendritic cells.	Mycophenolic Acid	175-192	CD8a molecule	Homo sapiens	0-3
24222014-4	2014	CD8(+) T cells are major agents in the rejection of allografts; the aim of this study is to investigate the effects exerted on CD8(+) T cells by human CD4(+) iTreg induced by mycophenolic acid-treated dendritic cells.	Mycophenolic Acid	175-192	CD8a molecule	Homo sapiens	127-130
24222014-4	2014	CD8(+) T cells are major agents in the rejection of allografts; the aim of this study is to investigate the effects exerted on CD8(+) T cells by human CD4(+) iTreg induced by mycophenolic acid-treated dendritic cells.	Mycophenolic Acid	175-192	CD4 molecule	Homo sapiens	151-154
24168326-0	2014	Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation.	Mycophenolic Acid	40-61	TERF1 interacting nuclear factor 2	Homo sapiens	178-183
24734071-0	2014	Cytochrome C and Caspase-3/7 are Involved in Mycophenolic Acid- Induced Apoptosis in Genetically Engineered PC12 Neuronal Cells Expressing the p53 gene.	Mycophenolic Acid	45-62	caspase 3	Rattus norvegicus	17-26
24460726-0	2014	Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset.	Mycophenolic Acid	108-129	C-C motif chemokine ligand 2	Homo sapiens	18-22
24460726-0	2014	Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset.	Mycophenolic Acid	108-129	C-X-C motif chemokine ligand 10	Homo sapiens	27-33
24329776-0	2014	Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.	Mycophenolic Acid	72-93	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	21-24
24329776-10	2014	CONCLUSIONS: These results demonstrated that short-term conversion from MMF to everolimus after one yr post-transplant may be a safe and effective alternate for ABO-incompatible kidney transplant recipients requiring temporary discontinuation of MMF.	Mycophenolic Acid	72-75	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	161-164
24734071-0	2014	Cytochrome C and Caspase-3/7 are Involved in Mycophenolic Acid- Induced Apoptosis in Genetically Engineered PC12 Neuronal Cells Expressing the p53 gene.	Mycophenolic Acid	45-62	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	143-146
24036158-4	2013	Our results show that at a clinically relevant concentration of 10 muM, mycophenolic acid inhibited both OAT1- and OAT3-mediated [(3)H]-MTX uptake.	Mycophenolic Acid	72-89	solute carrier family 22 member 6	Homo sapiens	105-109
24782687-1	2014	OBJECTIVES: Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2.	Mycophenolic Acid	72-89	ATP binding cassette subfamily C member 2	Homo sapiens	130-135
24782687-1	2014	OBJECTIVES: Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2.	Mycophenolic Acid	72-89	ATP binding cassette subfamily C member 2	Homo sapiens	180-184
24782687-1	2014	OBJECTIVES: Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2.	Mycophenolic Acid	91-94	ATP binding cassette subfamily C member 2	Homo sapiens	130-135
24782687-1	2014	OBJECTIVES: Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2.	Mycophenolic Acid	91-94	ATP binding cassette subfamily C member 2	Homo sapiens	180-184
24036158-4	2013	Our results show that at a clinically relevant concentration of 10 muM, mycophenolic acid inhibited both OAT1- and OAT3-mediated [(3)H]-MTX uptake.	Mycophenolic Acid	72-89	solute carrier family 22 member 8	Homo sapiens	115-119
23721685-0	2013	Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1alpha and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.	Mycophenolic Acid	123-140	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	25-31
23968808-6	2013	The proteinuria, blood urea nitrogen, and interleukin 6 levels were significantly reduced after MMF treatment.	Mycophenolic Acid	96-99	interleukin 6	Mus musculus	42-55
24216510-8	2013	Using X-inactivation mosaicism for the purine salvage gene Hprt, we found that reduced ENS precursor proliferation most likely causes mycophenolate-induced migration defects and aganglionosis.	Mycophenolic Acid	134-147	hypoxanthine guanine phosphoribosyl transferase	Mus musculus	59-63
23615344-7	2013	Mycophenolic acid (100 microg/mL) caused a significant decrease in cell viability (P &lt; 0.01) and higher caspase-3/7 activity (P &lt; 0.05) in both cell lines compared with untreated cells.	Mycophenolic Acid	0-17	caspase 3	Homo sapiens	107-116
24036158-4	2013	Our results show that at a clinically relevant concentration of 10 muM, mycophenolic acid inhibited both OAT1- and OAT3-mediated [(3)H]-MTX uptake.	Mycophenolic Acid	72-89	metaxin 1	Homo sapiens	136-139
24036158-7	2013	With regard to the apical efflux transporters, mycophenolic acid, cyclophosphamide, hydrocortisone, and tacrolimus inhibited MRP2 and MRP4, whereas mitoxantrone and dexamethasone stimulated [(3)H]-MTX transport by both transporters.	Mycophenolic Acid	47-64	ATP binding cassette subfamily C member 2	Homo sapiens	125-129
24036158-7	2013	With regard to the apical efflux transporters, mycophenolic acid, cyclophosphamide, hydrocortisone, and tacrolimus inhibited MRP2 and MRP4, whereas mitoxantrone and dexamethasone stimulated [(3)H]-MTX transport by both transporters.	Mycophenolic Acid	47-64	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
24036158-7	2013	With regard to the apical efflux transporters, mycophenolic acid, cyclophosphamide, hydrocortisone, and tacrolimus inhibited MRP2 and MRP4, whereas mitoxantrone and dexamethasone stimulated [(3)H]-MTX transport by both transporters.	Mycophenolic Acid	47-64	metaxin 1	Homo sapiens	197-200
23846223-0	2013	The role of thioredoxin 1 in the mycophenolic acid-induced apoptosis of insulin-producing cells.	Mycophenolic Acid	33-50	thioredoxin 1	Rattus norvegicus	12-25
24250211-1	2013	We report that one 18-year-old female patient with no epilepsia history developed severe epileptiform seizures while she was receiving "ciclosporin A (CsA)-mycophenolate-methylprednisolone" antirejection therapy after combining one week"s voriconazole administration following allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndromes (MDS).	Mycophenolic Acid	156-169	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	151-154
23339626-0	2013	The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on "Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus".	Mycophenolic Acid	40-57	ATP binding cassette subfamily C member 2	Homo sapiens	151-192
23645010-0	2013	Mycophenolic acid derivative 118 improves outcome of skin grafts by suppressing IL-17 production.	Mycophenolic Acid	0-17	interleukin 17A	Mus musculus	80-85
23645010-12	2013	CONCLUSION: Treatment with the mycophenolic acid derivative 118 improves murine allogeneic skin grafts by decreasing IL-23 expression and suppressing local IL-17 secretion in the grafts, rather than directly inhibiting Th17 differentiation.	Mycophenolic Acid	31-48	interleukin 23, alpha subunit p19	Mus musculus	117-122
23645010-12	2013	CONCLUSION: Treatment with the mycophenolic acid derivative 118 improves murine allogeneic skin grafts by decreasing IL-23 expression and suppressing local IL-17 secretion in the grafts, rather than directly inhibiting Th17 differentiation.	Mycophenolic Acid	31-48	interleukin 17A	Mus musculus	156-161
24250661-0	2013	Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients.	Mycophenolic Acid	33-50	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	10-16
24229832-0	2013	Addition of mycophenolate mofetil to tacrolimus is associated with decreases in food-specific IgE levels in a pediatric patient with liver transplantation-associated food allergy.	Mycophenolic Acid	12-33	immunoglobulin heavy constant epsilon	Homo sapiens	94-97
23775875-0	2013	Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.	Mycophenolic Acid	27-48	calcineurin binding protein 1	Homo sapiens	0-21
23775875-1	2013	Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation.	Mycophenolic Acid	0-21	calcineurin binding protein 1	Homo sapiens	67-88
23775875-1	2013	Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation.	Mycophenolic Acid	23-26	calcineurin binding protein 1	Homo sapiens	67-88
23755242-4	2013	Furthermore, using a immunodeficient mouse model that supports the engraftment of central memory derived human T cells, in vivo selection studies demonstrate that huEGFRt(+)DHFR(FS+)IMPDH2(IY+) T cells could be enriched following adoptive transfer either by systemic administration of MTX alone (4.4 -fold), MMF alone (2.9-fold), or combined MTX and MMF (4.9-fold).	Mycophenolic Acid	308-311	dihydrofolate reductase	Homo sapiens	173-177
23457378-1	2013	OBJECTIVE: Small series suggest mycophenolate mofetil (MMF) is well tolerated and may be an effective therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD).	Mycophenolic Acid	32-53	CTD	Homo sapiens	178-181
23457378-1	2013	OBJECTIVE: Small series suggest mycophenolate mofetil (MMF) is well tolerated and may be an effective therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD).	Mycophenolic Acid	55-58	CTD	Homo sapiens	178-181
23052409-0	2013	Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.	Mycophenolic Acid	69-86	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	17-23
23052409-0	2013	Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.	Mycophenolic Acid	69-86	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	28-34
23136028-10	2013	CONCLUSION: MPA can up-regulate the Cosmc expression and reverse the IgA1 aberrant O-glycosylation level in peripheral lymphocytes of IgAN patients, which might be the underlying mechanism of mycophenolate mofetil (MMF) therapy used in treating IgAN.	Mycophenolic Acid	192-213	IGAN1	Homo sapiens	134-138
23136028-10	2013	CONCLUSION: MPA can up-regulate the Cosmc expression and reverse the IgA1 aberrant O-glycosylation level in peripheral lymphocytes of IgAN patients, which might be the underlying mechanism of mycophenolate mofetil (MMF) therapy used in treating IgAN.	Mycophenolic Acid	192-213	IGAN1	Homo sapiens	245-249
23136028-10	2013	CONCLUSION: MPA can up-regulate the Cosmc expression and reverse the IgA1 aberrant O-glycosylation level in peripheral lymphocytes of IgAN patients, which might be the underlying mechanism of mycophenolate mofetil (MMF) therapy used in treating IgAN.	Mycophenolic Acid	215-218	IGAN1	Homo sapiens	134-138
23414365-5	2013	Children treated with a low-dose calcineurin inhibitor (CNI) together with an mTOR inhibitor exhibited decreased subclinical rejection (0% vs. 19%, p = 0.001) and decreased interstitial fibrosis and tubular atrophy (IF/TA) (15% vs. 42%, p = 0.013) compared with patients treated with a conventional regimen consisting of normal-dose CNI and mycophenolate mofetil.	Mycophenolic Acid	341-362	calcineurin binding protein 1	Homo sapiens	33-54
23414365-5	2013	Children treated with a low-dose calcineurin inhibitor (CNI) together with an mTOR inhibitor exhibited decreased subclinical rejection (0% vs. 19%, p = 0.001) and decreased interstitial fibrosis and tubular atrophy (IF/TA) (15% vs. 42%, p = 0.013) compared with patients treated with a conventional regimen consisting of normal-dose CNI and mycophenolate mofetil.	Mycophenolic Acid	341-362	calcineurin binding protein 1	Homo sapiens	56-59
23414365-5	2013	Children treated with a low-dose calcineurin inhibitor (CNI) together with an mTOR inhibitor exhibited decreased subclinical rejection (0% vs. 19%, p = 0.001) and decreased interstitial fibrosis and tubular atrophy (IF/TA) (15% vs. 42%, p = 0.013) compared with patients treated with a conventional regimen consisting of normal-dose CNI and mycophenolate mofetil.	Mycophenolic Acid	341-362	mechanistic target of rapamycin kinase	Homo sapiens	78-82
23319318-0	2013	Mycophenolic acid regulates spleen tyrosine kinase to repress tumour necrosis factor-alpha-induced monocyte chemotatic protein-1 production in cultured human aortic endothelial cells.	Mycophenolic Acid	0-17	C-C motif chemokine ligand 2	Homo sapiens	99-128
23689569-6	2013	In progressive IgAN patients whose clinical and pathological manifestations are more severe, active therapy may be considered including glucocorticoid therapy, cyclophosphamide, azathioprine, mycophenolate mofetil, tacrolimus, and other immunosuppressants.	Mycophenolic Acid	192-213	IGAN1	Homo sapiens	15-19
23726609-1	2013	BACKGROUND: Uridine diphosphate glucuronosyltransferase (UGT2B7) is responsible for conversion of mycophenolic acid to mycophenolic acyl-glucuronide (acylMPAG).	Mycophenolic Acid	98-115	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	57-63
23557548-0	2013	Mycophenolate mofetil affects monocyte Toll-like receptor 4 signaling during mouse renal ischemia/reperfusion injury.	Mycophenolic Acid	0-21	toll-like receptor 4	Mus musculus	39-59
23052409-8	2013	CONCLUSIONS: The current results indicate that UGT1A9 and UGT2B7 genotypes could significantly alter MPA pharmacokinetics in healthy Chinese volunteers after a single oral dose of MMF.	Mycophenolic Acid	180-183	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	47-53
23052409-8	2013	CONCLUSIONS: The current results indicate that UGT1A9 and UGT2B7 genotypes could significantly alter MPA pharmacokinetics in healthy Chinese volunteers after a single oral dose of MMF.	Mycophenolic Acid	180-183	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	58-64
23136028-0	2013	Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy.	Mycophenolic Acid	0-17	immunoglobulin heavy constant alpha 1	Homo sapiens	27-31
23136028-0	2013	Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy.	Mycophenolic Acid	0-17	C1GALT1 specific chaperone 1	Homo sapiens	77-82
23136028-0	2013	Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy.	Mycophenolic Acid	0-17	IGAN1	Homo sapiens	97-112
23136028-1	2013	OBJECTIVE: Impaired core I beta3-Gal-T-specific molecular chaperone (Cosmc) expression-caused IgA1 aberrant O-glycosylation is one of the main pathogeneses of IgA nephropathy (IgAN).This study tried to elucidate whether mycophenolic acid (MPA) could up-regulate Cosmc expression of peripheral lymphocytes in IgAN patients and reverse the dys-O-glycosylation.	Mycophenolic Acid	220-237	C1GALT1 specific chaperone 1	Homo sapiens	69-74
23136028-1	2013	OBJECTIVE: Impaired core I beta3-Gal-T-specific molecular chaperone (Cosmc) expression-caused IgA1 aberrant O-glycosylation is one of the main pathogeneses of IgA nephropathy (IgAN).This study tried to elucidate whether mycophenolic acid (MPA) could up-regulate Cosmc expression of peripheral lymphocytes in IgAN patients and reverse the dys-O-glycosylation.	Mycophenolic Acid	220-237	immunoglobulin heavy constant alpha 1	Homo sapiens	94-98
23136028-1	2013	OBJECTIVE: Impaired core I beta3-Gal-T-specific molecular chaperone (Cosmc) expression-caused IgA1 aberrant O-glycosylation is one of the main pathogeneses of IgA nephropathy (IgAN).This study tried to elucidate whether mycophenolic acid (MPA) could up-regulate Cosmc expression of peripheral lymphocytes in IgAN patients and reverse the dys-O-glycosylation.	Mycophenolic Acid	220-237	IGAN1	Homo sapiens	159-174
23136028-1	2013	OBJECTIVE: Impaired core I beta3-Gal-T-specific molecular chaperone (Cosmc) expression-caused IgA1 aberrant O-glycosylation is one of the main pathogeneses of IgA nephropathy (IgAN).This study tried to elucidate whether mycophenolic acid (MPA) could up-regulate Cosmc expression of peripheral lymphocytes in IgAN patients and reverse the dys-O-glycosylation.	Mycophenolic Acid	220-237	IGAN1	Homo sapiens	176-180
23136028-1	2013	OBJECTIVE: Impaired core I beta3-Gal-T-specific molecular chaperone (Cosmc) expression-caused IgA1 aberrant O-glycosylation is one of the main pathogeneses of IgA nephropathy (IgAN).This study tried to elucidate whether mycophenolic acid (MPA) could up-regulate Cosmc expression of peripheral lymphocytes in IgAN patients and reverse the dys-O-glycosylation.	Mycophenolic Acid	220-237	C1GALT1 specific chaperone 1	Homo sapiens	262-267
23136028-1	2013	OBJECTIVE: Impaired core I beta3-Gal-T-specific molecular chaperone (Cosmc) expression-caused IgA1 aberrant O-glycosylation is one of the main pathogeneses of IgA nephropathy (IgAN).This study tried to elucidate whether mycophenolic acid (MPA) could up-regulate Cosmc expression of peripheral lymphocytes in IgAN patients and reverse the dys-O-glycosylation.	Mycophenolic Acid	220-237	IGAN1	Homo sapiens	308-312
23136028-10	2013	CONCLUSION: MPA can up-regulate the Cosmc expression and reverse the IgA1 aberrant O-glycosylation level in peripheral lymphocytes of IgAN patients, which might be the underlying mechanism of mycophenolate mofetil (MMF) therapy used in treating IgAN.	Mycophenolic Acid	192-213	C1GALT1 specific chaperone 1	Homo sapiens	36-41
23136028-10	2013	CONCLUSION: MPA can up-regulate the Cosmc expression and reverse the IgA1 aberrant O-glycosylation level in peripheral lymphocytes of IgAN patients, which might be the underlying mechanism of mycophenolate mofetil (MMF) therapy used in treating IgAN.	Mycophenolic Acid	192-213	immunoglobulin heavy constant alpha 1	Homo sapiens	69-73
23517575-10	2013	cyclophosphamide pulses monthly for 6 doses, followed by mycophenolate mofetil that resulted in normal lung function tests, hemoglobin concentration, and anti-MPO level within four subsequent weeks.	Mycophenolic Acid	57-78	myeloperoxidase	Homo sapiens	159-162
22934787-2	2013	The purpose of this study was to investigate the contribution of MRP2 to the efflux of mycophenolic acid (MPA), and its phenyl glucuronide (MPAG) and acyl glucuronide (AcMPAG) metabolites, using Madin-Darby canine kidney II cells stably transfected with human MRP2 gene (MDCKII/MRP2 cells).	Mycophenolic Acid	87-104	ATP binding cassette subfamily C member 2	Canis lupus familiaris	65-69
22934787-2	2013	The purpose of this study was to investigate the contribution of MRP2 to the efflux of mycophenolic acid (MPA), and its phenyl glucuronide (MPAG) and acyl glucuronide (AcMPAG) metabolites, using Madin-Darby canine kidney II cells stably transfected with human MRP2 gene (MDCKII/MRP2 cells).	Mycophenolic Acid	87-104	ATP binding cassette subfamily C member 2	Homo sapiens	260-264
22934787-2	2013	The purpose of this study was to investigate the contribution of MRP2 to the efflux of mycophenolic acid (MPA), and its phenyl glucuronide (MPAG) and acyl glucuronide (AcMPAG) metabolites, using Madin-Darby canine kidney II cells stably transfected with human MRP2 gene (MDCKII/MRP2 cells).	Mycophenolic Acid	87-104	ATP binding cassette subfamily C member 2	Canis lupus familiaris	260-264
22934787-2	2013	The purpose of this study was to investigate the contribution of MRP2 to the efflux of mycophenolic acid (MPA), and its phenyl glucuronide (MPAG) and acyl glucuronide (AcMPAG) metabolites, using Madin-Darby canine kidney II cells stably transfected with human MRP2 gene (MDCKII/MRP2 cells).	Mycophenolic Acid	106-109	ATP binding cassette subfamily C member 2	Canis lupus familiaris	65-69
22934787-2	2013	The purpose of this study was to investigate the contribution of MRP2 to the efflux of mycophenolic acid (MPA), and its phenyl glucuronide (MPAG) and acyl glucuronide (AcMPAG) metabolites, using Madin-Darby canine kidney II cells stably transfected with human MRP2 gene (MDCKII/MRP2 cells).	Mycophenolic Acid	106-109	ATP binding cassette subfamily C member 2	Homo sapiens	260-264
22934787-2	2013	The purpose of this study was to investigate the contribution of MRP2 to the efflux of mycophenolic acid (MPA), and its phenyl glucuronide (MPAG) and acyl glucuronide (AcMPAG) metabolites, using Madin-Darby canine kidney II cells stably transfected with human MRP2 gene (MDCKII/MRP2 cells).	Mycophenolic Acid	106-109	ATP binding cassette subfamily C member 2	Canis lupus familiaris	260-264
23223314-1	2013	BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycophenolate-based regimens reduces the risk of development of squamous cell carcinoma of the skin (SCC) in kidney transplant recipients (KTRs).	Mycophenolic Acid	95-108	serpin family B member 3	Homo sapiens	196-199
22391559-5	2013	This RPS14-MDM2 binding was induced upon ribosomal stress caused by actinomycin D or mycophenolic acid.	Mycophenolic Acid	85-102	ribosomal protein S14	Homo sapiens	5-10
22391559-5	2013	This RPS14-MDM2 binding was induced upon ribosomal stress caused by actinomycin D or mycophenolic acid.	Mycophenolic Acid	85-102	MDM2 proto-oncogene	Homo sapiens	11-15
24158161-12	2013	CONCLUSION: Mycophenolate mofetil can protect renal function by increasing Bcl-2 expression and decreasing Bax expression and podocyte apoptosis rate, thereby reducing proteinuria.	Mycophenolic Acid	12-33	BCL2, apoptosis regulator	Rattus norvegicus	75-80
23555904-6	2013	Treatment with MPA and Prednisolone revealed significantly reduced CD107a expression in response to cell line stimulation.	Mycophenolic Acid	15-18	lysosomal associated membrane protein 1	Homo sapiens	67-73
24158161-12	2013	CONCLUSION: Mycophenolate mofetil can protect renal function by increasing Bcl-2 expression and decreasing Bax expression and podocyte apoptosis rate, thereby reducing proteinuria.	Mycophenolic Acid	12-33	BCL2 associated X, apoptosis regulator	Rattus norvegicus	107-110
23285477-10	2012	Lower mean cumulative doses of cyclosporine A (CyA) and mycophenolic acid (MPA) (P&lt;0.05) each were associated with thickened CIMT.	Mycophenolic Acid	56-73	CIMT	Homo sapiens	128-132
23285477-10	2012	Lower mean cumulative doses of cyclosporine A (CyA) and mycophenolic acid (MPA) (P&lt;0.05) each were associated with thickened CIMT.	Mycophenolic Acid	75-78	CIMT	Homo sapiens	128-132
23131697-0	2012	UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.	Mycophenolic Acid	47-64	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	0-6
23131697-0	2012	UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.	Mycophenolic Acid	47-64	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	8-14
23131697-0	2012	UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.	Mycophenolic Acid	47-64	ATP binding cassette subfamily C member 2	Homo sapiens	20-24
23146536-4	2012	We investigated here in, the effect of mycophenolate mofetil (MMF) and corticosteroids, usually used in combination with a calcineurin inhibitor on human CD4(+)CD25(+) Treg cells.	Mycophenolic Acid	39-60	CD4 molecule	Homo sapiens	154-157
23146841-0	2013	Effect of mycophenolic acid on cyclosporin A-induced fibronectin expression in rat mesangial cells.	Mycophenolic Acid	10-27	fibronectin 1	Rattus norvegicus	53-64
23146536-4	2012	We investigated here in, the effect of mycophenolate mofetil (MMF) and corticosteroids, usually used in combination with a calcineurin inhibitor on human CD4(+)CD25(+) Treg cells.	Mycophenolic Acid	62-65	CD4 molecule	Homo sapiens	154-157
22469198-6	2012	After adjusting for sex, body-weight and doses of corticosteroids and mycophenolate mofetil, we noted that CYP3A5 genotypes had the most profound effect on the dose and dose-adjusted trough levels of tacrolimus 1-5 years after transplantation (p &lt; 0.001).	Mycophenolic Acid	70-91	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	107-113
22327003-4	2012	Among the currently available immunosuppressive agents, cyclosporine, tacrolimus and mycophenolic acid are in vitro substrates of the UGT1A and 2B families of glucuronidation enzymes.	Mycophenolic Acid	85-102	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	134-146
22327003-9	2012	This paper reviews the current status of the genetic associations between germline UGT variants and the pharmacokinetics and pharmacodynamics of mycophenolic acid.	Mycophenolic Acid	145-162	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	83-86
21878834-1	2012	OBJECTIVE: We investigated the association between genetic polymorphisms in ABCB1 and SLCO1B and mycophenolic acid (MPA) pharmacokinetics, and MPA-related diarrhea and leukopenia in 338 kidney transplant recipients.	Mycophenolic Acid	97-114	ATP binding cassette subfamily B member 1	Homo sapiens	76-81
22707608-8	2012	High C-reactive protein levels were associated with IFI, along with other factors such as high disease activity, mechanical ventilation, treatment with antibiotics, hemodialysis, high doses of glucocorticoids (GC), and treatment with mycophenolate mofetil.	Mycophenolic Acid	234-255	C-reactive protein	Homo sapiens	5-23
23117946-6	2012	Acetylcholinesterase inhibitors are often the first modality of therapy for MG. As an immune-mediated disorder, MG can respond to several immunosuppressive agents, such as corticosteroids, azathioprine, mycophenolate mofetil, and cyclosporin.	Mycophenolic Acid	203-224	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
22213147-1	2012	UNLABELLED: Mycophenolic acid (MPA) is a highly effective immunosuppressant that has broad antiviral activity against different viruses and can act in synergy with interferon-alpha (IFN-alpha) on hepatitis C virus (HCV) replication.	Mycophenolic Acid	12-29	interferon alpha 1	Homo sapiens	182-191
22213147-1	2012	UNLABELLED: Mycophenolic acid (MPA) is a highly effective immunosuppressant that has broad antiviral activity against different viruses and can act in synergy with interferon-alpha (IFN-alpha) on hepatitis C virus (HCV) replication.	Mycophenolic Acid	31-34	interferon alpha 1	Homo sapiens	182-191
22213147-9	2012	However, similar to ribavirin, MPA induced expression of multiple antiviral ISGs, including interferon regulatory factor 1 (IRF1).	Mycophenolic Acid	31-34	interferon regulatory factor 1	Homo sapiens	92-122
22213147-9	2012	However, similar to ribavirin, MPA induced expression of multiple antiviral ISGs, including interferon regulatory factor 1 (IRF1).	Mycophenolic Acid	31-34	interferon regulatory factor 1	Homo sapiens	124-128
22664000-1	2012	BACKGROUND: To analyze the association between the principal immunosuppressive drugs (mycophenolate mofetil, calcineurin inhibitors and mammalian target of rapamycin [mTOR] inhibitors) used in the routine management of kidney transplant patients and the development of postoperative surgical complications.	Mycophenolic Acid	86-107	mechanistic target of rapamycin kinase	Homo sapiens	136-165
22664000-1	2012	BACKGROUND: To analyze the association between the principal immunosuppressive drugs (mycophenolate mofetil, calcineurin inhibitors and mammalian target of rapamycin [mTOR] inhibitors) used in the routine management of kidney transplant patients and the development of postoperative surgical complications.	Mycophenolic Acid	86-107	mechanistic target of rapamycin kinase	Homo sapiens	167-171
22538450-1	2012	BACKGROUND: Early calcineurin inhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine practice, due to concerns about excess acute rejection.	Mycophenolic Acid	62-83	calcineurin binding protein 1	Homo sapiens	18-39
22572835-0	2012	Mycophenolic acid-related anemia and leucopenia in renal transplant recipients are related to genetic polymorphisms in CYP2C8.	Mycophenolic Acid	0-17	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	119-125
22538450-1	2012	BACKGROUND: Early calcineurin inhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine practice, due to concerns about excess acute rejection.	Mycophenolic Acid	85-88	calcineurin binding protein 1	Homo sapiens	18-39
22558981-7	2012	CONCLUSION: Mycophenolate could inhibit the expressions of MCP-1 and FN in human mesangial cells and it might be expected to delay the development and progression of glomerular sclerosis and interstitial fibrosis.	Mycophenolic Acid	12-25	mast cell protease 1	Mus musculus	59-64
21976740-9	2012	After conversion from CsA to MMF, renal function improved significantly; the eGFR at last follow-up was 137 (range 106-198) mL/min x 1.73 m(2).	Mycophenolic Acid	29-32	epidermal growth factor receptor	Homo sapiens	77-81
22558981-0	2012	[Effect of mycophenolate on expression of MCP-1 and fibronectin in human mesangial cells induced by high glucose].	Mycophenolic Acid	11-24	C-C motif chemokine ligand 2	Homo sapiens	42-47
22227166-0	2012	The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.	Mycophenolic Acid	106-123	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	23-29
22558981-0	2012	[Effect of mycophenolate on expression of MCP-1 and fibronectin in human mesangial cells induced by high glucose].	Mycophenolic Acid	11-24	fibronectin 1	Homo sapiens	52-63
22558981-1	2012	AIM: To investigate the effect of high glucose and mycophenolate (MMF) on the expression of MCP-1 in human mesangial cells (HMCs) and fibronectin (FN).	Mycophenolic Acid	51-64	mast cell protease 1	Mus musculus	92-97
22558981-1	2012	AIM: To investigate the effect of high glucose and mycophenolate (MMF) on the expression of MCP-1 in human mesangial cells (HMCs) and fibronectin (FN).	Mycophenolic Acid	51-64	MKKS centrosomal shuttling protein	Homo sapiens	124-128
22227166-0	2012	The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.	Mycophenolic Acid	106-123	solute carrier organic anion transporter family member 1B3	Homo sapiens	31-38
22227166-0	2012	The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.	Mycophenolic Acid	106-123	ATP binding cassette subfamily C member 2	Homo sapiens	43-48
22227166-0	2012	The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.	Mycophenolic Acid	106-123	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	49-54
21953346-0	2012	Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.	Mycophenolic Acid	0-21	low density lipoprotein receptor	Mus musculus	85-89
22320241-1	2012	Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study).	Mycophenolic Acid	107-128	calcineurin binding protein 1	Homo sapiens	22-43
22320241-1	2012	Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study).	Mycophenolic Acid	130-133	calcineurin binding protein 1	Homo sapiens	22-43
22318725-5	2012	First, depletion of GTP by treating cells with mycophenolic acid decreased the level of NS without apparently affecting the levels of other nucleolar proteins.	Mycophenolic Acid	47-64	G protein nucleolar 3	Homo sapiens	88-90
23284981-3	2012	Here we determined if regional variation in the EMT response to TGFbeta1 underlies the bronchiolocentric fibrosis leading to BOS and whether EMT could be inhibited by azithromycin or mycophenolate.	Mycophenolic Acid	183-196	IL2 inducible T cell kinase	Homo sapiens	141-144
21725921-0	2012	Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression.	Mycophenolic Acid	51-72	IGAN1	Homo sapiens	76-91
22306777-9	2012	Blocking LAMP-2A expression with siRNA increased the level of cleaved caspase-3 and the number of propidium iodide-positive cells after hypoxic stress regardless of whether macroautophagy could occur, whereas the administration of mycophenolic acid, a potent CMA activator, rescued hypoxia-mediated cell death.	Mycophenolic Acid	231-248	lysosomal-associated membrane protein 2	Mus musculus	9-16
22961096-0	2012	Successful long-time treatment with mycophenolate-mofetil in a child with acquired factor VIII inhibitor.	Mycophenolic Acid	36-57	cytochrome c oxidase subunit 8A	Homo sapiens	90-94
21976399-0	2012	Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency.	Mycophenolic Acid	59-80	CD4 molecule	Homo sapiens	117-120
21883921-0	2011	Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival.	Mycophenolic Acid	25-42	CD274 antigen	Mus musculus	55-60
23013949-12	2012	Eighteen out 47 patients (38.2%) received prednisone and 29 (61.7%) mycophenolate with mTor before starting monotherapy.	Mycophenolic Acid	68-81	mechanistic target of rapamycin kinase	Homo sapiens	87-91
21883744-4	2011	Twenty-eight patients with heart transplantation were switched from CNI regimen to everolimus and mycophenolate, when cGFR was &lt;75 mL/min/1.73 m(2).	Mycophenolic Acid	98-111	CD59 molecule (CD59 blood group)	Homo sapiens	137-142
22005457-0	2011	Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARgamma-LXRalpha-ABCA1 pathway.	Mycophenolic Acid	0-17	ATP binding cassette subfamily A member 1	Homo sapiens	26-61
22005457-0	2011	Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARgamma-LXRalpha-ABCA1 pathway.	Mycophenolic Acid	0-17	ATP binding cassette subfamily A member 1	Homo sapiens	63-68
22005457-0	2011	Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARgamma-LXRalpha-ABCA1 pathway.	Mycophenolic Acid	0-17	peroxisome proliferator activated receptor gamma	Homo sapiens	93-102
22005457-0	2011	Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARgamma-LXRalpha-ABCA1 pathway.	Mycophenolic Acid	0-17	nuclear receptor subfamily 1 group H member 3	Homo sapiens	103-111
22005457-0	2011	Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARgamma-LXRalpha-ABCA1 pathway.	Mycophenolic Acid	0-17	ATP binding cassette subfamily A member 1	Homo sapiens	112-117
22005457-3	2011	Using this method in the present study, we found that mycophenolic acid (MPA) upregulated ABCA1 expression (EC50=0.09 muM).	Mycophenolic Acid	54-71	ATP binding cassette subfamily A member 1	Homo sapiens	90-95
22005457-3	2011	Using this method in the present study, we found that mycophenolic acid (MPA) upregulated ABCA1 expression (EC50=0.09 muM).	Mycophenolic Acid	54-71	latexin	Homo sapiens	118-121
22005457-3	2011	Using this method in the present study, we found that mycophenolic acid (MPA) upregulated ABCA1 expression (EC50=0.09 muM).	Mycophenolic Acid	73-76	ATP binding cassette subfamily A member 1	Homo sapiens	90-95
22005457-3	2011	Using this method in the present study, we found that mycophenolic acid (MPA) upregulated ABCA1 expression (EC50=0.09 muM).	Mycophenolic Acid	73-76	latexin	Homo sapiens	118-121
22005457-5	2011	Previous work has indicated that MPA is a potent agonist of peroxisome proliferator-activated receptor gamma (PPARgamma; EC50=5.2-9.3 muM).	Mycophenolic Acid	33-36	peroxisome proliferator activated receptor gamma	Homo sapiens	60-108
22005457-5	2011	Previous work has indicated that MPA is a potent agonist of peroxisome proliferator-activated receptor gamma (PPARgamma; EC50=5.2-9.3 muM).	Mycophenolic Acid	33-36	peroxisome proliferator activated receptor gamma	Homo sapiens	110-119
22005457-5	2011	Previous work has indicated that MPA is a potent agonist of peroxisome proliferator-activated receptor gamma (PPARgamma; EC50=5.2-9.3 muM).	Mycophenolic Acid	33-36	latexin	Homo sapiens	134-137
21960168-2	2011	A National Institutes of Health-funded FSGS multicenter study has suggested that a combination of mycophenolate mofetil and oral dexamethasone pulses was equivalent to cyclosporine.	Mycophenolic Acid	98-119	actinin alpha 4	Homo sapiens	39-43
22007615-1	2011	INTRODUCTION: Complete conversion of calcineurin inhibitor (CNI) immunosuppressant therapy to non-nephrotoxic agents such as mycophenolate mofetil (MMF) is controversial, but may be safe in selected patients, although appropriate protocols and long-term benefits of conversion are not well reported.	Mycophenolic Acid	148-151	calcineurin binding protein 1	Homo sapiens	37-58
22007615-1	2011	INTRODUCTION: Complete conversion of calcineurin inhibitor (CNI) immunosuppressant therapy to non-nephrotoxic agents such as mycophenolate mofetil (MMF) is controversial, but may be safe in selected patients, although appropriate protocols and long-term benefits of conversion are not well reported.	Mycophenolic Acid	148-151	calcineurin binding protein 1	Homo sapiens	60-63
21818055-7	2011	Accordingly, renal transplant patients treated with MPA in combination with minimized dose of tacrolimus tended to have lower circulating IL-17 levels than patients treated with tacrolimus alone given at conventional dose.	Mycophenolic Acid	52-55	interleukin 17A	Homo sapiens	138-143
21427078-1	2011	BACKGROUND: The aim of this study was to determine the relationship between single-nucleotide polymorphisms (SNPs) in MRP2 genes and mycophenolic acid (MPA) pharmacokinetics in renal transplant recipients of the Symphony Pharmacogenomic substudy.	Mycophenolic Acid	133-150	ATP binding cassette subfamily C member 2	Homo sapiens	118-122
21427078-1	2011	BACKGROUND: The aim of this study was to determine the relationship between single-nucleotide polymorphisms (SNPs) in MRP2 genes and mycophenolic acid (MPA) pharmacokinetics in renal transplant recipients of the Symphony Pharmacogenomic substudy.	Mycophenolic Acid	152-155	ATP binding cassette subfamily C member 2	Homo sapiens	118-122
21933383-6	2011	A significant apoptosis was observed after MPA treatment, as revealed by caspase 3 activity.	Mycophenolic Acid	43-46	caspase 3	Homo sapiens	73-82
21524190-7	2011	In addition, both mycophenolic acid (substrate of UGT1A9) and emodin (substrate of UGT1A8 and UGT1A10) could inhibit the glucuronidation of Picroside II with the half maximal inhibitory concentration (IC(50)) values of 173.6 and 76.2 muM, respectively.	Mycophenolic Acid	18-35	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	50-56
21836511-0	2011	De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results.	Mycophenolic Acid	72-93	calcineurin binding protein 1	Homo sapiens	8-29
21524190-7	2011	In addition, both mycophenolic acid (substrate of UGT1A9) and emodin (substrate of UGT1A8 and UGT1A10) could inhibit the glucuronidation of Picroside II with the half maximal inhibitory concentration (IC(50)) values of 173.6 and 76.2 muM, respectively.	Mycophenolic Acid	18-35	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	83-89
21524190-7	2011	In addition, both mycophenolic acid (substrate of UGT1A9) and emodin (substrate of UGT1A8 and UGT1A10) could inhibit the glucuronidation of Picroside II with the half maximal inhibitory concentration (IC(50)) values of 173.6 and 76.2 muM, respectively.	Mycophenolic Acid	18-35	latexin	Homo sapiens	234-237
21596236-1	2011	OBJECTIVES: This study tested whether immunosuppression with mycophenolate mofetil (MMF) inhibits atherosclerosis development in apolipoprotein-E-deficient (Apoe(-/-)) mice and investigated the mechanism.	Mycophenolic Acid	84-87	apolipoprotein E	Mus musculus	129-145
21544031-8	2011	CONCLUSIONS: Based on retrospectively collected data of 103 renal transplant recipients receiving tacrolimus in combination with mycophenolate mofetil and corticosteroids, we found that renal expression and localization of CYP3A5 but not P-gp is associated with the occurrence of CNIT.	Mycophenolic Acid	129-150	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	223-229
21349264-0	2011	Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARgamma.	Mycophenolic Acid	0-17	peroxisome proliferator activated receptor gamma	Homo sapiens	122-131
21349264-7	2011	However, RNA interference experiments showed that PPARgamma-knockdown cannot completely reverse the differentiated state of MDA-MB-231 cells after MPA treatment.	Mycophenolic Acid	147-150	peroxisome proliferator activated receptor gamma	Homo sapiens	50-59
21349934-3	2011	Mycophenolate mofetil (MMF) containing ILs was generated that targets the Thy1.1 antigen (OX-7) in rat mesangial cells.	Mycophenolic Acid	0-21	thymus cell antigen 1, theta	Mus musculus	74-80
21349934-3	2011	Mycophenolate mofetil (MMF) containing ILs was generated that targets the Thy1.1 antigen (OX-7) in rat mesangial cells.	Mycophenolic Acid	23-26	thymus cell antigen 1, theta	Mus musculus	74-80
21241803-1	2011	Mycophenolic acid (MPA) plasma concentrations were reported to be associated with a decrease in T-cell proliferation, and in both IL-2 alpha-chain (CD25) and transferin receptor (CD71) expression.	Mycophenolic Acid	0-17	interleukin 2	Homo sapiens	130-134
21241803-1	2011	Mycophenolic acid (MPA) plasma concentrations were reported to be associated with a decrease in T-cell proliferation, and in both IL-2 alpha-chain (CD25) and transferin receptor (CD71) expression.	Mycophenolic Acid	0-17	interleukin 2 receptor subunit alpha	Homo sapiens	148-152
21241803-1	2011	Mycophenolic acid (MPA) plasma concentrations were reported to be associated with a decrease in T-cell proliferation, and in both IL-2 alpha-chain (CD25) and transferin receptor (CD71) expression.	Mycophenolic Acid	0-17	transferrin receptor	Homo sapiens	179-183
21241803-1	2011	Mycophenolic acid (MPA) plasma concentrations were reported to be associated with a decrease in T-cell proliferation, and in both IL-2 alpha-chain (CD25) and transferin receptor (CD71) expression.	Mycophenolic Acid	19-22	interleukin 2	Homo sapiens	130-134
21241803-1	2011	Mycophenolic acid (MPA) plasma concentrations were reported to be associated with a decrease in T-cell proliferation, and in both IL-2 alpha-chain (CD25) and transferin receptor (CD71) expression.	Mycophenolic Acid	19-22	interleukin 2 receptor subunit alpha	Homo sapiens	148-152
21241803-1	2011	Mycophenolic acid (MPA) plasma concentrations were reported to be associated with a decrease in T-cell proliferation, and in both IL-2 alpha-chain (CD25) and transferin receptor (CD71) expression.	Mycophenolic Acid	19-22	transferrin receptor	Homo sapiens	179-183
21228337-5	2011	Depletion of endogenous GTP levels with mycophenolic acid significantly reduced glucose-induced activation of Rac1 and ROS generation in these cells.	Mycophenolic Acid	40-57	Rac family small GTPase 1	Rattus norvegicus	110-114
21451536-2	2011	The Spare the Nephron Trial describes the popular approach of early conversion from a CNI to the mTOR agent sirolimus for patients maintained on mycophenolate mofetil and steroids.	Mycophenolic Acid	145-166	mechanistic target of rapamycin kinase	Homo sapiens	97-101
21342445-0	2011	Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation.	Mycophenolic Acid	0-17	CD4 molecule	Homo sapiens	48-51
21342445-3	2011	Here, we present novel insights into the mechanisms underlying mycophenolic acid-mediated suppression of human CD4+ T cells.	Mycophenolic Acid	63-80	CD4 molecule	Homo sapiens	111-114
21342445-4	2011	Upon CD3/CD28 stimulation, mycophenolic acid inhibited T cell IL-17, IFN-gamma and TNF-alpha production but not IL-2 production.	Mycophenolic Acid	27-44	CD28 molecule	Homo sapiens	9-13
21342445-4	2011	Upon CD3/CD28 stimulation, mycophenolic acid inhibited T cell IL-17, IFN-gamma and TNF-alpha production but not IL-2 production.	Mycophenolic Acid	27-44	interleukin 17A	Homo sapiens	62-67
21342445-4	2011	Upon CD3/CD28 stimulation, mycophenolic acid inhibited T cell IL-17, IFN-gamma and TNF-alpha production but not IL-2 production.	Mycophenolic Acid	27-44	interferon gamma	Homo sapiens	69-78
21342445-4	2011	Upon CD3/CD28 stimulation, mycophenolic acid inhibited T cell IL-17, IFN-gamma and TNF-alpha production but not IL-2 production.	Mycophenolic Acid	27-44	tumor necrosis factor	Homo sapiens	83-92
21342445-8	2011	Interestingly, the co-stimulatory molecule CD70 was uniquely and dose-dependently upregulated on mycophenolic acid-treated T cells and found to be directly linked to target enzyme inhibition.	Mycophenolic Acid	97-114	CD70 molecule	Homo sapiens	43-47
21342445-9	2011	CD70 on mycophenolic acid-treated cells proved functional: an anti-CD70 agonist was found to restore both STAT5 and Akt/mTOR signaling and may thereby prevent apoptosis and promote survival.	Mycophenolic Acid	8-25	CD70 molecule	Homo sapiens	0-4
21342445-9	2011	CD70 on mycophenolic acid-treated cells proved functional: an anti-CD70 agonist was found to restore both STAT5 and Akt/mTOR signaling and may thereby prevent apoptosis and promote survival.	Mycophenolic Acid	8-25	CD70 molecule	Homo sapiens	67-71
21342445-9	2011	CD70 on mycophenolic acid-treated cells proved functional: an anti-CD70 agonist was found to restore both STAT5 and Akt/mTOR signaling and may thereby prevent apoptosis and promote survival.	Mycophenolic Acid	8-25	signal transducer and activator of transcription 5A	Homo sapiens	106-111
21342445-9	2011	CD70 on mycophenolic acid-treated cells proved functional: an anti-CD70 agonist was found to restore both STAT5 and Akt/mTOR signaling and may thereby prevent apoptosis and promote survival.	Mycophenolic Acid	8-25	AKT serine/threonine kinase 1	Homo sapiens	116-119
21342445-9	2011	CD70 on mycophenolic acid-treated cells proved functional: an anti-CD70 agonist was found to restore both STAT5 and Akt/mTOR signaling and may thereby prevent apoptosis and promote survival.	Mycophenolic Acid	8-25	mechanistic target of rapamycin kinase	Homo sapiens	120-124
21669047-12	2011	These data suggest that a combined, systemically  delivered immunosuppression regimen including FK506 and mycophenolate can significantly improve survival of human spinal stem cells after intraspinal transplantation in SOD1 (G93A) rats.	Mycophenolic Acid	106-119	superoxide dismutase 1	Homo sapiens	219-223
21321097-6	2011	Such an interpretation is supported by the finding that mycophenolic acid treatment resulted in the colocalization of polycystin-2 with GM130, a marker of the cis-Golgi apparatus.	Mycophenolic Acid	56-73	polycystin 2, transient receptor potential cation channel	Homo sapiens	118-130
21321097-6	2011	Such an interpretation is supported by the finding that mycophenolic acid treatment resulted in the colocalization of polycystin-2 with GM130, a marker of the cis-Golgi apparatus.	Mycophenolic Acid	56-73	golgin A2	Homo sapiens	136-141
21176018-6	2011	The use of anti-interleukin-2 inhibitors as induction therapy, with low-dose tacrolimus or in combination with mycophenolate mofetil, has a key role in preventing significant renal dysfunction and reducing infection and rejection.	Mycophenolic Acid	111-132	interleukin 2	Homo sapiens	16-29
21278621-1	2011	OBJECTIVE: The uptake carrier organic anion-transporting polypeptide 1B3 (OATP1B3, gene SLCO1B3) is involved in the hepatic clearance of xenobiotics including statins, taxanes, and mycophenolic acid.	Mycophenolic Acid	181-198	solute carrier organic anion transporter family member 1B3	Homo sapiens	30-72
21278621-1	2011	OBJECTIVE: The uptake carrier organic anion-transporting polypeptide 1B3 (OATP1B3, gene SLCO1B3) is involved in the hepatic clearance of xenobiotics including statins, taxanes, and mycophenolic acid.	Mycophenolic Acid	181-198	solute carrier organic anion transporter family member 1B3	Homo sapiens	74-81
21278621-1	2011	OBJECTIVE: The uptake carrier organic anion-transporting polypeptide 1B3 (OATP1B3, gene SLCO1B3) is involved in the hepatic clearance of xenobiotics including statins, taxanes, and mycophenolic acid.	Mycophenolic Acid	181-198	solute carrier organic anion transporter family member 1B3	Homo sapiens	88-95
20824504-0	2011	Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.	Mycophenolic Acid	28-49	calcineurin binding protein 1	Homo sapiens	116-119
20823294-0	2010	Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil.	Mycophenolic Acid	61-82	carboxylesterase 1	Homo sapiens	15-39
21468162-1	2011	INTRODUCTION: The combination of cyclosporin A (CsA) and mycophenolate mofetil (MMF) has a synergistic immunosuppressive effect and, as a result, it may induce remission of nephrotic syndrome in patients with steroid- and CsA-resistant focal segmental glomerulosclerosis (FSGS).	Mycophenolic Acid	57-78	actinin alpha 4	Homo sapiens	272-276
21468162-1	2011	INTRODUCTION: The combination of cyclosporin A (CsA) and mycophenolate mofetil (MMF) has a synergistic immunosuppressive effect and, as a result, it may induce remission of nephrotic syndrome in patients with steroid- and CsA-resistant focal segmental glomerulosclerosis (FSGS).	Mycophenolic Acid	80-83	actinin alpha 4	Homo sapiens	272-276
21613803-1	2011	AIM: The aim of this study was to investigate the effect of mycophenolate mofetil (MMF) using differential kidney proteome profiling of COL4A3-deficient mice as a model of progressive renal disease.	Mycophenolic Acid	60-81	collagen, type IV, alpha 3	Mus musculus	136-142
21613803-1	2011	AIM: The aim of this study was to investigate the effect of mycophenolate mofetil (MMF) using differential kidney proteome profiling of COL4A3-deficient mice as a model of progressive renal disease.	Mycophenolic Acid	83-86	collagen, type IV, alpha 3	Mus musculus	136-142
20718729-0	2010	Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.	Mycophenolic Acid	24-41	inosine monophosphate dehydrogenase 1	Homo sapiens	87-93
20718729-0	2010	Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.	Mycophenolic Acid	24-41	inosine monophosphate dehydrogenase 2	Homo sapiens	98-104
20718729-1	2010	BACKGROUND AND PURPOSE: Inosine monophosphate dehydrogenases, encoded by IMPDH1 and IMPDH2, are targets for the important immunosuppressive drug, mycophenolic acid (MPA).	Mycophenolic Acid	146-163	inosine monophosphate dehydrogenase 1	Homo sapiens	73-79
20718729-1	2010	BACKGROUND AND PURPOSE: Inosine monophosphate dehydrogenases, encoded by IMPDH1 and IMPDH2, are targets for the important immunosuppressive drug, mycophenolic acid (MPA).	Mycophenolic Acid	146-163	inosine monophosphate dehydrogenase 2	Homo sapiens	84-90
20718729-1	2010	BACKGROUND AND PURPOSE: Inosine monophosphate dehydrogenases, encoded by IMPDH1 and IMPDH2, are targets for the important immunosuppressive drug, mycophenolic acid (MPA).	Mycophenolic Acid	165-168	inosine monophosphate dehydrogenase 1	Homo sapiens	73-79
20718729-1	2010	BACKGROUND AND PURPOSE: Inosine monophosphate dehydrogenases, encoded by IMPDH1 and IMPDH2, are targets for the important immunosuppressive drug, mycophenolic acid (MPA).	Mycophenolic Acid	165-168	inosine monophosphate dehydrogenase 2	Homo sapiens	84-90
21189444-11	2010	Therefore with regard to our results, different suppressive effect of mycophenolic acid and rapamycin on VEGF production might also be dependent on VEGF genotype.	Mycophenolic Acid	70-87	vascular endothelial growth factor A	Homo sapiens	105-109
20864690-10	2010	Taken together, our data suggest that MPA directly induces expression of neutral endopeptidase, which may reduce proteinuria and slow the progression of renal damage in kidney transplant recipients.	Mycophenolic Acid	38-41	membrane metalloendopeptidase	Homo sapiens	73-94
21189444-11	2010	Therefore with regard to our results, different suppressive effect of mycophenolic acid and rapamycin on VEGF production might also be dependent on VEGF genotype.	Mycophenolic Acid	70-87	vascular endothelial growth factor A	Homo sapiens	148-152
21168674-0	2010	Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil.	Mycophenolic Acid	106-127	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
21142914-0	2010	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients.	Mycophenolic Acid	40-57	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
20637860-8	2010	We conclude that MPA-induced cell death in primary beta-cells and an insulin-secreting cell line proceeds through RhoGDI-alpha down-regulation linked to Rac1 activation, with subsequent activation of JNK.	Mycophenolic Acid	17-20	Rho GDP dissociation inhibitor alpha	Rattus norvegicus	114-126
20637860-8	2010	We conclude that MPA-induced cell death in primary beta-cells and an insulin-secreting cell line proceeds through RhoGDI-alpha down-regulation linked to Rac1 activation, with subsequent activation of JNK.	Mycophenolic Acid	17-20	Rac family small GTPase 1	Rattus norvegicus	153-157
20637860-8	2010	We conclude that MPA-induced cell death in primary beta-cells and an insulin-secreting cell line proceeds through RhoGDI-alpha down-regulation linked to Rac1 activation, with subsequent activation of JNK.	Mycophenolic Acid	17-20	mitogen-activated protein kinase 8	Rattus norvegicus	200-203
20649757-0	2010	Inosine 5"-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients.	Mycophenolic Acid	73-94	inosine monophosphate dehydrogenase 1	Homo sapiens	0-40
20973683-0	2010	Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.	Mycophenolic Acid	139-156	ATP binding cassette subfamily C member 2	Homo sapiens	76-117
20973683-1	2010	STUDY OBJECTIVE: To assess the contribution of polymorphisms in the uridine diphosphate glucuronosyltransferase gene (UGT) and the multidrug resistance-associated protein 2 gene (ABCC2) to mycophenolic acid (MPA) pharmacokinetics and clinical outcomes in thoracic transplant recipients.	Mycophenolic Acid	189-206	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	68-116
20973683-1	2010	STUDY OBJECTIVE: To assess the contribution of polymorphisms in the uridine diphosphate glucuronosyltransferase gene (UGT) and the multidrug resistance-associated protein 2 gene (ABCC2) to mycophenolic acid (MPA) pharmacokinetics and clinical outcomes in thoracic transplant recipients.	Mycophenolic Acid	189-206	ATP binding cassette subfamily C member 2	Homo sapiens	179-184
20973683-10	2010	CONCLUSION: UGT2B7 is a promising gene candidate that may influence MPA pharmacokinetics clinically; however, larger clinical pharmacogenetic studies in thoracic transplant subpopulations are warranted to corroborate the role of AcMPAG and UGT2B7 variants in optimizing mycophenolate mofetil therapy.	Mycophenolic Acid	270-291	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	12-18
21094806-9	2010	CONCLUSION: Low-dose CNI combined with an mTOR inhibitor, as a replacement for mycophenolate mofetil or enteric-coated mycophenolate sodium, seemed to prevent renal dysfunction for at least 6 months among renal transplant patients without allograft nephropathy.	Mycophenolic Acid	79-100	calcineurin binding protein 1	Homo sapiens	21-24
21094806-9	2010	CONCLUSION: Low-dose CNI combined with an mTOR inhibitor, as a replacement for mycophenolate mofetil or enteric-coated mycophenolate sodium, seemed to prevent renal dysfunction for at least 6 months among renal transplant patients without allograft nephropathy.	Mycophenolic Acid	79-100	mechanistic target of rapamycin kinase	Homo sapiens	42-46
21094806-9	2010	CONCLUSION: Low-dose CNI combined with an mTOR inhibitor, as a replacement for mycophenolate mofetil or enteric-coated mycophenolate sodium, seemed to prevent renal dysfunction for at least 6 months among renal transplant patients without allograft nephropathy.	Mycophenolic Acid	119-139	mechanistic target of rapamycin kinase	Homo sapiens	42-46
21094806-9	2010	CONCLUSION: Low-dose CNI combined with an mTOR inhibitor, as a replacement for mycophenolate mofetil or enteric-coated mycophenolate sodium, seemed to prevent renal dysfunction for at least 6 months among renal transplant patients without allograft nephropathy.	Mycophenolic Acid	119-139	calcineurin binding protein 1	Homo sapiens	21-24
20548261-0	2010	Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway.	Mycophenolic Acid	0-17	cytochrome b-245 beta chain	Rattus norvegicus	116-121
20644110-4	2010	In this study, we demonstrated that lipopolysaccharide-treated dendritic cells (DCs) were able to induce proliferation and cytotoxic activity of allogeneic CD8(+) T cells independently of CD4(+) T cells, while adding mycophenolic acid (MPA) to LPS abolished this capacity and resulted in anergic CD8(+) T cells that secreted high levels of interleukin-4 (IL-4), IL-5, IL-10, and transforming growth factor-beta.	Mycophenolic Acid	217-234	CD8a molecule	Homo sapiens	156-159
20671023-0	2010	Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.	Mycophenolic Acid	71-92	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
20548261-3	2010	RESULTS: We first demonstrated that Nox-2 and alpha-smooth muscle actin (SMA) were increased in renal tubules from kidney transplant recipients on calcineurin inhibitors, mycophenolic acid (MPA), and prednisone with IFTANOS, suggestive of EMT (n=6).	Mycophenolic Acid	171-188	cytochrome b-245 beta chain	Rattus norvegicus	36-41
20548261-3	2010	RESULTS: We first demonstrated that Nox-2 and alpha-smooth muscle actin (SMA) were increased in renal tubules from kidney transplant recipients on calcineurin inhibitors, mycophenolic acid (MPA), and prednisone with IFTANOS, suggestive of EMT (n=6).	Mycophenolic Acid	171-188	actin gamma 2, smooth muscle	Rattus norvegicus	46-71
20548261-3	2010	RESULTS: We first demonstrated that Nox-2 and alpha-smooth muscle actin (SMA) were increased in renal tubules from kidney transplant recipients on calcineurin inhibitors, mycophenolic acid (MPA), and prednisone with IFTANOS, suggestive of EMT (n=6).	Mycophenolic Acid	171-188	actin gamma 2, smooth muscle	Rattus norvegicus	73-76
20486914-5	2010	The type of calcineurin inhibitor (tacrolimus/cyclosporine) or use of mycophenolate did not affect treatment efficacy, although both tacrolimus and mycophenolate treated patients showed a lower rate of virological recurrence OR 0.51 (95% CI: 0.26-0.98; p = 0.044) and OR 0.45 (95% CI: 0.22-0.93; p = 0.031), respectively.	Mycophenolic Acid	148-161	calcineurin binding protein 1	Homo sapiens	12-33
20136638-0	2010	Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.	Mycophenolic Acid	78-95	inosine monophosphate dehydrogenase 1	Homo sapiens	15-21
20649565-0	2010	In rat renal fibroblasts, mycophenolic acid inhibits proliferation and production of the chemokine CCL2, stimulated by tumour necrosis factor-alpha.	Mycophenolic Acid	26-43	C-C motif chemokine ligand 2	Rattus norvegicus	99-103
20650041-0	2010	Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome.	Mycophenolic Acid	57-78	CD79a molecule	Homo sapiens	99-115
20649565-8	2010	KEY RESULTS: Mycophenolic acid dose-dependently inhibited steady-state proliferation of 49F cells by up-regulation of p21, p27 and p53, in association with a decrease in cyclins D2 and E.	Mycophenolic Acid	13-30	KRAS proto-oncogene, GTPase	Rattus norvegicus	118-121
20649565-8	2010	KEY RESULTS: Mycophenolic acid dose-dependently inhibited steady-state proliferation of 49F cells by up-regulation of p21, p27 and p53, in association with a decrease in cyclins D2 and E.	Mycophenolic Acid	13-30	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	123-126
20649565-8	2010	KEY RESULTS: Mycophenolic acid dose-dependently inhibited steady-state proliferation of 49F cells by up-regulation of p21, p27 and p53, in association with a decrease in cyclins D2 and E.	Mycophenolic Acid	13-30	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	131-134
20649565-8	2010	KEY RESULTS: Mycophenolic acid dose-dependently inhibited steady-state proliferation of 49F cells by up-regulation of p21, p27 and p53, in association with a decrease in cyclins D2 and E.	Mycophenolic Acid	13-30	cyclin D2	Rattus norvegicus	170-186
20979910-1	2010	OBJECTIVE: To study the effect of mycophenolic acid (MPA) on maturation, endocytotic capacity and allostimulatory properties of human myeloid dendritic cell (MDC).	Mycophenolic Acid	34-51	C-C motif chemokine ligand 22	Homo sapiens	158-161
20592645-9	2010	Moreover, in COL4A3-deficient mice treated with different doses of mycophenolate mofetil, we found no significant differences in the gene expression of the same genes supporting the idea of a TGFbeta-independent pathway of tubulointerstitial fibrosis in this model for progressive renal disease.	Mycophenolic Acid	67-88	collagen, type IV, alpha 3	Mus musculus	13-19
20382756-8	2010	In addition, TSA presented a potent inhibitory effect on the glucuronidation of typical UGT1A9 substrates propofol and mycophenolic acid, with an IC(50) value of 8.4 +/- 1.8 and 8.9 +/- 1.9 microM, respectively.	Mycophenolic Acid	119-136	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	88-94
20138622-0	2010	Mycophenolic acid attenuates tumor necrosis factor-alpha-induced endothelin-1 production in human aortic endothelial cells.	Mycophenolic Acid	0-17	tumor necrosis factor	Homo sapiens	29-56
20138622-0	2010	Mycophenolic acid attenuates tumor necrosis factor-alpha-induced endothelin-1 production in human aortic endothelial cells.	Mycophenolic Acid	0-17	endothelin 1	Homo sapiens	65-77
20138622-3	2010	This study was conducted to evaluate the effect of mycophenolic acid (MPA), an immunosuppressant for the transplant recipients, on tumor necrosis factor-alpha (TNF-alpha)-induced ET-1 production in aortic endothelial cells.	Mycophenolic Acid	51-68	tumor necrosis factor	Homo sapiens	131-158
20138622-3	2010	This study was conducted to evaluate the effect of mycophenolic acid (MPA), an immunosuppressant for the transplant recipients, on tumor necrosis factor-alpha (TNF-alpha)-induced ET-1 production in aortic endothelial cells.	Mycophenolic Acid	51-68	tumor necrosis factor	Homo sapiens	160-169
20138622-3	2010	This study was conducted to evaluate the effect of mycophenolic acid (MPA), an immunosuppressant for the transplant recipients, on tumor necrosis factor-alpha (TNF-alpha)-induced ET-1 production in aortic endothelial cells.	Mycophenolic Acid	51-68	endothelin 1	Homo sapiens	179-183
20138622-3	2010	This study was conducted to evaluate the effect of mycophenolic acid (MPA), an immunosuppressant for the transplant recipients, on tumor necrosis factor-alpha (TNF-alpha)-induced ET-1 production in aortic endothelial cells.	Mycophenolic Acid	70-73	tumor necrosis factor	Homo sapiens	131-158
20138622-3	2010	This study was conducted to evaluate the effect of mycophenolic acid (MPA), an immunosuppressant for the transplant recipients, on tumor necrosis factor-alpha (TNF-alpha)-induced ET-1 production in aortic endothelial cells.	Mycophenolic Acid	70-73	tumor necrosis factor	Homo sapiens	160-169
20138622-3	2010	This study was conducted to evaluate the effect of mycophenolic acid (MPA), an immunosuppressant for the transplant recipients, on tumor necrosis factor-alpha (TNF-alpha)-induced ET-1 production in aortic endothelial cells.	Mycophenolic Acid	70-73	endothelin 1	Homo sapiens	179-183
20375992-4	2010	To test whether mycophenolic acid induces neutropenia by inhibiting IL-17-producing T cells, we treated C57Bl/6 mice with mycophenolate-mofetil (the orally available pro-drug) and found a dose-dependent decrease in blood neutrophils.	Mycophenolic Acid	16-33	interleukin 17A	Mus musculus	68-73
20375992-4	2010	To test whether mycophenolic acid induces neutropenia by inhibiting IL-17-producing T cells, we treated C57Bl/6 mice with mycophenolate-mofetil (the orally available pro-drug) and found a dose-dependent decrease in blood neutrophils.	Mycophenolic Acid	122-143	interleukin 17A	Mus musculus	68-73
20375992-6	2010	Mycophenolic acid delayed myeloid recovery after bone marrow transplantation and decreased the percentage of IL-17-producing T cells in the spleen and thymus, and inhibited IL-17 production in human and mouse T cells in vitro.	Mycophenolic Acid	0-17	interleukin 17A	Homo sapiens	109-114
20375992-6	2010	Mycophenolic acid delayed myeloid recovery after bone marrow transplantation and decreased the percentage of IL-17-producing T cells in the spleen and thymus, and inhibited IL-17 production in human and mouse T cells in vitro.	Mycophenolic Acid	0-17	interleukin 17A	Homo sapiens	173-178
20375992-7	2010	Injection of IL-17 during mycophenolic acid treatment overcame the suppression of the circulating neutrophil levels.	Mycophenolic Acid	26-43	interleukin 17A	Mus musculus	13-18
20375992-8	2010	Our study shows that mycophenolic acid suppresses neutrophil production by inhibiting IL-17 expression, suggesting that measurement of this interleukin might be useful in estimating the risk of neutropenia in clinical settings.	Mycophenolic Acid	21-38	interleukin 17A	Mus musculus	86-91